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Summary 
 
In the human brain, the endothelial cells lining the cerebral microvessels form a uniquely tight cellular 
layer separating the brain tissue from the bloodstream. This cellular barrier, designated as “blood-brain 
barrier” (BBB), prevents the entry of xenobiotics and neurotoxic metabolites into the central nervous 
system (CNS) and thus protects the nerve tissue from chemical damage. More than 98% of small 
molecule drugs have been estimated to not cross the BBB. For drugs targeting the CNS, however, low 
BBB permeability may lead to limited brain penetration, culminating in insufficient drug 
concentrations at the target sites and thus therapeutic failure. On the other hand, low BBB permeation 
is desirable for non-CNS drugs, as this reduces the risk of CNS-related side effects. Regardless of the 
therapeutic area, drug lead candidates should therefore be screened for their ability to permeate the 
BBB already at an early stage of the drug development process, in order to reduce their attrition rate at 
a later stage. 
In the past years, a broad spectrum of cell-based in vitro BBB models has been developed and 
implemented in academia and industry to bring forward molecules with high potential for CNS 
exposure. Despite considerable efforts, there is still an urgent need for reliably predictive BBB 
models, in particular human ones. Primary human cells are difficult to obtain on ethical grounds, are 
laborious to cultivate, suffer from batch-to-batch variation, and are thus suitable only for low 
throughput screenings. To overcome these limitations, immortalized human brain microvascular 
endothelial cell lines have been generated by transfection with tumor genes. Unlike primary cultures, 
immortalized cells are easy to cultivate, proliferate indefinitely, and maintain their differentiating 
properties even after repeated passaging. These properties render them highly suitable for standardized 
screenings amenable to higher throughput. Regrettably, currently available immortalized human brain 
capillary endothelial cell lines often show deficiencies such as low barrier tightness, relatively high 
leakage of barrier integrity markers, and insufficient expression of key transporter systems. 
Consequently, careful optimization and validation of human cell line-based in vitro BBB models have 
to be carried out prior to their application to permeability screening of drug candidates.  
The aim of this thesis was to establish a human in vitro BBB model based on an immortalized human 
brain capillary endothelial cell line, to validate it with a representative series of drug substances known 
to cross the BBB to a varying extent, and to apply it to BBB permeability studies of promising lead 
compounds of natural origin. 
To establish an improved in vitro human BBB model, we evaluated in a first step four currently 
available immortalized human brain capillary endothelial cell lines (hCMEC/D3, hBEMC, TY10, and 
BB19) regarding their ability to produce endothelial cell monolayers with sufficient barrier tightness 
in a 24-well Transwell system. Transendothelial electrical resistance (TEER) values were recorded in 
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real-time using an automated CellZscope system to obtain highly standardized data. Culture conditions 
(growth medium composition, tissue culture insert material, coating material and procedure, cell 
seeding density) were systematically optimized, the impact of co-cultured immortalized human 
astrocytes (SVG-A cell line) and pericytes (HBPCT cell line) on barrier integrity of endothelial cell 
monolayers was investigated, and biochemical and immunocytochemical characterization of cell-type 
specific cellular junction proteins was performed. Under the conditions examined in our experiments, 
mono-cultures of hBMEC cell line exhibited highest TEER values (around 40 Ωcm2) and lowest 
leakage of two fluorescent barrier integrity markers (sodium fluorescein, Na-F; and lucifer yellow, 
LY) (apparent permeability coefficients (Papp) in the range of 3–5 x 10
-6
 cm/s). Furthermore, hBMEC 
cells were shown to express the tight junction proteins ZO-1 and claudin-5, and the endothelial marker 
protein VE-cadherin, confirming their endothelial lineage. Thus, we concluded that hBMEC cell line 
was the most suitable cell line in terms of barrier tightness for the establishment of an immortalized in 
vitro human BBB model. 
The hBMEC cell line-based in vitro human BBB model was validated in a next step with a 
representative series of structurally diverse compounds known to cross the BBB to a different extent. 
Antipyrine, caffeine, diazepam, and propranolol were selected as positive controls, while atenolol, 
cimetidine, quinidine, and vinblastine served as negative controls. For each compound, a quantitative 
ultra-high performance liquid chromatography tandem mass spectrometry (UHPLC-MS/MS) assay in 
Ringer HEPES buffer (RHB) was developed and validated in terms of selectivity, precision, and 
reliability according to current international guidelines. During method validation, numerous 
biological and analytical challenges were encountered, demonstrating that major precautions have to 
be taken prior to quantification, and underlining the importance of careful method development. All 
compounds were screened in the in vitro human BBB model with the barrier integrity marker Na-F in 
parallel, and endothelial permeability coefficients (Pe) across hBMEC monolayers were determined by 
means of the validated UHPLC-MS/MS methods. The in vitro human BBB model correctly predicted 
BBB permeability of the selected compounds, with the exception of one negative control (quinidine, a 
small basic lipophilic P-glycoprotein (P-gp) inhibitor and substrate). A limitation of the model may 
thus be the lack of discrimination between passively diffusing compounds and substrates of active 
efflux. Complementary assays to determine efflux pump interaction are therefore recommended. 
Nevertheless, we conclude that our model represents a promising tool for early BBB permeability 
assessment of lead candidates in drug discovery, as it is of human origin (thus reducing the risk for 
data confounded by species differences), easy and fast to set up, and thus amenable to moderate to 
higher throughput screening.  
After validation, we screened the alkaloid piperine from black pepper (Piper nigrum L.) and five 
selected piperine analogs with positive allosteric γ-aminobutyric acid type A (GABAA) receptor 
modulatory activity for their ability to permeate the BBB in the immortalized in vitro human BBB 
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model. Since GABAA receptors are expressed in the CNS, lead compounds modulating this target need 
to cross the BBB to reach their sites of action. For comparative purposes, the compounds were 
screened in parallel in a human stem cell-derived and in a well-established primary animal (bovine 
endothelial/rat astrocytes co-culture) in vitro BBB model. For each compound, a quantitative UHPLC-
MS/MS assay in the corresponding matrix was developed, and permeability coefficients in each model 
were determined. In vitro predictions from both human models were in good agreement, while 
permeability data from the animal model differed to some extent. In all three BBB models, piperine 
and the semisynthetic analog SCT-64 displayed highest BBB permeability, which was corroborated by 
in silico prediction data. For the other piperine analogs, BBB permeability was low to moderate in the 
two human models, and moderate to high in the animal model. Efflux ratios (ER) calculated from 
bidirectional permeability experiments indicated that the compounds were not substrates of active 
efflux transporters. 
In addition to GABAA receptor modulating compounds, the indolinone derivative (E,Z)-3-(4-hydroxy-
3,5-dimethoxybenzylidene)indolin-2-one (indolinone) from woad (Isatis tinctoria L.) was screened in 
our immortalized in vitro human BBB model. The compound had previously been shown to possess 
potent histamine release inhibitory and anti-inflammatory properties, and thus represents a promising 
lead candidate for the development of new anti-allergic drugs. In vitro data from the immortalized in 
vitro BBB model indicated a high BBB permeation potential for indolinone, which was corroborated 
by in vitro permeability data obtained from two well-established primary animal models, and by in 
silico prediction data. Furthermore, P-gp interaction of the compound was assessed with the aid of two 
specific efflux pump interaction assays. Both assays suggested that no active mediated transport 
mechanism was involved for the compound. 
In conclusion, we have successfully established and validated an easy and fast to set up human in vitro 
BBB model, and applied it to in-house BBB drug permeability assays of promising lead candidates of 
natural origin. 
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Zusammenfassung 
 
Die Blut-Hirn-Schranke ist eine zelluläre Barriere im menschlichen Gehirn, welche die Hirnsubstanz 
vom Blutstrom trennt. Sie besteht aus den dicht verbundenen Endothelzellen der zerebralen 
Blutgefässe, und schützt das zentrale Nervensystem (ZNS) vor im Blut zirkulierenden Xenobiotika 
und neurotoxischen Metaboliten. Schätzungen zufolge sind mehr als 98% aller niedermolekularen 
Verbindungen nicht in der Lage, die Blut-Hirn-Schranke zu durchdringen. Um eine therapeutische 
Wirkung entfalten zu können, müssen ZNS-aktive Arzneistoffe jedoch zwingend durch diese Barriere 
permeieren, um so ihren Wirkort im Gehirn zu erreichen. Demgegenüber ist eine geringe Blut-Hirn-
Schranken-Permeabilität erwünscht für Substanzen, deren Wirkort in der Peripherie ist, da dies das 
Risiko von unerwünschten ZNS-Nebenwirkungen minimiert. Leitstrukturen sollten dementsprechend 
bereits früh auf ihre Blut-Hirn-Schranken-Gängigkeit hin getestet werden, um ein späteres Scheitern 
der Substanzen in der präklinischen oder klinischen Phase zu verhindern. 
In den letzten Jahren wurde von Forschenden in Akademie und Industrie eine Vielzahl von 
zellbasierten in vitro Modellen etabliert, um vielversprechende Moleküle auf ihre Blut-Hirn-
Schranken-Permeabilität hin zu testen. Trotz erheblicher Bemühungen besteht jedoch weiterhin ein 
dringender Bedarf an verlässlichen in vitro Blut-Hirn-Schranken-Modellen, insbesondere an solchen 
menschlichen Ursprungs, welche die Permeabilität von Testsubstanzen korrekt voraussagen. Primäre 
menschliche Zellen sind aus ethischen Gründen nur schwer zugänglich, erfordern eine aufwändige 
Kultivierung, variieren beträchtlich von Charge zu Charge, und sind somit nur für Screenings mit 
geringem Durchsatz geeignet. Um diesen Nachteilen vorzubeugen, wurden in den letzten Jahren 
zahlreiche immortalisierte menschliche Endothelzelllinien durch die Transfektion mit Tumorgenen 
generiert. Diese sind im Gegensatz zu primären Zellen einfach zu kultivieren, proliferieren unbegrenzt, 
und erhalten ihre differenzierenden Eigenschaften selbst nach mehrfacher Passagierung. Dies ist für 
standardisierte Screenings mit höherem Durchsatz von grossem Vorteil. Die derzeit erhältlichen 
humanen Endothelzelllinien sind jedoch oftmals charakterisiert durch limitierte in vitro Schranken-
Dichte, erhöhte Durchlässigkeit von Negativkontrollen, und unzureichende Expression von 
Transportproteinen. Blut-Hirn-Schranken-Modelle, die auf diesen Zelllinien basieren, sollten aus 
diesem Grund sorgfältig optimiert und validiert werden, bevor sie für Permeabilitätsstudien von 
Substanzen eingesetzt werden. 
Das Ziel dieser Thesis war die Etablierung eines in vitro Blut-Hirn-Schranken-Modells basierend auf 
einer menschlichen zerebralen Endothelzelllinie, die Validierung des Modells mit strukturell 
verschiedenen Substanzen mit unterschiedlicher Blut-Hirn-Schranken-Gängigkeit, und das 
anschliessende Testen von Leitstrukturen pflanzlichen Ursprungs im Modell bezüglich ihrer Blut-
Hirn-Schranken-Permeabilität. 
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In einem ersten Schritt wurden vier derzeit verfügbare humane zerebrale Endothelzelllinien 
(hCMEC/D3, hBMEC, TY10 und BB19) auf ihre Fähigkeit hin untersucht, einen ausreichend dichten 
Zellmonolayer in einem Transwell-System (24-Well-Format) auszubilden. Der transendotheliale 
elektrische Widerstand (TEER) wurde in Echtzeit mithilfe eines automatisierten CellZscope-Systems 
gemessen, um hoch standardisierte Daten zu erhalten. Die Kultivierungsbedingungen wurden 
systematisch optimiert, und der Einfluss von ko-kultivierten immortalisierten menschlichen 
Astrozyten und Perizyten auf die Schranken-Dichte der Endothelzellen wurde untersucht. Zudem 
wurden zelltypspezifische Markerproteine biochemisch und immunozytochemisch nachgewiesen. 
Unter den durchgeführten experimentellen Bedingungen konnte gezeigt werden, dass Zellmonolayer 
der hBMEC-Zelllinie die höchsten TEER-Werte (ca. 40 Ωcm2) ausbildeten, sowie die geringste 
Durchlässigkeit von zwei fluoreszierenden Integritätsmarkern aufwiesen (Natrium-Fluorescein, Na-F; 
und Lucifer Yellow, LY) (Permeabilitätskoeffizienten ca. 3–5 x 10-6 cm/s). Des Weiteren konnte 
gezeigt werden, dass hBMEC-Zellen die Tight Junction Proteine ZO-1 und Claudin-5 sowie das 
endotheliale Markerprotein VE-Cadherin exprimieren. Die hBMEC-Zelllinie wurde somit als die am 
besten geeignete humane endotheliale Zelllinie in Bezug auf Schranken-Dichte für die Etablierung 
eines menschlichen in vitro Blut-Hirn-Schranken-Modells betrachtet.  
Das auf der humanen hBMEC-Zelllinie basierende in vitro Blut-Hirn-Schranken-Modell wurde in 
einem nächsten Schritt mit acht strukturell verschiedenen Wirkstoffen mit unterschiedlicher Blut-Hirn-
Schranken-Permeabilität validiert. Antipyrin, Coffein, Diazepam und Propranolol wurden als 
Positivkontrollen gewählt. Atenolol, Cimetidin, Chinidin und Vinblastin dienten als Negativ-
kontrollen. Für jede Substanz wurde eine Quantifizierungsmethode in Ringer-HEPES-Puffer mittels 
Ultra-Hochleistungs-Flüssigkeits-Chromatographie gekoppelt an Tandem-Massenspektrometrie 
(UHPLC-MS/MS) entwickelt, welche gemäss aktuellen internationalen Richtlinien hinsichtlich 
Selektivität, Präzision und Verlässlichkeit validiert wurde. Im Verlauf der Methodenvalidierung traten 
zahlreiche biologische und analytische Probleme auf, welchen durch entsprechende Massnahmen in 
der Probenvorbereitung und UHPLC-MS/MS-Analyse vorgebeugt wurde. Die Substanzen wurden im 
humanen in vitro Modell auf ihre Blut-Hirn-Schranken-Gängigkeit hin getestet, und Permeabilitäts-
koeffizienten wurden bestimmt. Das menschliche in vitro Blut-Hirn-Schranken-Modell war in der 
Lage, die Permeabilität der ausgewählten Testsubstanzen korrekt vorauszusagen, mit Ausnahme einer 
einzigen Negativkontrolle (Chinidin, ein Substrat und Inhibitor von P-Glykoprotein). Trotz dieser 
Limitation stellt das etablierte Modell ein vielversprechendes Hilfsmittel für Blut-Hirn-Schranken-
Permeabilitätsstudien dar, da es menschlichen Ursprungs ist (was das Risiko minimiert, verzerrte 
Daten aufgrund von Spezies-Unterschieden zu erhalten), einfach und schnell aufzusetzen ist, und sich 
somit für Screenings mit höherem Durchsatz eignet. 
Nach der Validierung des Modells wurden das in schwarzem Pfeffer (Piper nigrum L.) vorkommende 
Alkaloid Piperin sowie fünf Piperinanaloga mit positiver allosterischer GABAA-Rezeptor-Aktivität auf 
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ihre Blut-Hirn-Schranken-Gängigkeit hin überprüft. Leitstrukturen, die dieses Target modulieren, 
müssen die Blut-Hirn-Schranke überqueren können. Zu Vergleichszwecken wurden die Substanzen 
zusätzlich in einem auf menschlichen Stammzellen basierenden Modell sowie in einem gut etablierten 
tierischen Blut-Hirn-Schranken-Modell getestet. Um Permeabilitätskoeffizienten bestimmen zu 
können, wurde für jede Substanze eine UHPLC-MS/MS Quantifizierungsmethode in der 
entsprechenden Matrix entwickelt. In vitro Daten der beiden menschlichen Modelle wiesen auf eine 
hohe Blut-Hirn-Schranken-Gängigkeit von Piperin und dem semisynthetischen Derivat SCT-64 hin, 
während die übrigen Piperinanaloga nur geringe bis moderate Permeabilität zeigten. Dementgegen-
gesetzt zeigten alle Substanzen eine moderate bis hohe Blut-Hirn-Schranken-Gängigkeit im tierischen 
Modell. Bidirektionale Permeabilitätsexperimente wiesen darauf hin, dass die Substanzen keine 
Substrate von aktiven Efflux-Transportproteinen sind. 
Zusätzlich zu den GABAA-Rezeptor-Modulatoren wurde das Alkaloid (E,Z)-3-(4-Hydroxy-3,5-
dimethoxybenzyliden)indolin-2-on (Indolinon) aus Färberwaid (Isatis tinctoria L.) im 
immortalisierten humanen in vitro Blut-Hirn-Schranken-Modell getestet. Die Substanz wurde in 
vorangehenden Studien als eine vielversprechende Leitstruktur für die Entwicklung von neuartigen 
anti-allergischen Medikamenten identifiziert. In vitro Permeabilitätsdaten wiesen auf eine hohe Blut-
Hirn-Schranken-Gängigkeit von Indolinon hin, was durch in vitro Daten aus zwei gut etablierten in 
vitro Blut-Hirn-Schranken-Modellen tierischen Ursprungs sowie durch in silico Berechnungen 
bestätigt wurde. Des Weiteren wurde die Interaktion der Substanz mit P-Glykoprotein in zwei 
spezifischen Assays untersucht. Beide Assays wiesen darauf hin, dass kein aktiver Transport-
mechanismus für Indolinon in dessen Blut-Hirn-Schranken-Permeabilität involviert ist.  
Abschliessend kann gesagt werden, dass im Zuge dieser Dissertation ein einfach und schnell 
aufzusetzendes humanes in vitro Blut-Hirn-Schranken-Modell etabliert und validiert wurde, und 
ausgewählte Naturstoffe und Naturstoff-Analoga auf ihre Blut-Hirn-Schranken-Permeabilität hin im 
Modell getestet wurden. 
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1 Aim of the work 
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Central nervous system (CNS) drugs need to penetrate the brain in order to reach their target sites of 
action. This process is controlled by the blood-brain barrier (BBB), a tight cellular layer of endothelial 
cells lining the cerebral microvessels that prevents the entry of most molecules into the nerve tissue. 
Low permeability across the BBB, however, may lead to low brain exposure, culminating in 
insufficient drug concentrations at the target. For CNS drugs, high permeability across this barrier is 
thus favorable. For non-CNS drugs, on the other hand, limited BBB permeation is desirable, as this 
reduces the risk of causing CNS-related side effects. Regardless of the therapeutic area, BBB 
permeability of lead compounds should therefore be assessed at an early stage of the drug 
development process. 
Cell-based in vitro BBB models have been widely implemented in academia and industry for early 
prediction of brain penetration of lead candidates. However, there is still a considerable lack of 
reliably predictive BBB models, in particular of human ones. Primary cells of human origin are 
difficult to obtain due to ethical reasons. Moreover, isolation, purification, and cultivation of primary 
cultures are tedious and time-consuming, and yield and lifespan of endothelial cells are limited. To 
overcome these limitations, immortalized brain microvascular endothelial cell lines have been 
generated by transfection with various tumor genes. Unlike primary cultures, immortalized cells are 
easy to cultivate and maintain their phenotype after repeated passaging, which renders them suitable 
for standardized screenings. Regrettably, currently available immortalized human brain capillary 
endothelial cell lines show deficiencies such as low barrier tightness, relatively high leakage of barrier 
integrity markers, and insufficient expression of key transporter systems. Consequently, careful 
optimization and validation of human cell line-based in vitro BBB models have to be carried out prior 
to their application to permeability screening of drug candidates. 
The aim of this thesis was to establish and validate an immortalized human in vitro BBB model for the 
assessment of BBB permeability of natural product derived lead compounds with promising in vitro 
activity. 
In a first step, we aimed at establishing a human in vitro BBB model by comparing four available 
immortalized human brain capillary endothelial cell lines (hCMEC/D3, hBMEC, TY10, and BB19) 
regarding their ability to produce endothelial cell monolayers with sufficient barrier tightness. Our 
objective was to systematically optimize culture conditions, and to evaluate the influence of co-
cultured immortalized human astrocytes and pericytes on barrier integrity of the endothelial cells. 
The second part of the thesis aimed at validating the optimized human in vitro BBB model with a 
representative series of compounds known to cross or not to cross the BBB. Antipyrine, caffeine, 
diazepam, and propranolol were selected as positive controls. Atenolol, cimetidine, quinidine, and 
vinblastine served as negative controls. For each compound, the objective was to develop a 
quantitative ultra-high performance liquid chromatography tandem mass spectrometry (UHPLC-
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MS/MS) assay in Ringer HEPES buffer (RHB) and validate it with respect to selectivity, precision, 
and reliability according to current international guidelines. By means of the validated UHPLC-
MS/MS quantification methods, we aimed at determining permeability coefficients for each compound 
across the endothelial cell monolayers. 
CNS disorders such as anxiety, sleep disturbances, and epilepsy are currently treated primarily with γ-
aminobutyric acid type A (GABAA) receptor modulators including the benzodiazepines and other CNS 
depressants. However, these drugs induce clinically relevant side effects such as amnesia, unwanted 
sedation, and drug dependence, complicating their long-term application [1]. Hence, there is a high 
medical need for novel lead compounds acting on the GABAA receptor disposing of lower adverse 
effect profiles.  
In our research group, numerous studies have previously been carried out on the identification of 
GABAA receptor modulators from nature [2–4]. In order to reach their sites of action, lead candidates 
modulating this target need to enter the brain by crossing the BBB. The aim of the third part of the 
thesis was thus to screen the alkaloid piperine from Piper nigrum L. (Piperaceae) and five selected 
structurally modified piperine analogs with positive GABAA receptor modulatory activity for their 
ability to cross the BBB [4–7]. Also, we aimed at corroborating the in vitro data by calculation of in 
silico descriptors relevant for BBB permeation. 
Beyond the screening of GABAA receptor modulators, we aimed at evaluating the BBB permeability 
of the indolinone derivative (E,Z)-3-(4-hydroxy-3,5-dimethoxybenzylidene)indolin-2-one from Isatis 
tinctoria L. (Brassicaceae) in the immortalized human in vitro BBB model. The compound had 
previously been identified to possess potent histamine release inhibitory and anti-inflammatory 
properties, and thus represents a promising lead for the development of new anti-allergic drugs [8]. To 
minimize CNS-related adverse effects, low permeability of the compound across the BBB would be of 
advantage. 
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 2.1 Blood-brain barrier (BBB) 
 
2.1.1 Historic background 
The discovery of the blood-brain barrier (BBB) dates back to more than one hundred years. In 1885, 
the German scientist Paul Ehrlich (1854–1915) observed that after injecting water soluble aniline dyes 
into the peritoneum of rats, all animal organs were colored with the exception of brain and spinal cord 
[1,2]. Ehrlich initially attributed this effect to a different binding affinity of the dyes to different body 
tissues [3]. However, the early theory was outdated somewhat later when Ehrlich’s student Edwin 
Goldmann (1862–1913) reversed the dye experiment by injecting the acidic dye trypan blue directly 
into the cerebrospinal fluid (CSF) of dogs and rabbits [2,4]. He observed that brain and spinal cord 
were colored, but not the remaining body of the animals, providing hence first evidence for the 
existence of a physical barrier between brain and peripheral circulation [4]. Max Lewandowsky 
(1876–1918), a German neurologist, was the first to speak of the “Bluthirnschranke” (“blood-brain 
barrier”, abbreviated BBB). He introduced this term after performing experiments with cholic acid and 
ferrocyanide, two plasma membrane impermeable compounds. After injecting the substances directly 
into brain ventricles of animals, Lewandowsky observed neurological symptoms of the animals, while 
this was not the case after an intravenous application of the compounds [5]. A more detailed 
understanding of the BBB at a fine structural level was obtained in the 1960s with the emergence of 
the electron microscope [2]. In 1967, Reese and Karnovsky reported the existence of a “barrier” at the 
endothelium of vessels in the cerebral cortex [6]. By means of electron microscopy, the two scientists 
discovered that cerebral endothelial cells form a continuous, impermeable cellular layer, sealed by 
extremely dense tight junction (TJ) proteins [6]. In the meantime, considerable progress in the 
understanding of structure and function of the BBB has been achieved and numerous scientific studies 
have confirmed the concept of the BBB [7–9]. 
 
2.1.2 Structure and function of the BBB 
Anatomy and physiology 
The BBB in humans and mammals is located at the brain capillary vessels, which are composed of 
tightly sealed endothelial cells (Figure 1) [10]. These cells are connected to each other at their margins 
through TJ and adherens junction (AJ) proteins, and form a one cell layer thick lining [11]. Brain 
microvascular endothelial cells are relatively thin cells, resulting in a distance between luminal side 
(blood side) and abluminal side (brain side) of the plasma membrane of merely 500 nm or less [10]. In 
the human brain, around 100 billion capillaries are present, with a total length of 600 km and a total 
surface area of 20 m
2 
[12]. At the abluminal side of the BBB, the endothelial cells are discontinuously 
enclosed by pericytes (Figure 1) [10]. These cells are involved in various functional roles in the brain, 
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 such as regulation of microvascular blood flow and vascular permeability of the BBB [13–15]. Both 
endothelial cells and pericytes are embedded in a local basement membrane, the so-called basal lamina 
[10], which is composed of collagen and further structural proteins, and which is believed to exert an 
external support function for the endothelium [16]. Likewise, astrocytes are in close contact to the 
endothelium (Figure 1). Through perivascular endfeet, they are connected to the outer surface of the 
lamina-covered capillaries and provide a cellular link of the endothelial cells to surrounding neurons 
[17]. By secreting various signaling molecules and growth factors, astrocytes contribute to the 
formation of an increased barrier function of the endothelial cells [18]. In the perivascular space, 
further cerebral cells such as microglial cells and (in arterioles) smooth muscle cells are present [17]. 
The term “blood-brain barrier” refers to both the brain capillary endothelium and to its function as a 
restrictive barrier [11], which is described in the section “Functions of the BBB”.  
 
 
 
Figure 1: Schematic representation of the blood-brain barrier (BBB) in the human brain. Cerebral microvascular endothelial 
cells are connected to each other through tight junction (TJ) proteins and form a one cell layer thick lining that separates the 
bloodstream from brain tissue. Together with astrocytes, pericytes, neurons, and extracellular matrix (basal lamina), 
endothelial cells constitute a functional unit, which is often referred to as “neurovascular unit” [19]. Figure from Abbott et al. 
(2010) [10]. 
 
Tight junctions and adherens junctions  
TJ proteins along with AJ proteins are responsible for the tight sealing of cerebral endothelial cells 
(Figure 2). AJ complexes are composed of the transmembrane proteins VE-cadherin and of the 
cytoplasmic scaffolding proteins α-, β-, and γ-catenin [6]. Cadherins are crucial for the mutual 
attachment of endothelial cells, and are required for the formation of TJs [17]. TJs, also called zonulae 
occludentes, are composed of the transmembrane proteins occludin, claudin-3, and claudin-5 [17]. In 
the intercellular cleft, they interact mutually with respective proteins from neighbouring cells, hence 
enabling a tight cellular attachment. Occludin and claudins are anchored in the endothelial cytosol 
with the scaffolding and regulatory zonula occludens proteins 1 to 3 (ZO-1, ZO-2, and ZO-3). ZO 
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 proteins are in turn associated via cingulin, a 140 kDa protein localized in the cytoplasmic region of 
TJs [20], to the actin cytoskeleton of the cells. TJs in the human brain are denser than TJs in the 
peripheral vessels and rigorously restrict the paracellular diffusion of small polar molecules. 
Additionally, they act as a lateral fence and segregate transport proteins, efflux pumps, and lipid rafts, 
which enables a polarization of the endothelium [10]. Further proteins involved in cell-to-cell 
attachment are the junction-associated molecules (JAMs), and their expression affects TJ formation 
and function. JAMs belong to the immunoglobulin superfamily, and are believed to enable cell-
adhesion of leukocytes to the endothelial cells [21]. 
 
 
 
Figure 2: Brain microvascular endothelial cells are connected to each other through tight junctions (TJs), adherens junctions 
(AJs), and junction-associated molecules (JAMs). Figure from Abbott et al. (2010) [10]. 
 
Transport proteins at the BBB  
At the luminal and abluminal sides of the plasma membranes of brain microvascular endothelial cells, 
various transmembrane proteins are expressed which mediate the transport of substances across the 
BBB [10,22,23]. These proteins may be expressed predominantly at only one side of the plasma 
membrane (either luminal or abluminal), resulting in polarized endothelial cells, and leading to 
preferential transport of compounds across the BBB in either a blood-to-brain or brain-to-blood 
direction [10,24]. Transporter proteins can be categorized into efflux pumps (belonging to the ATP-
binding cassette (ABC) superfamily) and uptake transporters (belonging to the solute carrier (SLC) 
superfamily). Efflux pumps (ABC transporters) that are expressed in the luminal membrane of brain 
capillary endothelial cells, such as P-glycoprotein (P-gp), breast cancer resistance protein (BCRP), 
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 multidrug resistance-associated proteins (MRP)-1, MRP-4, and MRP-5, transport substrate molecules 
from the endothelial cytosol back into the blood, and thus reduce brain exposure to drugs and toxicants 
[24]. Uptake transporters that are expressed in the luminal and abluminal membranes at the BBB, such 
as the organic anion transporter 3 (OAT3), mediate the uptake of various polar substances from the 
blood into the brain, thus providing the CNS with essential nutrients such as glucose, amino acids, 
nucleosides, and endogenous hormones [22–24]. In summary, all transport systems including ABC 
and SLC transport proteins work closely together to protect and support the brain [22]. 
 
Characteristics of the BBB 
Brain capillaries show several unique features which distinguish them from blood vessels in the 
periphery. Cerebral capillary endothelial cells 1) form blood vessels which are tighter than anywhere 
else in the human body (due to the presence of denser TJs in the brain than in the periphery); 2) show 
a lower pinocytotic activity than other endothelial cells, resulting in reduced transcellular flux; 3) do 
not show wall fenestration, resulting in reduced paracellular flux [11]; 4) dispose of specialized 
transport systems across the endothelium [10,23]; and 5) have a higher mitochondrial content and high 
abundance of cytoplasmic enzymes such as cytochrome CYP3A4, indicating high metabolic activity 
[18,25]. All these characteristics lead to a unique physical barrier (tight vessels, low pinocytotic 
activity, no fenestration), transport barrier (efflux pumps and uptake proteins), and 
metabolic/enzymatic barrier (mitochondria and enzymes) [17]. 
 
Routes of transport across the BBB 
There are various different transport routes of a substance across the BBB (Figure 3) [17]. Non-polar, 
lipid soluble substances may enter the brain by passive diffusion through the endothelial cell layer 
(Figure 3b). Some of the passively diffusing compounds, however, may be substrates of P-gp and/or 
BCRP or other efflux pumps, and may hence be pumped back into the bloodstream (Figure 3c). Polar 
and water soluble compounds are normally not able to cross the BBB (Figure 3a), unless these 
substances are substrates of uptake proteins (SLC transporters) that actively transport them from the 
bloodstream into the brain. Macromolecules may enter the central nervous system (CNS) via 
transcytosis, a process involving vesicles which transport their content across the endothelial cells. In 
receptor-mediated transcytosis, peptides and proteins bind to a specific receptor, whereupon 
internalization of ligand and receptor into the cell is initiated (Figure 3d). In adsorptive transcytosis, 
positively charged macromolecules adsorb to the cell surface in a non-specific manner, triggering 
endocytosis followed by transcytosis (Figure 3e). Cells such as leukocytes, monocytes, and 
macrophages may enter the CNS by diapedesis across the endothelial cell layer or, paracellularly, 
through altered TJs [10]. 
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Figure 3: Routes of transport across the BBB. (a) Water soluble and polar substances may normally overcome a cellular 
barrier via the paracellular pathway. However, this route is greatly restricted at the BBB due to the presence of dense TJs. (b) 
Small lipophilic compounds may enter the brain by transcellular diffusion through the endothelial cells. (c) Lipophilic 
compounds that enter the endothelial cells by diffusion may be substrates of efflux pumps, and may hence be transported 
back into the bloodstream. On the other hand, small polar compounds (e.g. glucose, amino acids, and nucleosides) may be 
transported from the bloodstream into the endothelial cells via uptake transporters. Peptides and proteins may reach the brain 
via (d) receptor-mediated transcytosis or via (e) adsorptive transcytosis. Figure from Abbott et al. (2006) [17]. 
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 Functions of the BBB 
The BBB serves several purposes: 1) it enables brain homeostasis for optimal neuronal signaling by 
protecting brain interstitial fluid (ISF) from ion fluctuations in the blood that may occur after meal or 
exercise (compared to blood plasma, brain ISF has a lower content of proteins, lower concentrations of 
K
+
 and Ca
2+
, but a higher concentration of Mg
+
); 2) it prevents toxic endogenous metabolites, 
xenobiotics, and bacteria from entering the brain and, hence, causing damage to the nerve tissue; 3) it 
mediates efflux of waste products from the brain back into the bloodstream; 4) it supplies the brain 
with essential nutrients; 5) it separates the pools of neurotransmitters in the CNS and neuroactive 
agents in the periphery, enabling them to act in the two different compartments without interfering 
with each other. Taken together, the BBB enables, regulates, and maintains an appropriate 
microenvironment in the brain that is required for optimal CNS activity [17,24,26]. 
 
2.1.3 Other barriers in the central nervous system (CNS) 
In addition to the BBB, further cellular barriers in the human brain exist, namely the blood-CSF 
barrier (BCSFB), the arachnoid barrier, the fetal CSF-brain barrier, and the blood-spinal cord barrier 
(BSCB) (Figure 4). The BCSFB is located at the choroid plexus in the four ventricles of the human 
brain and is formed by specialized epithelial cells (Figure 4b). These epithelial cells produce and 
secret CSF into the ventricles and build a physical barrier between intraventricular CSF and blood due 
to the presence of TJs between adjacent cells. Hence, paracellular diffusion of polar compounds from 
the blood directly into the CSF is reduced. In contrast to the BBB, the microvasculature underlying the 
epithelial choroid plexus cells shows fenestration, and is not the barrier itself. The BCSFB is thus a 
barrier built up by epithelial cells, and not by endothelial cells. At the brain-facing surface of the 
ventricles, neuroependymal cells form a functional barrier which separates CSF from brain 
parenchyma (Figure 4d). However, this barrier is only present in the embryo [3]. In the adult brain, the 
barrier function of the neuroependymal cells is lost, and free diffusion of molecules from one brain 
compartment to the other is possible (Figure 4e). A further barrier in the human brain is formed by the 
arachnoid membrane, which is a multi-layered epithelium completely enclosing the brain (Figure 4c) 
[10]. This barrier separates blood and subarachnoid CSF [17]. At last, a barrier between the blood and 
the spinal cord (BSCB) exists, which provides a specialized microenvironment for the cells 
constituting the spinal cord [27]. Similarly to the BBB, the BSCB is composed of nonfenestrated 
endothelial cells tightly sealed by TJ proteins [27,28]. 
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Figure 4: Cellular barriers in the human brain. (a) Blood-brain barrier (BBB). (b) Blood-CSF barrier (BCSFB). (c) 
Arachnoid barrier. PIA: pia mater, innermost layer of the meninges. SAS: CSF-filled subarachnoid space. (d) Fetal CSF-
brain barrier, formed by neuroependymal cells separating CSF and brain parenchyma. This barrier is only present in the 
embryo. (e) In the adult brain, the barrier function of the neuroependymal cells on the brain-facing surface of the ventricles is 
lost, and free exchange of molecules from brain tissue into CSF is enabled. Figure from Neuwelt et al. (2011) [29].  
 
2.1.4 Importance of the BBB for drug delivery to the brain 
In order to elicit pharmacological effects at their target sites, CNS drugs need to penetrate the brain by 
permeating the barriers that separate the brain tissue from the bloodstream. Even though the BBB is 
not the only restrictive barrier in the human brain, it is by far the most important cerebral barrier from 
a pharmaceutical point of view. With a total surface area of 20 m
2 
[12], the BBB disposes of the 
largest surface area for the exchange of substances from blood to brain [10]. Furthermore, each brain 
cell is very close to a brain vessel (separated by a distance of not more than approx. 25 µm), and 
practically every neuron is supplied by its own capillary [30]. Diffusion paths of drug molecules from 
endothelial cells to brain cells are thus short [10], which is particularly favorable for drug candidates 
targeting these cells. Intracerebroventricular (ICV) administration of drugs may be an alternative route 
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 of drug delivery to the brain. ICV injected drugs, however, need to diffuse from the CSF 
compartments into brain tissue in order to reach their targets (e.g. neurons). In principle, this is 
possible, as the CSF-brain barrier in adults has lost its barrier function and free exchange of molecules 
from CSF into brain tissue is enabled (Figure 3e). However, this diffusion process is greatly 
counteracted by the CSF bulk flow from the ventricles through the subarachnoid space into the 
arachnoid villi [31]. Drugs administered ICV are, therefore, transported relatively rapidly out of the 
brain into the blood. Delivering drugs to the brain cells via the BBB remains thus the favored route of 
drug delivery to the brain [10].  
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 2.2 CNS drug discovery 
 
2.2.1 The burden of CNS disorders 
Disorders of the CNS encompass an enormous diversity of psychiatric and neurological diseases. They 
are highly prevalent at all levels of society and represent an immense worldwide burden in many 
aspects [1]. Depression and schizophrenia, for instance, have been ranked by the World Health 
Organization (WHO) among the top ten leading causes for disability in males and females in the 
Global Burden of Disease report of 2008 [2]. Moreover, economical costs of brain diseases have been 
valued at nearly 800 billion US$ per year in the United States [1,3]. Due to the remarkable increase of 
the human life expectancy in the past century, CNS disorders that are associated with ageing (e.g. 
Alzheimer’s and Parkinson’s disease, brain cancer, stroke) are estimated to cause a financial burden of 
trillions of US dollars in the future [4,5]. Yet, the treatment of neuropsychiatric illnesses has so far 
remained relatively limited, and only a handful of new drugs with novel mechanisms of action has 
been approved in recent years [6]. New therapies that are more effective, act faster, and show fewer 
side effects for the treatment of CNS disorders are thus urgently needed [7]. 
 
2.2.2 Challenges in CNS drug discovery 
Discovering and developing drugs is a long and expensive process. On average, it costs a 
pharmaceutical company 10–12 years and over 2 billion US$ to bring a single new drug to the market. 
For drugs targeting the CNS, this process has been estimated to be even more time-consuming (lasting 
up to 16 years) and costly, with the risk of failure being higher than in any other therapeutic area 
[5,8,9]. While on average 11% of drugs that enter clinical development reach the US market, only  
3–5% of CNS drugs are eventually successful [6,10]. Reasons for this low success rate of 
neurotherapeutic drugs are manifold, but may be related, to a large extent, to the intricate anatomy and 
physiology of the human brain [11].  
The human brain is one of the most complex organs of the human body. Despite tremendous 
advancements in diagnosing and treating CNS disorders in recent years, we still lack considerable 
knowledge about their etiology and underlying pathophysiology [3,11]. Identification of the right 
molecular targets in CNS drug discovery thus represents a major challenge [12]. With the successful 
sequencing of the human genome more than 10 years ago, a breakthrough was expected in this area 
[8,13]. It was anticipated that specific disease-associated genetic targets could be identified, 
facilitating the discovery of improved and more selective CNS drugs. However, neuropsychiatric 
diseases have shown to be linked to a large number of genes at the same time. For schizophrenia for 
instance, over 30 disease-associated genes have been identified, yet none of these has proven to be a 
34
 viable and specific drug target to date [13]. On the other hand, various genetic polymorphisms have 
been found to occur in several CNS disorders simultaneously, which drastically limits their 
attractiveness as selective biological targets [13]. 
Another persisting difficulty in CNS drug development is the lack of valid preclinical models. 
Experience has shown that animal models for neuropsychiatric disorders are mostly not able to 
correctly predict human efficacy [10]. While laboratory animals may certainly model various disease 
features and mechanisms, they are not able to model the disease itself [10].  
Furthermore, clinical trials evaluating CNS drug efficacy are notoriously difficult to perform [14]. 
Obtaining sufficient numbers of study participants in the recruitment phase is challenging, and patient 
selection is problematic due the heterogeneity of brain illnesses coupled with relatively poor diagnosis 
techniques. Schizophrenia and depression, for example, are up to date still defined mainly by the 
patient’s clinical symptoms rather than by pharmacological mechanisms. In clinical studies, where a 
mechanistic drug candidate is administered to patients that were diagnosed based only on symptoms, 
many non-responders may thus be found, concealing a possible positive outcome in a sub-population 
of patients [11]. Further difficulties are associated with the high liability of CNS drugs to cause 
potentially dangerous central side effects (e.g. dizziness and seizures), the frequently observed high 
placebo effect in control groups (particularly in studies of depression and anxiety), and the lack of 
valid biomarkers, resulting in ambiguous clinical endpoints [14]. 
Eventually, achieving adequate drug concentrations in the brain is difficult [15]. CNS drugs need to 
penetrate the brain, a process which is controlled by the BBB. This unique cellular barrier is highly 
restrictive to a wide spectrum of molecules and represents a major hurdle for neurotherapeutic drug 
candidates. In fact, only a minor percentage (2%) of small molecules has been estimated to 
successfully overcome the BBB [16]. Low permeation across the BBB, however, may lead to limited 
brain penetration of a compound and to inadequate concentrations at the target sites, culminating in 
insufficient efficacy [11,15].  
Due to these difficulties, growing regulatory hurdles, and the increasing patient demand for safer, 
more efficacious, and innovative pharmaceuticals, bringing forward effective CNS drugs has proven to 
be one of the most difficult tasks for the pharmaceutical industry today [4,6,11]. This is reflected by 
the recent announcement of several Big Pharma companies such as GlaxoSmithKline (GSK), Astra 
Zeneca, and Pfizer to shut down their research activities within the neuroscience area [17,18]. 
Strategies that might increase the success rate of CNS pharmaceuticals are thus becoming more and 
more important for the future sustainability of neuroscience drug research [6]. 
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 2.2.3 How can the success rate of CNS drugs be improved? 
Improving CNS drug discovery and development is a multi-facetted and difficult task [6]. For 
instance, endeavors should be made to identify novel CNS targets and disease pathways. Also, for 
each CNS disease, targeting multiple molecular targets and pathways may be of advantage due to the 
inherent complexity of neuropsychiatric illnesses [6]. Moreover, it is recommended to evaluate large 
numbers of structurally diverse compounds to have back-up lead candidates if compound-specific 
toxicity is encountered [6]. In order to avoid that a drug that has shown efficacy in animals fails later 
on in humans, efforts to develop better and more predictive preclinical models are urgently needed. 
Regarding clinical trials, pharmacogenetics might contribute to the identification and selection of 
study population groups that most likely respond to the administered drug. Furthermore, there is a 
need to develop valid biomarkers that indicate the presence, stage, and progression of the disease, 
which would enable more precise and concrete endpoints in clinical trials [14]. Finally, adequate 
exposure of the neurotherapeutic agent to the target within the CNS should be assessed, which 
includes the assessment of BBB permeability of drug candidates at an early stage of drug development 
[6]. Since there is no generally satisfying model for this purpose available today, there is an urgent 
need for better and valid in vitro BBB models which are amenable to the screening of compounds in a 
medium to high throughput manner. 
 
2.2.4 CNS drug discovery and natural products 
Natural products have played a significant role in the discovery process of new drugs since a long 
time. This is clearly reflected in the study by Newman and Cragg, in which 34% of all small molecule 
drugs that were approved by regulatory authorities from 1981 to 2010 were identified either as pure 
natural products (6%) or as natural product-derived substances (28%) [19]. Another 30% of the 
approved therapeutic agents were identified as “natural product mimics” (i.e. designed based on the 
information gained from a natural product) or as compounds that contain a pharmacophore from a 
natural product [19]. The main therapeutic areas where a large number of potent drugs have been 
developed from natural sources are infectious diseases and oncology [19]. However, also in the area of 
CNS diseases, several potent drugs have been discovered and developed from natural sources (Table 
1) and various promising lead candidates are currently being tested in clinical trials [20]. 
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 Table 1: Selection of marketed CNS drugs originating from natural sources [20–24]. 
Drug  
(trade name) 
Classifi-
cation 
Lead 
compound 
Natural 
source 
Year 
introduced 
Mechanism Indication 
Morphine NP - 
Papaver 
somniferum 
Early 1800s 
Opioid µ-receptor 
agonism 
Pain 
Acetylsalicylic 
acid (Aspirin) 
NP 
derivative 
Salicylic acid Salix species 1899 COX inhibition Pain 
Dihydro-
ergotamine 
(Dihydergot) 
NP 
derivative 
Ergotamine 
Claviceps 
species 
1946 
Serotonin receptor 
agonism 
Migraine and 
cluster headache 
Bromocriptin 
(Parlodel) 
NP 
derivative 
Ergot alkaloids 
Claviceps 
species 
1975 
Dopamine receptor 
agonism 
Hyperprolactinemia, 
Parkinson’s disease 
Rivastigmine 
(Exelon) 
NP 
analog 
Physostigmine 
Physostigma 
venenosum 
1997 AChE inhibition Alzheimer’s disease 
Galanthamine 
(Reminyl)  
NP - 
Galanthus 
nivalis 
2001 AChE inhibition Alzheimer’s disease 
Ziconotid 
(Prialt) 
Synthetic 
form of 
NP 
ω-Conotoxin 
(peptide) 
Conus 
magnus 
2005 
N-type voltage-
sensitive calcium 
channel blocking 
Severe chronic pain 
Fingolimod 
(Gilenya) 
NP 
analog 
Myriocin 
Isaria 
singclairii  
2010 
Sphingosine 1-
phosphate receptor 
modulation 
Multiple sclerosis 
NP: natural product; AChE: acetylcholinesterase; COX: cyclooxygenase 
 
Despite the undisputed success of pharmaceuticals originating from natural sources, pharmaceutical 
companies have largely reduced or even stopped their research activities in the natural products sector 
in the past decades and have shifted to more synthetic approaches [25]. Novel techniques such as 
combinatorial chemistry and high-throughput screening in the early 1990s have enabled the 
establishment of large synthetic compound libraries and the fast identification of synthetic lead 
molecules against biological targets. With the rapid turnaround of high-throughput-based discovery 
programs however, the classical and rather slow approach of natural product-based drug discovery 
could initially not keep up and received less and less attention [26,27].  
Finding lead candidates from nature is linked to a variety of challenges. Secured access and supply of 
the natural source may, for example, be problematic and can be severely hampered by intellectual 
property issues [25]. Even if supply of the source is warranted, crude extracts are in the majority of the 
cases highly complex mixtures and may contain the biologically active compound only in extremely 
small amounts, which may complicate the supply of the drug candidate for preclinical and clinical 
studies if total synthesis is not feasible [25,28]. When plant extracts or fractions are subjected to high- 
throughput screening, several constituents may exert synergistic or antagonistic effects at the 
biological target (which may be lost upon separation of the compounds), and stability and solubility 
issues of the bioactive compound in the extract or solvent may be encountered [25]. Additionally, 
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 bioactive natural products are likely to be highly complex in their structure, which may decelerate the 
identification and structure elucidation process [25]. 
Interestingly, despite considerable efforts and investments, the economic output of the synthetic 
approach to find new lead candidates has remained relatively modest to date [29]. This may be 
attributable to the fact that natural products are much more complex and diverse in their molecular 
structure compared to synthetic compounds, and often exhibit highly selective biological activities 
[30]. Furthermore, since natural products are natural metabolites, they are more likely to be the 
substrates of carrier proteins that can transport the compounds to an intracellular therapeutic target 
[26]. These assets of natural compounds, together with remarkable technological improvements, have 
contributed to the recent revived interest in drug discovery from natural sources [26]. Notably, only 
few higher plants (6% of the approximately 300’000 known species) and microorganisms, and hardly 
any marine sources, have been investigated pharmacologically [30]. Nature is therefore expected to 
retain a vast unexplored potential of compound diversity, and natural products are believed to continue 
being a valuable direct and indirect source in the discovery of pharmaceuticals for the treatment of 
human illnesses. 
 
2.2.5 GABAA receptors – example of an important pharmacological target in 
the CNS 
The γ-aminobutyric acid type A (GABAA) receptors are ligand-gated ion channels in the membrane of 
neurons that mediate most fast synaptic inhibition in the CNS [31,32]. They are composed of five 
protein subunits of different classes forming a central pore selective for chloride ions [33,34]. Upon 
activation by the endogenous neurotransmitter GABA, the ion channels open, leading to an increased 
anion influx into the neuronal cell. This causes a hyperpolarization of the cell membrane and 
inhibition of neuronal activity [31]. Depending on their subunit composition, GABAA receptors 
exhibit distinct physiological and pharmacological properties [32].  
Compounds that positively modulate GABAA receptors, such as the benzodiazepines, are currently 
used to treat a large variety of CNS diseases including anxiety, panic disorders, sleep disturbances, 
depression, and epilepsy [35]. However, these drugs lack GABAA receptor subtype selectivity, and 
induce thus clinically relevant side effects such as amnesia, unwanted sedation, and drug dependence, 
complicating their long-term application [35]. Hence, there is a high medical need for novel 
compounds that selectively interact with GABAA receptor subtypes and thus exhibit a lower adverse 
effect profile. Interestingly, various promising natural product derived lead candidates with selective 
GABAA receptor modulatory activity have been identified in recent years [36–39]. These compounds 
will need to be further evaluated in terms of their pharmacokinetic and toxicokinetic profile and, 
importantly, regarding their ability to permeate the BBB. 
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 2.3 Models to predict brain penetration 
 
2.3.1 Brain penetration of drugs 
Brain penetration of drugs has two fundamental components: 1) rate (at the initial state), and 2) extent 
(at steady state) (Figure 5) [1]. The rate of brain penetration depends on the permeability of the 
compounds across the BBB (by passive diffusion, active uptake and/or efflux). The extent of brain 
penetration is determined by the distribution of the drug between brain and plasma, and is affected by 
multiple factors including metabolic clearance, plasma protein binding, non-specific binding to brain 
tissue, and drug clearance from brain ISF into CSF [2]. Models to assess CNS penetration have 
typically been designed to measure either one of these two components (rate or extent).  
 
 
 
Figure 5: CNS penetration of a drug is impacted by the permeation across the BBB (determining the rate of penetration), and 
by the distribution to (and within) the brain (determining the extent of penetration). Figure modified from Reichel A. (2009) 
[3]. 
 
In the past decades, a broad spectrum of in silico, in vitro, and in vivo models providing parameters on 
different aspects of brain penetration has been developed and implemented in academia and industry 
to bring forward molecules with high potential for CNS exposure. In the following sections, several 
important models are discussed in more detail (for extensive reviews, please refer to references [4–7]). 
 
2.3.2 Rule-based approaches and in silico models 
Brain penetration of a molecule is greatly affected by its physicochemical properties such as 
lipophilicity, polar surface area (PSA), molecular weight (MW), hydrogen bonding, and ionization 
state. Researchers have therefore analyzed many data sets of CNS drugs and proposed various 
recommendations in terms of physicochemical properties required for optimal brain penetration. One 
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 of the first set of rules was introduced in 1995 by Pardridge [8]. He stated that BBB permeability of a 
drug is likely if the number of total H-bonds is < 8–10, the MW < 400–600 Da, and if the compound is 
not an acid [8]. Subsequent studies have suggested that BBB permeation is favored if the sum of 
oxygen and nitrogen is ≤ 5, the PSA < 60–70 Å2, the MW < 450 Da, and the LogD (at pH 7.4) 
between 1–3 [9–11].  
Due to the increased need for high throughput methods in drug discovery in the past years, 
computational models to predict rate and extent of brain penetration of drug molecules have become 
increasingly popular. Various software programs have been developed, which are commercially or 
freely available (e.g. B3PP by Martins et al. 2012 [12]). These models are considerably cheaper and 
faster compared to in vitro and in vivo methods, thus offering the great advantage of high screening 
capability at early stages of the drug discovery process. Nevertheless, data obtained by in silico 
experiments must be interpreted with caution, as many factors that affect CNS drug exposure (efflux, 
uptake, plasma protein and brain tissue binding, metabolic clearance etc.) complicate the correct 
modeling of drug brain penetration. 
 
2.3.3 In vitro models 
In vitro models can be subdivided into physicochemical methods and cell-based methods. The latter 
are performed using living cells, and are considered to be closer to the physiological BBB than 
physicochemical methods [13]. Generally, in vitro assays are applicable to medium to high throughput 
screening (depending on the assay set-up), and provide important information on BBB permeability 
(passive diffusion, efflux and/or uptake) and brain distribution at a relatively early stage of drug 
discovery and development.  
 
Physicochemical methods 
PAMPA-BBB (rate): The parallel artificial membrane permeation assay for BBB (PAMPA-BBB) is a 
simple and rapid method to predict passive transcellular diffusion of a compound through the BBB 
(which is mimicked by a porcine brain lipid extract on a solid support). The assay is a modification of 
the original PAMPA method, which was developed by Kansy et al. for intestinal permeability studies 
[14]. Advantages of the assay are its high throughput capability, its reproducibility, and the low 
associated costs. The main drawback of the method, however, is that it only provides information on 
passive BBB permeation of a drug [13].  
 
IAM-HPLC (rate): Immobilized artificial membrane high performance liquid chromatography (IAM-
HPLC) is a further method to predict BBB permeability of a compound [13]. For this technique, a 
HPLC system and a commercially available IAM column (packed with a stationary phase consisting 
of phospholipids bonded to the solid support) are required. By comparing retention times of test 
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 compounds with those of standard drugs, BBB permeation of the former can be estimated. Limitations 
of the method are that prediction of BBB permeability may be poor if brain uptake is affected by 
active transport, plasma protein binding and/or metabolism, and that the approach has proved to be 
unsuitable for medium to high throughput operation [2,6]. 
 
Equilibrium dialysis (extent): Equilibrium dialysis is a high throughput in vitro method to obtain 
information on protein binding in brain homogenate and plasma and, hence, on the free (unbound) 
drug fractions in both matrices. On the one hand, information on free drug fractions in plasma is 
important as only unbound molecules are available to cross the BBB. Thus, if plasma protein binding 
is too high, the extent of brain penetration may be insufficient [15]. However, attention must be paid 
when using in vitro data on plasma protein binding of compounds. It has been shown that bound 
molecules within brain capillaries are able to dissociate more readily than in in vitro models, and thus 
the bioavailable fraction in vivo may be higher than expected [15]. Unbound drug fractions in the 
brain, on the other hand, can be used for the calculation of unbound drug concentrations in the brain, if 
in vivo data on total brain levels are available [16]. Finally, the ratio of free plasma to free brain 
fraction has been suggested as a parameter to predict the in vivo extent of brain distribution [17]. 
 
Cell-based methods 
Isolated brain capillaries (rate): Brain microvessels from human or animal sources have been used 
in BBB research since their successful isolation more than three decades ago [18]. However, they are 
not suitable for in vitro BBB permeability screenings since the luminal side (blood side) of the 
capillaries is hardly accessible [5]. 
 
Cell culture models (rate): Cell-based in vitro BBB methods are used for the determination of the 
permeability of a compound across the BBB. Major advantages of these models are that, depending on 
the selection of cells, information on possible transporter interaction (e.g. P-gp and BCRP) can be 
obtained in addition to data on passive transcellular diffusion. 
Cell culture-based models are primarily carried out in two-chamber vertical diffusion systems 
(branded as “Transwell” systems by Corning Costar®), which consist of commercial well plates and 
corresponding tissue culture inserts (available in the 6, 12, 24, and 96-well format) (Figure 6). Animal 
or human cells are seeded onto the semi-permeable filter membrane at the bottom of the tissue culture 
inserts, where they form a confluent monolayer mimicking the BBB. Usually, the filter membranes are 
coated with collagen or other structural proteins (representing the basal lamina). The test compound is 
introduced into the apical (luminal) compartment (blood side) of the two-chamber system, and the 
velocity of the compound to appear in the basolateral (abluminal) compartment (brain side) by 
diffusion through the cell monolayer is quantified, providing apparent or endothelial permeability 
coefficients (abbreviated as Papp or Pe, respectively, usually in the unit cm/s). To obtain information on 
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 possible transporter interaction of a compound, the permeability experiments can be carried out in the 
reverse direction (from basolateral to apical). The ratio of the basolateral-to-apical to the apical-to-
basolateral permeability (= efflux ratio, ER) reflects the potential of a compound to be transported out 
of or into the brain by efflux or uptake proteins (efflux is assumed if the ER is > 2, uptake if the ER is 
< 0.5) [19,20].  
 
                 
 
Figure 6: In vitro BBB model (24-well format) for the prediction of BBB permeability of a drug. Cells from animal or 
human origin are grown on collagen coated semi-permeable filter membranes of the tissue culture inserts, where they form a 
cell monolayer representing the BBB. Depending on the model, astrocytes and/or pericytes are cultured at the bottom of the 
wells or at the bottom side of the inserts. Test compounds are placed into the apical or basolateral chamber of the Transwell 
system, and their passage to the other compartment is measured over time. Figure by Tabea Gollin (2015). 
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 The first in vitro BBB model using the two-chamber vertical diffusion system was established by 
Bowman et al. in 1983 by using freshly isolated bovine brain endothelial cells [21]. Since then, 
primary cells (i.e. cells directly obtained from living tissue) from porcine, murine, rat, monkey, and 
human origin have been used for the implementation of in vitro BBB models [22]. As mono-culture 
systems (with only endothelial cells) represent extremely simplified models, other brain-derived cells 
being part of the neurovascular unit, such as astrocytes, pericytes, and/or neurons have been 
incorporated into double and triple co-culture in vitro BBB models (Figure 6). Several of these cells 
(in particular astrocytes) have repeatedly been shown to favorably induce barrier tightness of 
endothelial cells [23,24].  
The use of primary cells, however, suffers from various restraints. Isolation and purification 
procedures of the cells are cumbersome and time-consuming, the yield of cells is relatively low, the 
lifespan of cells is limited (rapid de-differentiation and loss of phenotype occur), and animal 
endothelial cells show differences in the expression of uptake proteins and efflux pumps when 
compared to human endothelial cells [25,26]. The use of primary cultures from human origin would 
avoid interspecies pharmacogenetic variation, but the availability of these cells is greatly limited due 
to ethical reasons.  
Therefore, various immortalized cell lines from human and animal origin (Tables 2 and 3) have been 
used to model the BBB in vitro. These cell lines originate either from spontaneous transformation of 
the cells into tumor cells (e.g. ECV304), or were generated by transfection with a tumor gene (e.g. 
SV40 large-T antigen) after their isolation. Unlike primary cells, immortalized cells are easy to 
culture, proliferate indefinitely, and preserve their differentiating properties even after repetitive 
passaging. These properties render them highly suitable for high throughput and standardized 
screenings. Among immortalized cell lines, those originating from human brains are of greatest 
interest. Regrettably, currently available human brain capillary endothelial cell lines (Table 2) often 
show deficiencies (e.g. low transendothelial electrical resistance (TEER) values, relatively high 
paracellular permeation of negative control compounds, insufficient expression of key transporter 
systems). Hence, systematic optimization of culture conditions and careful validation of human cell 
line-based in vitro BBB models are needed. Significant advances in modeling the human BBB in vitro 
have been achieved recently by using endothelial cells derived from human pluripotent and 
hematopoietic stem cells [27,28]. As stem cells offer a high capacity of expansion by self-renewal 
while maintaining a homogenous genetic profile, stem cell-based models are promising, but require 
systematic benchmarking against established in vitro and in vivo models [29]. 
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 Table 2: Immortalized human brain capillary endothelial cell lines for the establishment of in vitro human BBB models. 
Brain capillary 
endothelial cell line 
Transfection method 
Year (first 
publication) 
Reference 
BB19 E6E7 genes of HPV 1996 Prudhomme et al. [30] 
HBEC-5I SV40T 1996 Xiao et al. [31] 
SV-HCEC SV40T 1997 Muruganandam et al. [32] 
hBMEC SV40T 2001 Stins et al. [33] 
hTERT-HBEC hTERT 2003 Gu et al. [34] 
hCMEC/D3 hTERT and SV40T 2005 Weksler et al. [35] 
NKIM-6 E6E7 genes of HPV type 16 2007 Ketabi-Kiyanvash et al. [36] 
TY08 hTERT and temperature-sensitive SV40T 2010 Sano et al. [37] 
TY09 hTERT and temperature-sensitive SV40T 2010 Sano et al. [37] 
HBMEC/ciβ hTERT and temperature-sensitive SV40T 2012 Kamiichi et al. [38] 
TY10 hTERT and temperature-sensitive SV40T 2012 Maeda et al. [39] 
HPV: human papilloma virus; SV40T: simian virus 40 large-T antigen; hTERT: human telomerase reverse transcriptase 
 
 
Table 3: Immortalized animal and non-brain human cell lines used to model the BBB in vitro. 
Cell line Description Origin Remarks 
Caco-2 
Human epithelial colon 
adenocarcinoma cell line  
Human (colon) 
Limited prediction of BBB permeability (poor 
correlation of in vitro Caco-2 and in vivo BBB 
permeability data) [40] 
ECV304 
Human endothelial 
umbilical vein 
(HUVEC) cell line [41]  
Human 
(umbilical cord) 
Non-brain origin, but cells show endothelial features, 
barrier tightness can be increased (up to TEER of 200 
Ωcm2) by co-cultivation with immortalized rat glioma 
cells (C6 cell line) or C6 conditioned medium [6,22]  
LLC-PK1 
Porcine kidney epithelial 
cell line [42] 
Pig (kidney) 
Relatively tight monolayers, cell line can be transfected 
with transporter genes (e.g. MDR1) for efflux studies  
MDCK  
Madin Darby Canine 
Kidney epithelial cell 
line [43] 
Dog (kidney) 
Tight monolayers (high TEER values), assay straight 
forward (3–4 days of culture), but only useful for 
determination of passive permeation (due to low 
expression of transporter proteins) [44,45] 
MDR1-MDCK 
(type I or II) and 
BCRP-MDCK 
MDCK transfected with 
human MDR1 gene (P-
gp) or BCRP 
Dog (kidney) 
Tight monolayers (high TEER values), polarized 
expression of P-gp/BCRP, useful for P-gp/BCRP efflux 
studies (bidirectional transport assays) [46]  
RBE4 
Rat brain capillary 
endothelial cell line [47] 
Rat (brain) 
Leaky monolayers (relatively high permeability to small 
molecules) [47] 
cEND 
Murine immortalized 
brain (cerebral) capillary 
endothelial cell line [48] 
Mouse (brain) 
Relatively tight monolayers depending on cultivation 
protocol (TEER values up to 1000 Ωcm2) [48] 
bEnd3 and bEnd5 
Mouse brain micro-
vascular endothelial cell 
lines [49,50] 
Mouse (brain) 
Leaky monolayers (relatively low TEER values: bEnd3 
40–130 Ωcm2, bEnd5 around 120 Ωcm2) [22,51] 
TEER: transendothelial electrical resistance (reflects barrier tightness); TEER in vivo has been estimated to exceed 1000 
Ωcm2 [52,53]  
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 2.3.4 In vivo models 
In vivo models to assess CNS exposure of drug candidates provide some of the most reliable data 
concerning BBB permeability (rate) and brain distribution (extent) [2]. However, the methods are 
labor-intensive and low throughput, and are therefore mainly applied at later stages of the drug 
development process. Furthermore, in vivo methods are mostly not applicable to humans (with a few 
exceptions such as CSF sampling and receptor occupancy studies). This represents a major challenge, 
as in vivo data on brain penetration from animal models can be confounded due to species differences 
(e.g. in the expression and functional activity of efflux and uptake transporters, in brain lipid 
composition, and rate of CSF production) [54].  
 
In situ brain perfusion (rate): In situ brain perfusion is a generally accepted and reliable method to 
determine BBB permeability of a drug [46]. A catheter is inserted into the common carotid artery of an 
anesthetized animal (rat, mouse, guinea pig, rabbit) and a solution containing the test compound is 
slowly perfused through the brain capillaries [55]. Drug concentrations are quantified in the perfused 
brain hemisphere of the sacrificed animals, and permeability surface area (PS) values, reflecting BBB 
permeability, are calculated [56]. Limitations of the method are that it is costly, labor-intensive, and 
requires surgical skills and expertise [2]. 
 
Total brain-to-plasma ratio (extent): Determination of the total brain-to-plasma ratio (Kp) is the 
most widely implemented in vivo method to obtain data on brain distribution [13]. After animals are 
dosed with a test drug, they are sacrificed at designated time-point(s), and drug concentrations in brain 
homogenate and blood plasma are quantified. Kp values (or logBB = logarithm of Kp) are subsequently 
calculated based on the respective drug concentrations or areas under the curve (AUC) from both 
matrices (Kp = Cbrain/Cplasma or AUCbrain/AUCplasma). Single time-point Kp values are of limited 
reliability, especially if the selected time-point was before the system could reach steady state [2,16]. 
Kp values based on AUC may be more useful, but require more resources in terms of costs, labor, and 
animals [54]. A disadvantage of this method is that Kp values are primarily determined by non-specific 
binding of a substance to brain tissue [57]. Optimizing drug candidates in terms of this parameter may 
thus bring forward only very lipophilic compounds with high non-specific binding to brain tissue, 
resulting in lower free drug concentrations at the target site.  
 
Brain microdialysis (extent): Brain microdialysis is the method of choice to determine the free 
concentration of a compound in brain ISF [16]. A microdialysis probe with a semi-permeable 
membrane at the tip is implanted into a specific brain region of an animal (rat or mouse). Unbound 
molecules in brain ISF below a certain molecular weight freely diffuse through the membrane, and are 
captured in the fluid perfused through the microdialysis probe [58]. The unbound brain concentration 
can then be related to the unbound drug concentration in plasma, providing the parameter Kp,uu 
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 (unbound brain-to-plasma ratio), which has proved to be more predictive than Kp values (total brain-
to-plasma ratios) [3]. Regrettably, brain microdialysis is a technique with several limitations. Local 
brain tissue and the BBB may be damaged during implantation of the microdialysis probe, depending 
on the shape of the probe, surgical procedure, and technical skills. Additionally, problems with 
lipophilic compounds adsorbing to the membrane of the probe may be encountered. Also, due to its 
invasiveness, the method cannot readily be applied to humans [59]. 
 
CSF sampling (extent): CSF sampling is one of the few in vivo methods applicable to humans. 
Various studies have suggested using CSF concentrations to predict free drug concentration in brain 
ISF (as CSF protein levels are very low, and because CSF and brain ISF compartments are separated 
from each other by only a single layer of ependymal cells). However, data interpretation of CSF levels 
is complicated by the fact that molecules may enter the CSF compartment via the BCSFB, a barrier 
that differs in its transport activity from the BBB [60]. Hence, if a drug is subject to active uptake or 
efflux at only one of the two barriers, CSF concentrations will not correctly predict free drug 
concentrations in brain ISF. Further limitations of the method are the high turnover rate of CSF 
(around 6 hours in humans), which requires that CSF sampling is done at very specific time-points, 
and that the CSF compartment is not well-mixed, resulting in varying concentrations depending on the 
site of sample collection [19,54]. 
 
2.3.5 Favorable brain penetration characteristics of CNS drug candidates 
For CNS drugs, a high rate of brain penetration (high BBB permeability) is favorable, in particular for 
diseases requiring rapid onset (e.g. epilepsy, stroke), and for compounds that are rapidly cleared from 
brain ISF into CSF [1]. If permeation of a compound across the BBB is too low, brain penetration may 
be limited [19]. Regarding interactions with transport proteins, CNS drugs should not be substrates of 
P-gp, BCRP, and/or other efflux pumps [19]. Active uptake of a drug, however, may be beneficial, as 
the case of gabapentin has shown (a hydrophilic antiepileptic drug which is actively carried across the 
BBB into the brain by an amino acid transporter) [44,61]. Additionally, high extent of brain 
penetration is advantageous for CNS drugs in order to obtain sufficiently high concentrations in the 
brain. One has to be aware, however, that only unbound molecules are able to interact with the target 
according to the free drug hypothesis. Hence, the free drug concentration at the site of action in the 
brain (and not the total brain concentration) is the critical factor for pharmacological activity [1]. 
Notably, compounds may have a high rate of brain penetration, but a low extent, or vice versa [1]. 
Evaluating both aspects of brain penetration of lead candidates is therefore of great importance, 
especially for molecules targeting the brain, but also for non-CNS drugs. For the latter, low rate and 
extent of brain penetration are beneficial, as this reduces the risk of causing CNS-related side effects. 
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 2.3.6 Strategies for assessing brain penetration of lead candidates 
Given the large variety of established models to predict brain penetration of lead compounds, the 
question arises as to which models should be utilized at which time point in the CNS drug discovery 
and development process. Generally, costs increase and throughput decreases with more complex 
models [13]. It is therefore recommended to initially utilize high to medium throughput models (in 
silico and in vitro methods) to screen larger numbers of compounds. A selected series of compounds 
showing favorable in vitro data may then be advanced to more sophisticated studies for assessment of 
in vivo brain exposure.  
Since brain penetration can be differentiated into rate and extent, several complementary in vitro and 
in vivo parameters should be combined, taking into account that CNS exposure is affected by multiple 
factors [1]. Additionally, efforts should be made to measure pharmacologically relevant free drug 
concentrations at the target site and not total brain concentrations, given that the use of Kp values (total 
brain-to-plasma ratios) to evaluate brain distribution of a compound can be misleading [54]. Also, one 
has to recognize that the brain can be divided into several compartments (brain ISF, intracellular fluid, 
and CSF compartment), and that concentrations in one compartment (e.g. CSF) may not necessarily be 
predictive for drug concentrations in another compartment (e.g. brain ISF). Eventually, one has to be 
aware that species differences may confound in vivo data of brain exposure, and that various disease 
conditions (e.g. epilepsy and multiple sclerosis) can modify BBB permeability [54]. 
In an industrial setting, the following in vitro assays are currently being used: PAMPA-BBB (rate, 
passive diffusion), Transwell assays with MDR1-MDCK cells or Caco-2 cells (rate, passive diffusion, 
and P-gp efflux), and equilibrium dialysis (extent) [1]. At an early stage of the drug development 
process, it would be of great advantage to increasingly utilize humanized models (e.g. Transwell 
assays with immortalized brain capillary endothelial cells of human origin) to minimize brain 
penetration data confounded by species differences. Regrettably, no generally satisfying human model 
is yet available. Regarding in vivo methods, brain perfusion (rate) and determination of brain-to-
plasma ratio (extent) are frequently applied. Importantly, data from the latter experiment should be 
combined with data from in vitro equilibrium dialysis, in order to obtain unbound drug concentrations 
in the brain. 
Despite the rather large diversity of different models, assessment of brain penetration has remained a 
challenge due to the many limitations of in vitro and in vivo approaches. Nevertheless, past failures of 
CNS drug candidates in clinical trials strongly suggest that an early application of in vitro and in vivo 
models will improve the translation from animals into humans, and the clinical success of a compound 
[29].  
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 2.4 Bioanalysis 
 
2.4.1 Definition 
Bioanalysis is a section of analytical chemistry focusing on the qualitative and quantitative 
determination of drugs, metabolites, and biomarkers in biological matrices such as blood, plasma, 
serum, CSF, urine, saliva, and tissue [1,2]. Detection and quantification of analytes in these matrices 
find application in the entire drug discovery and development process, ranging from in vitro testing to 
preclinical and clinical studies (e.g. bioavailability, bioequivalence, pharmacokinetic, and 
toxicokinetic studies), and in daily clinical routine [1,3–5].  
 
2.4.2 Bioanalytical techniques 
For qualitative and quantitative analysis of compounds in biological matrices, various techniques are 
employed. These include chromatography-based methods such as liquid chromatography (LC) and gas 
chromatography (GC) coupled to specific detectors (spectrophotometric, fluorescence, mass 
spectrometry (MS) detectors), and ligand-binding assays such as enzyme-linked immunosorbent 
assays (ELISA) and radio-immunoassays (RIA). 
ELISA and RIA have been widely used in bioanalysis since their invention more than 40 years ago 
[6,7]. They both offer high sensitivity (analyte concentrations in the picogram range can be 
determined), are relatively easy to perform, and can be automated [8]. However, major drawbacks are 
the requirement of expensive analyte-specific antibodies and the occurrence of cross-reactions, which 
may lead to false positive outcomes. Moreover, RIA are hazardous to human health and produce 
radioactive waste. An alternative to ligand-binding assays are chromatography-based methods. For a 
long time, quantification was carried out using LC hyphenated to spectrophotometric detection such as 
ultraviolet/visible (UV/Vis) absorbance or, occasionally, fluorescence [9]. Both techniques are 
relatively robust, but require analytes that contain a chromophore or fluorophore, respectively. While 
fluorescence offers high sensitivity and specificity, UV/Vis absorbance generally does not [9]. 
Therefore, careful sample clean-up procedures and relatively long run times for reduction of 
interferences from co-eluting compounds may be necessary [9]. A considerably more sensitive 
technique than LC-UV/Vis is GC-MS. For this method, spectral libraries of compounds are available 
which facilitate the detection of known drugs, for example, in toxicological laboratories [8]. However, 
analytes for GC-MS analysis need to be sufficiently volatile and thermally stable, which is not the case 
for many drugs, endogenous metabolites, and biomolecules [10]. 
In the 1980s, the hyphenation of LC with MS became feasible with the introduction of atmospheric 
pressure ionization (API) interfaces [11,12]. Since then, LC-MS has gradually superseded any other 
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 bioanalytical technique and has become the method-of-choice in bioanalysis of small drugs [13,14]. 
For most applications, a specific type of mass spectrometer is selected, namely the triple quadrupole 
mass analyzer (MS/MS) [15,16]. LC coupled to this detector (LC-MS/MS) is a highly sensitive, 
selective, and robust technique, and thus ideally suited for the determination of an analyte in a 
complex biological matrix. By using ultra-high performance liquid chromatography (UHPLC), run 
times of less than one minute can be achieved, resulting in increased speed required for higher 
throughput. A limitation of triple quadrupole mass spectrometers is that no full scan data can be 
collected when the instrument is operated in selected reaction monitoring (SRM) mode (the preferred 
mode in quantitative drug bioanalyis). Therefore, high-resolution mass analyzers (using either time-of-
flight (TOF) or Orbitrap technology) that are able to simultaneously provide qualitative and 
quantitative analyses in the same LC run have increasingly been used in recent years [17]. However, 
LC coupled to high-resolution MS has not yet been widely accepted in bioanalytical laboratories, and 
international guidelines for method validation still remain to be elaborated by regulatory agencies [18].  
Currently, LC-MS is the method-of-choice in particular for the analysis of small molecules (MW 
below 800 Da) [13]. For the quantification of therapeutic peptides, proteins, oligonucleotides, and 
biomarkers, on the other hand, ligand-binding assays are still mostly employed [13]. Yet, there seems 
to be a trend in recent years towards the use of LC-MS also in the analysis of larger molecules due to 
higher selectivity, wider linearity range, and faster method development for this technique compared 
to conventional ligand-binding assays [13,19]. 
 
2.4.3 Liquid chromatography coupled to triple quadrupole mass spectrometry 
(LC-MS/MS) 
LC-MS/MS is the joining of two techniques: LC (for the separation of a complex mixture between two 
immiscible phases based on the physicochemical properties of the constituents) and triple (or tandem) 
quadrupole MS (for selective and sensitive detection of analytes). As LC system, HPLC or UHPLC 
can be selected (the acronym UPLC may also be used, but is strictly speaking a trademark of the 
manufacturer Waters Corp.). UHPLC instruments are able to operate at higher back-pressure than 
conventional HPLC systems, allowing the use of shorter columns with smaller particles as stationary 
phase [20,21]. This results in an enhancement of chromatographic performance (efficiency) and speed, 
which are major advantages for routine bioanalysis where high throughput of samples is required [21].  
LC systems are predominantly coupled to triple quadrupole detectors via electrospray ionization (ESI) 
or atmospheric pressure chemical ionization (APCI) interfaces [16]. ESI and APCI are both soft 
ionization techniques, by which the analytes eluting from the LC column are ionized to positively 
(M+H
+
) or negatively (M-H
-
) charged ions which are transferred into gas phase, and finally introduced 
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 into the MS detector [22]. While ESI sources are capable of ionizing almost any polar molecule, APCI 
sources are more suited for ionization of less polar and non-polar compounds [22].  
Triple quadrupole mass spectrometers consist of three quadrupoles connected in series (Figure 7) 
[15,23]. A quadrupole typically consists of four molybdenum rods on which alternating DC (direct 
current) and RF (radio frequency) voltages are applied [23]. At a particular DC/RF ratio, only ions 
with a certain m/z value have a stable trajectory and are able to pass through the quadrupole [23]. In 
quantitative bioanalysis, triple quadrupole detectors are primarily operated in SRM mode. In this 
mode, the first (Q1) and third (Q3) quadrupole act as selective mass filters, while the second 
quadrupole (Q2), located between Q1 and Q3, serves as collision cell (RF voltage applied only) 
(Figure 7) [24]. Thus, only selected precursor ions with specific m/z values are allowed to pass through 
Q1. They subsequently collide in the collision cell (Q2) with inert gas (argon or nitrogen) and are 
fragmented into numerous product ions, a process called collision induced fragmentation (CID) [15]. 
Only selected product ions with certain m/z values are allowed to pass through Q3 and are finally 
detected typically by some type of electron multiplier (Figure 7) [25]. SRM mode offers highest 
selectivity and sensitivity, and ensures that only analytes of interest are being quantified, while 
interfering compounds such as matrix constituents are not detected. 
 
 
 
Figure 7: Schematic representation of a triple quadrupole mass detector. Figure from Ni et al. (2012) [26]. 
 
2.4.4 Sample preparation for LC-MS/MS 
Biological matrices are extremely complex and contain a wide spectrum of cell components such as 
proteins, lipids, salts, and other endogenous substances. These components may interfere with the 
bioanalytical assay, and may thus lead to erroneous results and higher variation from sample to sample 
[27,28]. Therefore, a clean-up procedure (i.e. sample preparation) is necessary to obtain samples free 
from matrix components before sample analysis [27]. If done efficiently, sample preparation enhances 
selectivity and sensitivity of the LC-MS/MS methods, leads to higher reproducibility of data, and 
increases lifetime of LC column and instrumentation. In addition to purification from interfering 
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 substances, main objectives of the clean-up procedure are the concentration of the analyte to improve 
detection limits, and dissolution of the analyte in a suitable solvent for instrumental analysis [27,29]. 
The most commonly used sample preparation procedures are dilution, protein precipitation (PP), 
liquid-liquid extraction (LLE), and solid-phase extraction (SPE) [1]. Besides these methods, newer 
techniques such as supported-liquid extraction (SLE) have emerged recently [30].  
 
Dilution: Dilution of samples is a rapid clean-up procedure, during which biological samples (such as 
urine) are simply diluted with water or mobile phase solution prior to injection into the LC-MS (hence 
often referred to as “dilute-and-shoot” method) [8]. While this type of sample preparation is simple 
and time-efficient, its disadvantages are the missing step of removing interfering compounds and the 
lack of an analyte pre-concentration step, which may lead to insufficient selectivity and/or sensitivity 
[8].  
 
Protein precipitation (PP): Protein precipitation (PP) is an efficient sample preparation technique by 
which proteins in the biological matrix are denatured by the use of a strong acid/base (resulting in a 
change of pH), by the application of heat, or by the addition of organic solvents such as methanol or 
acetonitrile [1,30]. During the denaturation process, proteins undergo a change in their tertiary and 
secondary structure, and analytes become thus freely soluble in the denaturing solvent. After 
centrifugation of samples, the denatured proteins form a pellet at the bottom of the tube, while the 
analytes are dissolved in the supernatant. After evaporation of the supernatant to dryness, and 
subsequent reconstitution in mobile phase or injection solvent, the sample is ready for LC-MS/MS 
analysis [27]. PP is simple, fast, and inexpensive, but results in samples which are less clean compared 
to samples obtained by LLE, SLE, or SPE [25].  
 
Liquid-liquid extraction (LLE): The principle of liquid-liquid extraction (LLE) is based on the 
different solubility and partitioning equilibrium of a compound between an aqueous and an organic 
phase. Analytes are extracted from the original sample (aqueous phase) into an organic phase (e.g. 
ethyl acetate, methyl tert-butyl ether (MTBE), methylene chloride, hexane) which is immiscible with 
the water phase [20]. Small lipophilic drugs are easily extracted from the aqueous biological sample, 
while larger polar molecules (e.g. matrix components) remain in the water phase and are thus 
separated from the analyte. The LLE technique results in cleaner samples than PP, but it has a number 
of disadvantages: the extraction of hydrophilic analytes is limited, recoveries may be variable, and 
relatively large biological sample volumes are needed [1].  
 
Solid-phase extraction (SPE): In solid-phase extraction (SPE), analytes are separated from the 
biological matrix by means of a solid (stationary) phase. The principle of this technique is based on the 
same separation principle as LC, where different affinities of substances towards a stationary phase are 
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 exploited [27]. Biological samples are loaded onto a SPE cartridge filled with a stationary phase, 
where analytes are retained, but matrix constituents not. After a washing process, analytes are eluted 
using an appropriate elution solvent. As stationary phases, similar materials as in LC are being used, 
and both reverse and normal phase cartridges are commercially available. SPE is an efficient method 
which leads to relatively clean samples, but costs of this technique are considerably higher compared 
to PP and LLE.  
 
Supported-liquid extraction (SLE): Supported-liquid extraction (SLE) has been developed in recent 
years by various manufacturers and is performed by using commercial 96-well plates (e.g. Isolute
®
 
SLE+ from Biotage) [31]. Each well is packed with a modified form of diatomaceous earth with a high 
capacity for retaining aqueous samples [30]. When a biological sample is loaded onto a well, the 
aqueous portion of the sample adsorbs as a thin film to the hydrophilic surface of the packing material 
(also called “support”), and analytes can subsequently be eluted by applying an appropriate eluent 
[31]. SLE results in clean extracts and offers high recovery and reproducibility, but is more expensive 
than PP and LLE [31].  
 
2.4.5 Quantitative bioanalysis by LC-MS/MS 
The ultimate goal of quantitative bioanalysis by LC-MS/MS is the determination of accurate drug 
concentrations in biological fluids or tissues. This process is difficult and challenging, as analyte 
concentrations are usually low and matrices are highly complex [32]. Erroneous results, however, may 
lead to wrong interpretation of findings, and may culminate, for example, in an inappropriate dosing of 
patients in the clinics with possibly fatal outcomes. Every effort should, therefore, be made to ensure 
that a quantification method is able to provide reliable and consistent results, and that it is suitable for 
the intended purpose [3]. The process of demonstrating the suitability of a method for biomedical 
application is called bioanalytical method validation. It can be divided into three phases: method 
development, method validation, and method application (study sample analysis) (Figure 8). 
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Figure 8: Quantitative bioanalysis of small molecules by LC-MS/MS consists of method development, method validation, 
and method application (study sample analysis). Figure by Tabea Gollin (2015). 
 
2.4.6 Method development 
Method development for LC-MS/MS encompasses several distinct steps which are carried out 
consecutively: 1) consideration of physicochemical properties of the analyte; 2) selection of a suitable 
internal standard (I.S.); 3) optimization of MS/MS parameters; 4) chromatographic method 
development; 5) selection of a sample preparation technique; and 6) determination of quantification 
range and evaluation of carry-over. Each step requires time and resources, but contributes significantly 
to a successful method validation and application later on.  
 
(1) Physicochemical properties: As a first step (prior to starting with the development on the 
benchtop), physicochemical properties of the analyte(s) should be taken into consideration, such as 
solubility of the analyte in various solvents, lipophilicity (LogP/LogD), acidity (pKa), thermal and 
light stability, and molecular structure. Thus, suitable solvents can be selected and appropriate 
measures taken for successful sample processing (e.g. working in the dark with light sensitive 
compounds).  
 
(2) Selection of a suitable internal standard (I.S.): An internal standard (I.S.) is a compound that is 
added at a known concentration to every quantification sample, correcting for variation in sample 
extraction, transfer/injection volumes, ionization efficiency, and detector response [33]. As first 
choice, stable isotopic-labeled analytes should be selected as I.S. due to equal physicochemical 
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 characteristics and, thus, identical behavior as the unlabeled analyte during all steps of the analytical 
procedure. Regrettably, D (
2
H), 
13
C, 
15
N, and 
17
O-labeled compounds are expensive and may in certain 
cases not be available (e.g. for most natural products). As an alternative, structurally similar 
compounds may be employed, which closely mimic the analyte’s properties [34]. These compounds 
should exhibit only small differences in functional groups when compared to the analyte, and should 
have similar chromatographic properties [34].  
 
(3) Optimization of MS/MS parameters: After selection of an I.S., MS/MS parameters (SRM 
transitions, cone voltage, collision energy etc.) for both analyte and I.S. need to be generated and 
optimized for highest sensitivity and selectivity of the quantification method. This is usually done 
using a designated software program provided by the instrument manufacturer. If the sensitivity for 
the analyte is insufficient and/or no SRM transitions could be generated, a different ionization polarity 
(positive or negative) and/or ionization source may be tested (e.g. APCI instead of ESI).  
 
(4) Chromatographic method development: After generation of MS/MS parameters, a 
chromatographic method needs to be developed in order to separate the analyte(s) of interest from 
interfering compounds in the sample. Different (U)HPLC columns (reverse phase, normal phase, 
hydrophilic interaction (HILIC) etc.) and mobile phases (eluents) are hereby tested. An optimal 
gradient is determined, and mobile phase flow rate and column oven temperature are optimized. If 
structure analogs are used as I.S., care should be taken that the retention times of analyte and I.S. are 
relatively close, as emerging matrix effects may otherwise not be compensated sufficiently.  
 
(5) Selection of sample preparation technique: Since biological matrices are highly complex, an 
appropriate sample preparation technique (clean-up procedure) needs to be selected to extract the 
compound(s) of interest. The traditional approach is to start with the simplest extraction method such 
as PP or dilution [35]. If not successful, more sophisticated extraction methods such as LLE, SPE, and 
SLE may be evaluated. Also, phospholipid-removal plates (e.g. Ostro
TM
 plates from Waters) may be 
tested to specifically remove phospholipids from plasma samples. 
 
(6) Quantification range and carry-over: The last steps during bioanalytical method development 
are the determination of the quantification range, and the evaluation of the carry-over for both analyte 
and I.S.. The quantification range should be defined based on the sample concentrations expected in a 
particular study, and the linearity of the analyte in the biological matrix in the selected concentration 
range has to be proven. Nowadays, lower limits of quantification (LLOQ; calibration standard with the 
lowest concentration) in the pg/mL range can be achieved in LC-MS/MS, depending on the type of 
triple quadrupole detector, HPLC separation, and sample clean-up procedure.  
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 The carry-over should be evaluated by injecting a blank sample (pure matrix) after the upper limit of 
quantification (ULOQ; calibration standard with the highest concentration). According to EMA 
guidelines, carry-over should not exceed 20% for the analyte and 5% for the I.S. [36]. If these criteria 
are not met, appropriate measures should be taken to minimize the carry-over (e.g. change of washing 
needle solution, adaption of the quantification range, injection of blank samples after each sample). 
 
2.4.7 Method validation 
As soon as the LC-MS/MS method has been developed, method validation can be initiated. To which 
degree the validation should be performed depends on various factors: type of study, research field, 
and regulatory requirements. Typically, the most reliable bioanalytical data are obtained by means of 
methods validated according to good laboratory practice (GLP) guidelines defined by regulatory 
agencies. Among these recommendations, the European Medicines Agency (EMA) “Guideline on 
Bioanalytical Method Validation” (2009) and the US Food and Drug Administration (FDA) 
“Guidance for Industry, Bioanalytical Method Validation” (2001; new draft in 2013) belong to the 
most widely accepted ones [36–39]. Substantial efforts have been made to align different guidelines in 
recent years. A harmonized global guideline, however, does not yet exist [40].  
In the pharmaceutical industry, bioanalytical method validation plays a pivotal role particularly in 
preclinical and clinical drug development (e.g. in bioavailability, bioequivalence, pharmacokinetic, 
and toxicokinetic studies in animals and humans) [9]. At the drug discovery stage, on the other hand, 
where studies are employed to select drug candidates for further development, validation is often 
reduced for the benefit of high throughput [9]. In an academic setting, requirements for how and to 
what extent to perform method validation may not be as clear as for the pharmaceutical industry. 
However, peer reviewed scientific journals have increasingly higher requirements concerning method 
validation [4].  
 
Full validation, partial validation, and cross-validation 
The EMA and FDA have defined different degrees of bioanalytical method validation in their 
guidelines. These are: full validation, partial validation, and cross-validation [36,37]. A full validation 
is required if a method is implemented for the first time, or if metabolites (i.e. new analytes) are added 
to an already existing method. If a fully validated method is slightly modified, a new full validation 
may be avoided by partially validating the method. Such modifications can be e.g. the transfer of the 
method from one laboratory to another, the change of the biological matrix within a species (e.g. 
human urine to human plasma), or the alteration of the sample processing procedure. Partial validation 
of a method may include as little as one intra-assay accuracy and precision determination, but it may 
also require an almost full validation if major modifications were performed. Cross-validation of a 
method is required if samples from one single study are analyzed in two different laboratories, or if 
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 two or more different bioanalytical techniques (e.g. ELISA and LC-MS/MS) are employed for sample 
analysis.  
 
Validation parameters 
EMA and FDA guidelines have defined various validation parameters according to which quantitative 
LC-MS/MS methods should be validated. These include: calibration curve, LLOQ, carry-over, 
selectivity, specificity, matrix effects, accuracy, precision, recovery, dilution integrity, and stability 
[36,37]. 
Calibration curve and LLOQ: A calibration curve should consist of calibration standards 
(calibrators) and quality controls (QCs) at a minimum of three concentrations levels (low = 
QCL, middle = QCM, high = QCH) [36,37]. QCL should be within 3 times the lowest 
calibrator (LLOQ), QCM should be in the middle of the quantification range, and QCH should 
be approaching the high end of the range [36,37]. Calibrators and QCs should be prepared in 
the same biological fluid as the study samples by spiking the matrix with known 
concentrations of the analyte [37]. The calibration curve should be recorded as follows: a 
blank sample, a zero sample (sample processed with I.S., but without analyte), and six to eight 
calibrators covering the selected concentration range [37]. After the highest calibrator 
(ULOQ), another blank sample should be injected for carry-over assessment. For the LLOQ, 
the following conditions need to be met: the analyte response should be at least 5 times higher 
than the analyte response in the blank sample, and the signal to noise (S/N) ratio should be > 
10 [36,37,41]. Each analytical run should begin and end with a series of calibrators (bracketed 
between blank samples) injected in increasing concentration. Between the two calibrator sets, 
six QCs should be inserted randomly into the analytical run. The simplest model that is able to 
appropriately describe the concentration versus MS response curve should be applied [37]. For 
75% of calibrators and 67% of QCs (four out of six), the back-calculated concentrations 
should be within ± 15% of the nominal values, with exception of the LLOQ, for which a 
deviation of ± 20% is allowed [37].  
Carry-over: Carry-over of analyte and I.S. should already be evaluated during method 
development by injecting a blank sample after each ULOQ. If carry-over occurs, it should be 
minimized as best as possible [36,38]. According to EMA guidelines, carry-over is not 
allowed to exceed 20% for the analyte and 5% for the I.S. [36]. During method validation and 
application, carry-over needs to be further monitored [36,38].  
Selectivity and specificity: Selectivity is defined as the ability of an analytical method to 
differentiate and quantify the analyte in the presence of endogenous matrix components or 
other compounds in the sample [37]. It should be ensured at the LLOQ by using different 
batches of the same biological matrix [36,37]. Specificity of the method should be proven by 
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 using independent sources of the same matrix [37]. It should be noted that selectivity is not the 
same as specificity. While selectivity can be graded, specificity cannot. It is an absolute 
characteristic that may be regarded as ultimate selectivity [42]. 
Matrix effects: In LC-MS, a common problem is the occurrence of matrix effects. This 
phenomenon is caused by molecules originating from the biological matrix that co-elute with 
the analyte(s) and may interfere with the ionization process in the mass spectrometer (leading 
to ion suppression or enhancement) [43,44]. Matrix effects can occur in diverse and 
unexpected forms and may have a negative impact on precision and accuracy of a 
bioanalytical method. Therefore, they should be carefully investigated in the course of method 
validation to ensure that precision, selectivity, and sensitivity of the assay are not 
compromised [36,37]. 
Accuracy and precision: Accuracy of a bioanalytical method describes the closeness of mean 
test results obtained by the method to the nominal (true) value (concentration) of the 
compound. It is expressed as relative error (RE %). Precision describes the closeness of 
repeated individual measures, and is expressed as coefficient of variation (CV %).  
 
𝑅𝐸 (%) =  
𝑀𝑒𝑎𝑛 𝑒𝑥𝑝𝑒𝑟𝑖𝑚𝑒𝑛𝑡𝑎𝑙 𝑐𝑜𝑛𝑐. −𝑁𝑜𝑚𝑖𝑛𝑎𝑙 𝑐𝑜𝑛𝑐.
𝑁𝑜𝑚𝑖𝑛𝑎𝑙 𝑐𝑜𝑛𝑐.
 × 100 
 
𝐶𝑉 (%) =  
𝑆𝑡𝑎𝑛𝑑𝑎𝑟𝑑 𝑑𝑒𝑣𝑖𝑎𝑡𝑖𝑜𝑛 (𝑆. 𝐷. )
𝑀𝑒𝑎𝑛 𝑒𝑥𝑝𝑒𝑟𝑖𝑚𝑒𝑛𝑡𝑎𝑙 𝑐𝑜𝑛𝑐.
 × 100 
 
Accuracy and precision of a method can be subdivided into within-run and between-run 
accuracy and precision. The latter (between-run) reflects the reproducibility of a method 
[36,37]. During method validation, both within-run and between-run accuracy and precision 
should be assessed by replicate analysis of samples (at least five) at a minimum of three 
different concentration levels [37]. Means and S.D. should be calculated, from which RE % 
and CV % can be deduced. RE % should be within ± 15% (± 20% at the LLOQ), and CV % 
should not exceed 15% (20% at the LLOQ) of the nominal values. 
Recovery (extraction yield): Recovery indicates the extraction efficiency (extraction yield) of 
a bioanalytical method, and should be assessed by comparison of extracted samples at three 
concentration levels (QCL, QCM, and QCH) with unextracted samples representing 100% 
recovery [37, 45]. According to FDA guidance, recovery does not need to be 100%, but it 
should be consistent, precise, and reproducible [37].  
Dilution integrity: Study samples may need to be diluted if the analyte concentration is 
higher than the ULOQ. However, dilution of samples should not have an impact on accuracy 
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 and precision of the bioanalytical method. Therefore, representative tests should be carried out 
during method validation in order to demonstrate that dilution of study samples later on does 
not interfere with the method [36,37]. 
Stability: During the entire bioanalysis chain (beginning with sample collection and ending 
with sample analysis after long-term and short-term storages), stability of the analyte in the 
biofluid should be guaranteed. Therefore, various stability tests should be carried out during 
method validation. According to FDA/EMA guidelines, these include: freeze and thaw (F/T) 
stability, benchtop stability (at room temperature), long-term stability at planned storage 
conditions, post-preparative stability (autosampler stability), and stock solution stability [37]. 
Importantly, conditions used in all these stability tests should reflect the conditions expected to 
be encountered during real sample handling and analysis.  
 
Validation reports 
After method validation, a report needs to be compiled which includes an operational description of 
the bioanalytical method, the performed validation tests, and obtained validation parameters [37]. 
Also, any deviation from standard operating procedures (SOP) or protocols needs to be noted and 
justified [37]. Finally, a SOP has to be written which can be used for the routine analysis of study 
samples. This protocol should describe the bioanalytical method in detail, i.e. should include 
information on storage conditions, preparation of calibrators and QCs, sample extraction, LC-MS/MS 
parameters, and calibration curve acceptance criteria [37].  
 
2.4.8 Method application (analysis of study samples) 
After successful method validation, the LC-MS/MS method can be applied to analyze study samples. 
Knowledge gained during method validation on the stability of analyte and I.S. and correct processing 
of samples needs to be taken into consideration, and SOPs need to be closely followed. Similarly as 
for method validation, an analytical run should consist of two series of calibrators (including two 
blank samples and one zero calibrator) injected at the beginning and at the end of the run. Study 
samples together with six QCs (duplicates of QCL, QCM, and QCH) are inserted randomly between 
the two calibrator series. An analytical run is only valid if the back-calculated concentrations of 75% 
of calibrators and 76% of QCs (four out of six) are within ± 15% (± 20% at the LLOQ) of the nominal 
values. 
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brain capillary endothelial cell lines, hCMEC/D3,
hBMEC, TY10, and BB19, and optimization of
culture conditions, for an in vitro blood–brain
barrier model for drug permeability studies
Daniela E Eigenmann1, Gongda Xue2, Kwang S Kim3, Ashlee V Moses4, Matthias Hamburger1 and Mouhssin Oufir1*Abstract
Background: Reliable human in vitro blood–brain barrier (BBB) models suitable for high-throughput screening are
urgently needed in early drug discovery and development for assessing the ability of promising bioactive compounds
to overcome the BBB. To establish an improved human in vitro BBB model, we compared four currently available and
well characterized immortalized human brain capillary endothelial cell lines, hCMEC/D3, hBMEC, TY10, and BB19, with
respect to barrier tightness and paracellular permeability. Co-culture systems using immortalized human astrocytes
(SVG-A cell line) and immortalized human pericytes (HBPCT cell line) were designed with the aim of positively
influencing barrier tightness.
Methods: Tight junction (TJ) formation was assessed by transendothelial electrical resistance (TEER)
measurements using a conventional epithelial voltohmmeter (EVOM) and an automated CellZscope system
which records TEER and cell layer capacitance (CCL) in real-time.
Paracellular permeability was assessed using two fluorescent marker compounds with low BBB penetration
(sodium fluorescein (Na-F) and lucifer yellow (LY)). Conditions were optimized for each endothelial cell line by
screening a series of 24-well tissue culture inserts from different providers. For hBMEC cells, further
optimization was carried out by varying coating material, coating procedure, cell seeding density, and growth
media composition. Biochemical characterization of cell type-specific transmembrane adherens junction protein
VE-cadherin and of TJ proteins ZO-1 and claudin-5 were carried out for each endothelial cell line. In addition,
immunostaining for ZO-1 in hBMEC cell line was performed.
Results: The four cell lines all expressed the endothelial cell type-specific adherens junction protein VE-cadherin. The TJ
protein ZO-1 was expressed in hCMEC/D3 and in hBMEC cells. ZO-1 expression could be confirmed in hBMEC cells by
immunocytochemical staining. Claudin-5 expression was detected in hCMEC/D3, TY10, and at a very low level in hBMEC
cells. Highest TEER values and lowest paracellular permeability for Na-F and LY were obtained with mono-cultures of
hBMEC cell line when cultivated on 24-well tissue culture inserts from Greiner Bio-oneW (transparent PET membrane,
3.0 μm pore size). In co-culture models with SVG-A and HBPCT cells, no increase of TEER could be observed, suggesting
that none of the investigated endothelial cell lines responded positively to stimuli from immortalized astrocytic or
pericytic cells.
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Conclusions: Under the conditions examined in our experiments, hBMEC proved to be the most suitable human cell
line for an in vitro BBB model concerning barrier tightness in a 24-well mono-culture system intended for higher
throughput. This BBB model is being validated with several compounds (known to cross or not to cross the BBB),
and will potentially be selected for the assessment of BBB permeation of bioactive natural products.
Keywords: Endothelial cell line, In vitro human blood–brain barrier (BBB) model, 24-well tissue culture insert,
Transendothelial electrical resistance (TEER), Paracellular permeability, CellZscopeBackground
Endothelial microvascular capillary cells in the human
brain constitute a unique cellular barrier to sustain brain
homeostasis and to protect the brain from xenobiotics
and neurotoxic metabolites circulating in the blood-
stream. It has been estimated that more than 98% of
small-molecule drugs are not able to cross the blood–
brain barrier (BBB) [1]. Hence, BBB penetration is a
major challenge in the development of drugs acting on
the central nervous system (CNS), where penetration
into the brain is pivotal for achieving therapeutic effects
[2]. On the other hand, low CNS penetration is desirable
for drugs acting in the periphery. In early drug discovery
and development, new chemical entities (NCEs) are now
screened for their ability to cross the BBB.
For this purpose, a wide range of in silico, in vitro, and
in vivo BBB models for early prediction of brain perme-
ability of compounds have been developed and estab-
lished [3]. Computational models and physicochemical
methods such as the Parallel Artificial Membrane
Permeability Assay (PAMPA-BBB) offer high-throughput
screening capability at early stages of drug discovery, but
are only able to predict passive permeation [4,5]. In con-
trast, in vivo models such as in situ brain perfusion pro-
vide high-quality data and some of the most reliable
measurements of BBB drug penetration [6]. However, they
are expensive in terms of time and resources and, there-
fore, only suitable for testing of compounds at more ad-
vanced stages of development [7]. Cell-based in vitro BBB
models using primary or immortalized brain capillary
endothelial cells from animal or human origin cultivated
on microporous filter membranes of Transwell systems
may bridge the gap between in silico and in vivo studies.
They have been used for in vitro drug BBB permeability
assessment for a long time, and their simple design al-
lows for cost-efficient high-throughput screening [8-10].
Since mono-culture systems represent a highly simpli-
fied model and are far from mimicking in vivo conditions,
further brain-derived cells being part of the neurovascular
unit, such as astrocytes, pericytes, and/or neurons, have
been incorporated into double and triple co-culture
in vitro BBB models [10]. Whereas astrocytes have repeat-
edly been shown to favorably influence barrier tightness of
endothelial cells [11-14], the impact of pericytes on BBB72models is still a matter of controversy. It was shown
that a syngeneic tri-culture model with primary rat brain
capillary endothelial cells, astrocytes, and pericytes yielded
highest transendothelial electrical resistance (TEER) values
[15]. In contrast, another study showed that a barrier
strengthening effect of pericytes critically depended on
the differentiation state of cells [16].
In vitro animal BBB models using primary or low pas-
sage porcine, bovine, rat, or mouse cells, partly in double
and triple co-culture systems, are generally characterized
by relatively high TEER values and by low paracellular
permeability of marker compounds [17]. Despite these
favorable features, in vitro animal models show major
drawbacks. Isolation and purification procedures of pri-
mary cells are tedious and time-consuming and require
substantial experience [9]. Yields and lifespan of isolated
cells are limited, and animal endothelial cells show dif-
ferences in the expression of drug transporters and ef-
flux pumps when compared to human brain capillary
endothelial cells [18]. The use of primary cultures from
human origin would avoid interspecies pharmacogenetic
variation, yet the availability of these cells is greatly lim-
ited on ethical grounds [19]. Immortalized human brain
capillary endothelial cells can be used as an alternative.
These cells proliferate indefinitely and preserve their dif-
ferentiating properties after repetitive passages, which is
desirable for standardized screenings [9]. However, the
establishment of a reliable human cell-line based BBB
model has proven to be difficult [17]. These cells typically
form only limited restrictive monolayers in vitro, with
TEER values in the range 20 to 200 Ωcm2 [17,20,21].
Compared to in vivo conditions where TEER values have
been estimated to exceed 1000 Ωcm2 [22,23], this is con-
siderably lower. Despite this limitation, in vitro models
with human immortalized cell lines possess several advan-
tages and may be favorable tools for obtaining first mech-
anistic insights into BBB permeability of drugs. However,
optimization of in vitro human BBB models for best bar-
rier tightness is a prerequisite.
This study provides comparative data on four known
immortalized human brain capillary endothelial cell lines,
hCMEC/D3 [24], hBMEC [25], TY10 [26], and BB19 [27],
regarding their ability to form a restrictive barrier in an
in vitro 24-well format BBB model intended for higher
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immortalized human astrocytes (SVG-A cell line [28]) and
immortalized human pericytes (HBPCT cell line [29])
were included into co-culture models with these endothe-
lial cell lines, with the objective to increase barrier tight-
ness. We also present here a large set of in vitro TEER
data recorded for each endothelial cell line cultivated on a
range of tissue culture inserts from different manufac-
turers, with the aid of a CellZscope on-line TEER record-
ing system [30]. This information was important prior to
optimizing an in vitro BBB model with a particular cell
line, since material and pore size of the filter membrane of
the tissue culture inserts have been reported to strongly
affect the adherence of cells and barrier tightness [31,32].
Subsequent optimization of a model with hBMEC cells
was done by systematically screening various coating
materials and coating procedures, by testing a variety
of growth media containing barrier-strengthening com-
pounds, by replacing the commonly used fetal bovine
serum (FBS) with human serum (HS), and by using
astrocyte-conditioned medium (ACM). In addition to
TEER measurements, paracellular permeability of two
fluorescent tracer molecules that do not cross the BBB
in a significant amount (sodium fluorescein (Na-F) and luci-
fer yellow (LY)) was assessed. Biochemical characterization
of VE-cadherin, ZO-1, and claudin-5, three major
components of adherens and tight endothelial junc-
tions, was carried out for each endothelial cell line.
Furthermore, we performed immunostaining for ZO-1
in hBMEC cells.
Methods
Chemicals and materials
NaCl, CaCl2, MgCl2, KCl, glucose, 4-(2-hydroxyethyl)
piperazine-1-ethanesulfonic acid (HEPES), NaHCO3,
Dulbecco’s modified Eagle medium (DMEM), human
collagen type IV, fibronectin, hydrocortisone (HC), dexa-
methasone, human epidermal growth factor (hEGF),
8-(4-chlorophenylthio) adenosine-3’,5’-cyclic monopho-
sphate sodium salt (8-(4-CPT)cAMP), 4-(3-butoxy-4-
methoxybenzyl) imidazolidin-2-one (RO-20-1724), so-
dium fluorescein (Na-F), radio-immunoprecipitation assay
(RIPA) lysis buffer, phosphate buffered saline (PBS), Triton
X-100, bovine serum albumin (BSA), and 4’,6-diamidino-
2-phenylindole dihydrochloride (DAPI) were purchased
from Sigma-Aldrich (Steinheim, Germany). Fetal bo-
vine serum (FBS) “Gold” was from PAA Laboratories
(Pasching, Austria). Human AB serum (HS) from a
healthy female donor was obtained from the blood donor
bank (Blutspendezentrum Universität Basel, Switzerland).
Both sera were heat inactivated for 30 min at 56°C before
use. EBM-2 and Single-Quots (human vascular endothelial
growth factor, insulin-like growth factor-1, human fibro-
blast growth factor-B, hEGF, ascorbic acid, heparin, and73HC) were from Lonza (Basel, Switzerland). Lucifer Yellow
VS dilithium salt (LY) was purchased from Santa Cruz
(Heidelberg, Germany). Antibiotic-antimycotic solution,
secondary antibody (Alexa Fluor 488 conjugation), and
phalloidin (Alexa Fluor 647) were received from Life
Technologies (Paisley, UK). Rat-tail collagen type I and
matrigel were purchased from BD Biosciences (Bedford,
USA) and from Trevigen (Gaithersburg, MD, USA). The
antibodies specific for zonula occludens (ZO)-1 protein,
claudin-5, and vascular endothelial (VE)-cadherin were
from Abcam (Cambridge, UK). Protease inhibitor cocktail
was from Roche (Basel, Switzerland). Tissue culture flasks
were from BD Biosciences (Bedford, USA) and from TPP
(Trasadingen, Switzerland). 24-well tissue culture inserts
and 24-well plates were from Corning IncorporatedW
(Corning, NY, USA), Greiner Bio-oneW (Frickenhausen,
Germany), BD FalconW (Le Pont de Claix, France), MilliporeW
(Billerica, MA, USA), NuncW (Roskilde, Denmark), and
BrandW (Wertheim, Germany).
Cell cultures
In this study, four immortalized human brain capillary
endothelial cell lines, hCMEC/D3 [24], hBMEC [25],
TY10 [26], and BB19 [27], were used (Figure 1). Immor-
talized hCMEC/D3 cell line was kindly provided by Prof.
Pierre-Olivier Couraud (Institut Cochin, Université René
Descartes, Paris, France). hBMEC cell line was obtained
from Prof. Kwang Sik Kim and Prof. Dennis Grab (John
Hopkins University, Baltimore, MD, USA) through the
Swiss Tropical and Public Health Institute (Prof. Reto
Brun, STPH, Basel, Switzerland). TY10 cell line, a new
generation of conditionally immortalized cells coming
from TY08 [33], which was established by the same
method as TY09 cell line [34], was obtained from Prof.
Takashi Kanda (Yamaguchi University Graduate School
of Medicine, Ube, Yamaguchi, Japan). BB19 cells were
kindly provided by Prof. Ashlee V. Moses (Oregon Health
and Science University, Portland, OR, USA). The immor-
talized SVG-A cell line, an astrocytic cell subclone of the
astroglial SVG cell line [28,35], was a generous gift from
Prof. Avindra Nath (National Institute of Neurological
Disorders and Stroke, Bethesda, MD, USA) and the
immortalized human pericyte cell line HBPCT [29] was
provided by Prof. Takashi Kanda (Yamaguchi University
Graduate School of Medicine, Ube, Yamaguchi, Japan).
All cell lines (except TY10) were cultured and grown
to confluence in rat-tail collagen type I coated tissue cul-
ture flasks at 37°C and 5% CO2 in humid atmosphere.
TY10 cells were cultured under similar conditions but at
33°C, since this cell line was immortalized with a hTERT
and a temperature-sensitive SV40 large-T antigen allow-
ing the cells to grow at the permissive temperature of
33°C and to differentiate into physiological endothelial
cells at the non-permissive temperature of 37°C [26,33,34].
Figure 1 Phase contrast microscopy of four immortalized human brain capillary endothelial cell lines. Four endothelial cell lines were
cultured in growth medium containing 20% FBS for 2 days and the representative cell morphology was imaged with a phase contrast
microscope. Scale bar: 150 μm.
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supplemented with Single-Quots, antibiotic-antimycotic so-
lution, and 20% FBS (growth medium 20% FBS). hCMEC/
D3 cells were cultured either in growth medium con-
taining 20% FBS, or in the initial culture medium con-
taining 5% FBS as described previously [24]. Culture
medium for SVG-A and HBPCT cells was DMEM supple-
mented with antibiotic-antimycotic solution and 10% FBS.
For experiments, hCMEC/D3 cells were between passage
(P) 25 and 32, hBMEC cells were between P12 and P25,
TY10 cells between P10 and P19, BB19 cells between P11
and P19, SVG-A cells between P7 and P10, and HBPCT
cells between P13 and P19. All endothelial cell lines used
in this study have been reported to preserve their pheno-
type for a limited range of passages (for hCMEC/D3: up
to P33 [24], for hBMEC: up to P25, for TY10: at least up
to P50 [34], and for BB19: up to P21 [27]).
Biochemical and immunocytochemical characterization of
cellular junctions
Examined cells were lysed in standard RIPA lysis buffer
supplied with protease inhibitor cocktail for 30 min on
ice. Cleared supernatant corresponding to 50 μg of total
protein per sample was subjected to SDS-PAGE and
western blotting analysis. For immunochemistry studies,
hBMEC cells grown on coverslips coated with rat-tail
collagen type I were fixed with paraformaldehyde for
20 min at room temperature and subsequently perme-
abilized with PBS containing 0.2% Triton X-100 for
10 min. The cells were then blocked with 3% BSA for7430 min and incubated with ZO-1 antibody (1:100) at 4°C
overnight. Secondary antibody (Alexa Fluor 488 con-
jugation) was incubated together with phalloidin (Alexa
Fluor 647) for 1 h and the representative images were
taken using a fluorescent microscope (Zeiss Z1). The nu-
clei were stained with DAPI.
In vitro co-culture BBB models and TEER measurements
Contact and non-contact co-culture BBB models using
immortalized brain capillary endothelial cells and im-
mortalized astrocytes or immortalized pericytes were
established as follows. hCMEC/D3 (grown with initial
medium), hBMEC, TY10, and BB19 cells were seeded
separately on the apical side of the filter membranes of
24-well tissue culture inserts from CorningW (polycar-
bonate (PC) and polyester (PES) membranes, 0.4 μm
and 3.0 μm pore size), coated with rat-tail collagen type
I (10 μg/cm2). The cell seeding density varied between
3.0 × 104 and 15 × 104 cells/cm2 (hCMEC/D3: 6.0 × 104
cells/cm2, hBMEC: between 3.0 × 104 and 4.5 × 104
cells/cm2, TY10: 3.0 × 104 cells/cm2, and BB19: between
7.5 × 104 and 15 × 104 cells/cm2). Beforehand, SVG-A
or HBPCT cells were seeded on the collagen type I
coated (10 μg/cm2) basal side of the porous filter mem-
brane (SVG-A: between 3.0 × 104 and 9.0 × 104 cells/
cm2, HBPCT: 3.0 × 104 cells/cm2) and allowed to attach
for 1 h. For non-contact models, SVG-A cells were
seeded at a cell density of 1.6 × 104 cells/cm2 onto the
culture plate and incubation thereafter was 2 h (37°C,
5% CO2). After the start of the experiment, TEER values
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thelial voltohmmeter (EVOM) coupled to an Endohm-6
measurement chamber (World Precision Instruments,
USA). Each TEER reading was followed by an exchange
of medium. TEER values for cell layers, expressed in
Ωcm2, were calculated by subtracting the resistance of a
coated control insert without cells from a coated insert
with cells and by subsequent correction for surface area.
For each experiment, at least 2 replicates were mea-
sured. Results are expressed as means ± S.E.M.
Screening of 24-well inserts from different providers for
mono-culture BBB models
For the screening of 24-well tissue culture inserts from
different providers (CorningW, Greiner Bio-OneW, BD
FalconW, MilliporeW, NuncW, and BrandW), each endo-
thelial cell line (hCMEC/D3 (cultured with growth
medium 20% FBS), hBMEC, TY10, and BB19) was
seeded separately on the apical side of the filter mem-
brane at a density varying between 1.5 × 104 and 17 ×
104 cells/cm2. Prior to seeding, the membranes were
coated with rat-tail collagen type I. The tissue culture in-
serts were placed into a 24-well cell module of a CellZ-
scope system (NanoAnalytics, Münster, Germany) [30]
which was placed inside an incubator (37°C and 5%
CO2). For in vitro models with TY10 cells, further exper-
iments were performed for which the CellZscope system
was first placed at 33°C (5% CO2) for 2 days and subse-
quently transferred to 37°C (5% CO2). The medium was
refreshed every 2–4 days. TEER values were recorded in
real-time every hour. TEER values for cell layers, expressed
in Ωcm2, were obtained by subtracting the TEER of a
coated control insert without cells from a coated insert
with cells. After placing the CellZscope system into the in-
cubator, the cell module needs at least 6 h to reach 37°C.
Since TEER values are highly temperature sensitive [36],
recorded TEER values in this time period were not consid-
ered to be valid and are not reported. For each in vitro
experiment, 2 or 3 replicates were measured. Results are
expressed as means ± S.E.M. In addition to TEER values,
the CellZscope system monitors the cell layer capacitance
(CCL) which reflects the membrane surface area. CCL
values in the range of 0.5-5.0 μF/cm2 indicate cell con-
fluency and validate TEER values [37,38]. All reported
TEER values in the result section belong to a CCL within
this range, if not reported otherwise.
Optimization of mono-culture in vitro BBB models
For further optimization of mono-culture systems with
hBMEC, various insert coating procedures using matrigel
(80 μg/cm2) and a mixture of collagen type IV/fibronectin
(80/20 μg/cm2) were assessed. Several growth media were
tested containing compounds such as HC (500 nM; 1500
nM; in addition to HC already included in Single-Quots),75dexamethasone (500 nM; 1000 nM), hEGF (50 ng/mL;
100 ng/mL; in addition to hEGF already included in
Single-Quots), 8-(4-CPT)cAMP (250 μM), and RO-20-
1724 (17.5 μM), which have been used in BBB studies to
induce barrier tightness [17,21,39,40]. To avoid cytotoxic
effects of DMSO or ethanol, their final concentration in
the growth medium was below 0.25% [41]. Moreover, a
culture medium (EBM-2, Single-Quots, and antibiotic-
antimycotic solution) called “HS medium” supplemented
with HS (10% and 20%, respectively) instead of FBS was
evaluated. Astrocyte-conditioned media (ACM) were
collected from SVG-A cells cultured with either growth
medium for endothelial cell lines (ACM-1) or culture
medium for SVG-A (ACM-2) and stored at −20°C
until use.
BBB permeability studies with Na-F and LY
To further assess tight junction (TJ) integrity of endo-
thelial cell layers, paracellular permeabilities of Na-F
(MW 376.27) and LY (MW 550.39) were measured. These
two fluorescent, non-P-glycoprotein (P-gp) substrate mol-
ecules have low BBB penetration and are widely used as
barrier integrity markers for in vitro models. To obtain
comparative data, hCMEC/D3 cells, hBMEC cells, and
TY10 cells were seeded onto 24-well tissue culture inserts
(Greiner Bio-oneW, transparent polyethylene terephthalate
(PET) membrane, 3.0 μm pore size, 0.6 × 106 pores/cm2)
and incubated at 37°C (5% CO2) (except TY10 cells) inside
the CellZscope cell module (Figure 2). For TY10, the
CellZscope system was first put at 33°C (5% CO2) for
2 days and was thereafter transferred to 37°C (5% CO2)
for 2 days prior to the permeability assay (Figure 3D). Cell
seeding density for hCMEC/D3 and hBMEC was 6.0 × 104
cells/cm2, and for TY10 it was 3.0 × 104 cells/cm2. For
hBMEC, contact co-culture models with SVG-A cells
(9.0 × 104 cells/cm2) or HBPCT cells (6.0 × 104 cells/cm2)
on the basal side of the coated filter membranes were
tested.
TEER and CCL values before and after the assays were
monitored continuously for integrity control. All experi-
ments for Na-F permeability were carried out at the time
indicated with a black arrow in Figures 3A-D. For LY
permeability assessment, TEER values were in the same
range (graphs not shown). BB19 cells were not included
in this permeability study since TEER values were ex-
tremely low.
For the permeability assay, tissue culture inserts were
transferred into a 24-well plate containing 700 μL of
pre-warmed (37°C) Ringer HEPES buffer (150 mM NaCl,
2.2 mM CaCl2, 0.2 mM MgCl2, 5.2 mM KCl, 2.8 mM
glucose, 5 mM HEPES, and 6 mM NaHCO3, pH 7.4) in
each well (basolateral compartment). Medium in inserts
(apical compartment) was then replaced with 300 μL of
a pre-warmed (37°C) working solution containing Na-F
Figure 2 Scheme of preparation of the in vitro human BBB model. After subculturing the human cell lines for several days, the brain capillary
endothelial cells were seeded on microporous filter membranes of 24-well tissue culture inserts (Greiner Bio-oneW, transparent PET membrane,
3.0 μm pore size). The inserts were immediately transferred to a 24-well cell module of a CellZscope system which was placed inside an incubator
(37°C and 5% CO2). TEER and CCL values were recorded on-line every hour. After 2–4 days (at the maximal TEER), paracellular permeability of Na-F
and LY was assessed. To monitor barrier integrity after the assay, TEER and CCL values were again recorded real-time using the CellZscope system.
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plate was incubated at 37°C on an orbital shaker (ELMI
DTS-2, Riga, Latvia) with moderate speed (100 rpm) and
aliquots of 250 μL of both apical and basolateral com-
partments were collected after 1 h. All experiments were
performed at least in triplicate. Quantification of fluores-
cence (Na-F: excitation 490 nm, emission 514 nm; LY:
excitation 430 nm, emission 535 nm) was carried out
using a Chameleon microplate reader (Hidex, Turku,
Finland). The apparent permeability coefficient (Papp) for
Na-F and LY was calculated in centimeters/second (cm/s)
according to the equation:
Papp cm=sð Þ ¼ VB= ACA0ð Þ  ΔCB=Δtð Þ;
[42] where VB is the volume in the basolateral compart-
ment, A is the surface area of the filter membrane
(0.336 cm2 for Greiner Bio-oneW inserts), CA0 is the initial
concentration in the apical compartment, and ΔCB/Δt is
the change of concentration over time in the basolateral
compartment.
Recovery (mass balance) of Na-F and LY was calcu-
lated with the following equation:
Recovery %ð Þ ¼ CAfVA þ CBfVBð Þ= CA0VAð Þ
 100%;
[43] where CAf and CBf are the final concentrations of
the compound in the apical and basolateral compart-
ment, respectively, CA0 is the initial concentration in the
apical compartment, and VA and VB are the volumes in76the apical and basolateral compartments, respectively.
All results are expressed as means ± S.E.M.
Results
Biochemical and immunocytochemical characterization of
cellular junctions
The four endothelial cell lines all expressed the endothe-
lial marker protein VE-cadherin, albeit at different levels
(Figure 4). The TJ protein ZO-1 was detected in
hCMEC/D3 and in hBMEC at the same level, but it was
expressed at much lower levels in BB19 and TY10 cell
lines (Figure 4). ZO-1 expression in hBMEC cells was
confirmed by immunocytochemical staining (Figure 5).
Claudin-5 was not detected in BB19 cells, but was
expressed at a high level in TY10 cells, at a low level in
hCMEC/D3 cells, and at an even lower level in hBMEC
cells (Figure 4).
Co-culture in vitro BBB models
In the beginning of this study, we aimed to establish an
all-human in vitro BBB model by co-culturing separately
several human brain capillary endothelial cell lines
(hCMEC/D3, hBMEC, TY10, and BB19) with the human
astrocyte cell line SVG-A and with the human pericyte
cell line HBPCT. To find the most effective model re-
garding TJ resistance, each endothelial cell line was
grown separately on the apical filter membrane with
SVG-A cells or HBPCT cells grown on the basal filter
membrane (contact models), or in the culture plate
(non-contact models). Various 24-well tissue culture
Figure 3 Mean TEER values (blue curve) and CCL values (black curve) recorded real-time by the CellZscope system of four human brain
capillary endothelial cell lines grown on 24-well tissue culture inserts. Black arrows indicate the time when the permeability assay with Na-F
was performed (for resulting Papp values see Figures 7A and B). For hCMEC/D3 and TY10, the permeability assay was performed at TEER values in
the range of 10 Ωcm2 (hCMEC/D3: *cultured with initial medium (A), **cultured with growth medium 20% FBS (B). For hBMEC, the assay was
carried out at TEER values in the range of 30 Ωcm2. TEER values after the assay were in the same range or even higher as before, suggesting that
cell layers were robust during the experiment and barrier integrity was maintained (A-D). For each of the three cell lines, CCL values were in the
acceptable range of 0.5-5.0 μF/cm2, indicating that cells were confluent. BB19 cell line (E) yielded very low TEER values in the range of 5 Ωcm2.
Since CCL values were drastically increasing after 55 h, the experiment was stopped. BB19 cells were not included into permeability studies with
Na-F and LY due to their low TEER. All experiments were performed with Greiner Bio-oneW inserts (transparent PET membrane, 3.0 μm pore size,
0.6 × 106 pores/cm2, n = 2–5).
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Figure 4 Western blot analysis of tight junction proteins ZO-1,
claudin-5, and adherens junction protein VE-cadherin from cell
lysates of four endothelial cell lines. The cells were lysed with
RIPA buffer. 50 μg of total protein was subjected to SDS-PAGE and
western blotting analysis for individual markers. Actin was used as
loading control. The four cell lines all expressed the adherens
junction protein VE-cadherin. The TJ protein ZO-1 was detected in
hCMEC/D3, in hBMEC, and at much lower levels in BB19 and TY10
cell lines. Claudin-5 expression was detected in hCMEC/D3, TY10,
and at a very low level in hBMEC cells.
Figure 5 Immunofluorescence staining of tight junction protein
ZO-1 in hBMEC cell line. hBMEC cells were grown on collagen-
coated glass coverslips for 48 h followed by paraformaldehyde
fixation. Even with a high background noise level especially on
nuclei, ZO-1 was detected at the leading edge of migrating hBMEC
cells (see white arrows). Scale bar: 30 μm.
Eigenmann et al. Fluids and Barriers of the CNS 2013, 10:33 Page 8 of 16
http://www.fluidsbarrierscns.com/content/10/1/33inserts from CorningW with PC and PES membrane and
pore sizes 0.4 μm and 3.0 μm were tested, since these in-
sert types are mostly used for drug transport studies.
Maximal TEER values measured with the EVOM were
obtained with mono-cultures of hBMEC cells (30.7 ±
0.660 Ωcm2 on day 12) on tissue culture insert with PES
membrane and 0.4 μm pore size (Figure 6, red curve).
hBMEC cells grown in contact or non-contact co-
culture models with SVG-A cells on the same kind of in-
serts resulted in lower maximal TEER values (24.3 ± 1.16
Ωcm2 on day 7 and 22.3 ± 0.165 Ωcm2 on day 9, re-
spectively) (Figure 6, blue and black curves). In contact
co-culture models with HBPCT cells, maximal TEER
values were also lower than for hBMEC mono-cultures
(26.2 ± 0.165 Ωcm2 on day 12 compared to 30.7 ± 0.660
Ωcm2 on day 12) (Figure 6, green curve). TEER values
for hBMEC cells on additional tested 24-well tissue cul-
ture inserts, and TEER values for all other models using
hCMEC/D3, TY10, and BB19 cells (in mono-cultures
and in co-cultures), yielded maximal TEER values below
20 Ωcm2 (data not shown). SVG-A cells and HBPCT
cells did not significantly increase or decrease TEER
values (data not shown).78Screening of 24-well tissue culture inserts for each
endothelial cell line using the CellZscope
In the above described co-culture experiments, we ob-
served i) that Transwell co-culture models with immor-
talized astrocytes and immortalized pericytes did not
increase TJ resistance of the immortalized brain micro-
vascular endothelial cells included in this study (for
hBMEC, see Figure 6), and ii) that membrane material
and pore size had a significant impact on barrier tight-
ness. Therefore, we decided to optimize mono-culture
models by systematically screening a range of 24-well
tissue culture inserts from various providers (CorningW,
Greiner Bio-oneW, MilliporeW, BD FalconW, NuncW, and
BrandW) for each endothelial cell line, with the aim to
increase TEER. For this screening, an automated CellZ-
scope device [30] was used, which records the TEER
in real-time every hour inside the incubator at 37°C
and 5% CO2. TEER values could not be recorded with
24-well tissue culture inserts from NuncW (PC, 0.4 μm
and 3.0 μm pore size) or BrandW (translucent PC, 0.4 μm
and 3.0 μm pore size), because their particular design
rendered them incompatible with the CellZscope cell
module.
hCMEC/D3 mono-cultures
For hCMEC/D3 monolayers, low TEER values between
5.09 and 11.9 Ωcm2 were obtained on all tested inserts
(Table 1). It was not possible to identify conclusively the
Table 1 Summary of maximal TEER values recorded real-time by the CellZscope system for hCMEC/D3, hBMEC,
and TY10 mono-cultures
24-well tissue culture insert
coated with collagen type I
hCMEC/D3 hBMEC TY10
Time (d) Mean max. TEER ±
S.E.M. (Ωcm2)
Time (d) Mean max. TEER ±
S.E.M. (Ωcm2)
Time (d) Mean max. TEER ±
S.E.M. (Ωcm2)
Corning® (translucent PC, 0.4 μm,
1.0 × 108 pores/cm2, 0.33 cm2)
4.75 6.72 (± 0.113) 2.46 2.79 (± 0.410) 2.37 4.56 (± 1.06)
Corning® (translucent PC, 3.0 μm,
2.0 × 106 pores/cm2, 0.33 cm2)
5.07 8.56 (± 0.217) 5.19 #9.09 (± 0.103) 7.73** #11.2 (± 0.904)
Corning® (transparent PES, 0.4 μm,
4.0 × 106 pores/cm2, 0.33 cm2)
1.97* 7.04 (± 0.231) 2.79* 17.7 (± 0.152) 1.96 6.96 (± 0.199)
Corning® (transparent PES, 3.0 μm,
2.0 × 106 pores/cm2, 0.33 cm2)
3.38 9.44 (± 0.0877) 2.81 6.24 (± 0.0805) 2.37 7.94 (± 0.110)
Greiner Bio-one® (transparent PET,
0.4 μm, 2.0 × 106 pores/cm2, 0.336 cm2)
2.47 6.48 (± 0.125) 1.85 #7.27 (± 2.36) 1.45* 9.37 (± 0.690)
Greiner Bio-one® (translucent PET,
0.4 μm, 1.0 × 108 pores/cm2, 0.336 cm2)
2.34 5.18 (± 0.222) 5.13 7.42 (± 0.288) 1.66* 12.4 (± 2.11)
Greiner Bio-one® (transparent PET,
3.0 μm, 0.6 × 106 pores/cm2, 0.336 cm2)
2.34 11.9 (± 0.118) 2.75 28.4 (± 2.47) 1.15* 13.0 (± 0.0151)
Greiner Bio-one® (translucent PET,
3.0 μm, 2.0 × 106 pores/cm2, 0.336 cm2)
2.34 9.39 (± 0.166) 2.49 5.85 (± 0.357) 1.32* 7.26 (± 0.0949)
Millipore® (translucent PET, 0.4 μm,
1.0 × 108 pores/cm2, 0.33 cm2)
2.34 5.35 (± 0.312) 2.49 2.92 (± 0.164) 1.37* 5.98 (± 0.200)
Millipore® (translucent PET, 3.0 μm,
2.0 × 106 pores/cm2, 0.33 cm2)
2.34 10.2 (± 0.0304) 2.53 15.0 (± 0.348) 2.37 11.2 (± 0.806)
BD Falcon® (transparent PET, 0.4 μm,
2.0 × 106 pores/cm2, 0.3 cm2)
2.34 5.09 (± 0.133) 3.34 8.40 (± 0.524) 3.11 4.72 (± 0.00525)
BD Falcon® (transparent PET, 3.0 μm,
0.8 × 106 pores/cm2, 0.3 cm2)
2.34 8.75 (± 0.180) 3.21 24.1 (± 0.0595) 1.54* 6.19 (± 0.429)
All tested 24-well tissue culture inserts were coated with collagen type I. The cell seeding density varied between 3.0 × 104 and 15 × 104 cells/cm2 for hCMEC/D3,
between 4.5 × 104 and 17 × 104 cells/cm2 for hBMEC, and between 1.5 × 104 and 15 × 104 cells/cm2 for TY10 (n = 2–3).
#CCL outside the acceptable range of 0.5-5.0 μF/cm
2 almost during the whole experiment, indicating that cells were not confluent; PC: polycarbonate;
PES: polyester; PET: polyethylene terephthalate; *before first change of medium; **after third change of medium.
Figure 6 Mean TEER values for hBMEC cell line in mono-cultures and co-cultures with immortalized astrocytes (SVG-A) and immortalized
pericytes (HBPCT). Experiments using 24-well tissue culture inserts from CorningW (transparent PES membrane, 0.4 μm pore size, 4.0 × 106 pores/cm2,
n = 2). Maximal TEER values (30.7 ± 0.660 Ωcm2 on day 12) were obtained with hBMEC mono-cultures. Co-culture models with SVG-A and HBPCT cells
did not result in increased TEER values. Data were recorded with an EVOM coupled to an Endohm-6 measurement chamber.
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differences between TEER values were not significant.
Highest TEER values were observed with 24-well tissue
culture inserts from CorningW (transparent PES mem-
brane, 3.0 μm pore size, 2.0 × 106 pores/cm2), from
MilliporeW (translucent PET membrane, 3.0 μm pore
size, 2.0 × 106 pores/cm2), and from Greiner Bio-oneW
(transparent PET membrane, 3.0 μm pore size, 0.6 × 106
pores/cm2), with a maximum TEER up to 12 Ωcm2
(Table 1). For these experiments, hCMEC/D3 cells were
cultured with growth medium containing 20% FBS to
allow for direct comparisons between all cell lines. When
hCMEC/D3 cells were cultured with initial medium con-
taining 5% FBS, maximal TEER values were in the same
range (around 10 Ωcm2) as when cultured in growth
medium containing 20% FBS (Figures 3A and B).
hBMEC mono-cultures
TEER values of hBMEC monolayers were between 2.79
and 28.4 Ωcm2. The highest value was measured on
24-well tissue culture inserts (transparent PET membrane,
3.0 μm pore size, 0.6 × 106 pores/cm2) from Greiner
Bio-oneW (Table 1 and Figure 3C).
TY10 mono-cultures
TEER values for TY10 monolayers were between 4.56
and 13.0 Ωcm2. The highest value was recorded when
cells were cultured at 37°C from the start of the experi-
ment on inserts from Greiner Bio-oneW (transparent
PET membrane, 3.0 μm pore size, 0.6 × 106 pores/cm2)
(Table 1). TEER values were not increased when cul-
turing TY10 monolayers at the permissive temperature
of 33°C for 2 days before transferring them to 37°C
(Figure 3D).
BB19 mono-cultures
With monolayers of BB19 cells on various 24-well tissue
culture inserts, only extremely low TEER values in the
range of 5 Ωcm2 were obtained (Figure 3E). Despite re-
peated experiments, CCL values remained outside of the
acceptable range of 0.5-5.0 μF/cm2, indicating that cell
layers were not confluent. Since barrier restriction with
such a low TJ resistance was not sufficient for reliable
in vitro BBB models, BB19 cell line was not further in-
cluded in our studies for paracellular tightness assess-
ment using the integrity markers Na-F and LY.
Further optimization of hBMEC mono-cultures
Since TEER values were highest (28.4 ± 2.47 Ωcm2) with
monolayers of hBMEC cells cultivated on Greiner Bio-
oneW inserts (transparent PET membrane, 3.0 μm pore
size, 0.6 × 106 pores/cm2) coated with collagen type I
(Table 1), we optimized this particular mono-culture sys-
tem by varying parameters such as cell seeding density,80coating material and procedure, and by testing different
growth media compositions.
Optimization resulted in TEER values in the range of
40 Ωcm2 (Table 2). A maximal TEER value of 43.6 ±
3.89 Ωcm2 (after 3.19 days in vitro) was obtained when
hBMEC cells were cultured under normal growth condi-
tions (growth medium containing 20% FBS) at a seeding
density of 4.5 × 104 cells/cm2 (Table 2). Lower or higher
cell seeding densities resulted in decreased maximal
TEER values (25.9 ± 0.635 Ωcm2 at 3.0 × 104 cells/cm2
and 28.4 ± 2.47 Ωcm2 at 15 × 104 cells/cm2). The duration
of coating the tissue culture inserts with collagen type I
did not have an impact on TEER (data not shown). Coat-
ing the inserts with collagen type IV/fibronectin did not
further improve barrier tightness. However, coating the
tissue culture inserts with matrigel resulted in a decrease
of maximal TEER values (16.6 ± 0.183 Ωcm2 compared to
28.4 ± 2.47 Ωcm2). Growth media containing barrier indu-
cing compounds such as dexamethasone (500 nM and
1000 nM, respectively), 8-(4-CPT)-cAMP (250 μM),
RO-20-1724 (17.5 μM), additional HC (500 nM and
1500 nM, respectively), or additional hEGF (50 ng/mL
and 100 ng/mL, respectively) did not significantly in-
crease the TEER of hBMEC monolayers. Growth medium
supplemented with HS (10% and 20%, respectively) in-
stead of 20% FBS resulted in a decreased maximal TEER
(20.4 ± 0.867 Ωcm2 and 26.2 ± 0.324 Ωcm2, respectively,
compared to 28.4 ± 2.47 Ωcm2). The use of ACM-1 re-
sulted in a decrease of the maximal TEER (13.5 ± 0.614
Ωcm2, compared to 28.4 ± 2.47 Ωcm2). A similar result,
i.e. a decrease of maximal TEER, was obtained when
using a mixture of ACM-2 and growth medium 20%
FBS (1:1) (23.8 ± 0.572 Ωcm2, compared to 28.4 ± 2.47
Ωcm2).
Evaluation of paracellular permeability through
mono-cultures
Since highest TEER values were observed when hBMEC
monolayers were cultured on rat-tail collagen type I
coated Greiner Bio-oneW inserts (transparent PET mem-
brane, pore size 3.0 μm, 0.6 × 106 pores/cm2) at a cell
seeding density of 4.5 × 104 cells/cm2 (Table 1), this in-
sert was selected for permeability studies using Na-F
(MW 376.27) and LY (MW 550.39). For hBMEC cell
line, the mean Papp for Na-F was 5.08 ± 0.220 × 10
-6 cm/s
(Figure 7A). For LY, the mean Papp was 5.39 ± 0.364 ×
10-6 cm/s (Figure 7B). For hCMEC/D3, mean Papp
values for Na-F and LY were 12.5 ± 0.326 × 10-6 cm/s
and 10.0 ± 0.498 × 10-6 cm/s, respectively, when cells
were grown with initial medium containing 5% FBS
(Figures 7A and B). When hCMEC/D3 cells were cul-
tivated with growth medium containing 20% FBS, mean
Papp values for Na-F and LY were 13.4 ± 0.484 × 10
-6 cm/s
and 11.7 ± 0.957 × 10-6 cm/s, respectively (Figures 7A
Table 2 Summary of maximal TEER values recorded real-time by the CellZscope system for hBMEC mono-cultures using
a range of different culture conditions
Culture conditions Cell seeding
density (cells/cm2)
Time (d) Mean max. TEER ±
S.E.M. (Ωcm2)
Cell seeding density: 3.0 × 104 cells/cm2, coating: collagen type I (10 μg/cm2) 3.0 × 104 1.72* 25.9 (± 0.635)
Cell seeding density: 4.5 × 104 cells/cm2, coating: collagen type I (10 μg/cm2) 4.5 × 104 3.19 43.6 (± 3.89)
Growth medium with additional HC (500 nM) for 3 days (only apical),
coating: collagen type I (10 μg/cm2)
4.5 × 104 3.19 43.2 (± 4.27)
Growth medium with additional HC (1500 nM) for 3 days (only apical),
coating: collagen type I (10 μg/cm2)
4.5 × 104 3.19 40.4 (± 0.646)
Cell seeding density: 6.0 × 104 cells/cm2, coating: collagen type I (10 μg/cm2) 6.0 × 104 1.72* 36.3 (± 2.06)
Cell seeding density: 9.0 × 104 cells/cm2, coating: collagen type I (10 μg/cm2) 9.0 × 104 4.15 38.9 (± 0.928)
Growth medium with dexamethasone (500 nM) for 3 days (only apical),
coating: collagen type I (10 μg/cm2)
9.0 × 104 4.15 35.9 (± 0.338)
Growth medium with dexamethasone (1000 nM) for 3 days (only apical),
coating: collagen type I (10 μg/cm2)
9.0 × 104 4.15 38.0 (± 1.26)
Growth medium with additional hEGF (50 ng/mL) for 3 days (only apical),
coating: collagen type I (10 μg/cm2)
9.0 × 104 4.15 36.4 (± 0.902)
Growth medium with additional hEGF (100 ng/mL) for 3 days (only apical),
coating: collagen type I (10 μg/cm2)
9.0 × 104 4.15 40.0 (± 1.94)
Growth medium with 8-(4-CPT)cAMP (250 μM) and RO-20-1724 (17.5 μM)
(apical and basolateral), coating: collagen type I (10 μg/cm2)
9.0 × 104 2.84 20.0 (± 0.509)
Growth medium with 8-(4-CPT)cAMP (250 μM) and RO-20-1724 (17.5 μM),
added after 2 days in vitro (apical and basolateral), coating: collagen type I (10 μg/cm2)
9.0 × 104 2.84 20.9 (± 1.36)
Cell seeding density: 15 × 104 cells/cm2, coating: collagen type I (10 μg/cm2) 15 × 104 2.75 28.4 (± 2.47)
Coating: collagen type IV/fibronectin (80/20 μg/cm2) 15 × 104 2.75 29.3 (± 1.10)
Coating: matrigel (80 μg/cm2) 15 × 104 2.75 16.6 (± 0.183)
Growth medium with 10% HS (apical and basolateral), coating: collagen type I (10 μg/cm2) 15 × 104 1.26* 20.4 (± 0.867)
Growth medium with 20% HS (apical and basolateral), coating: collagen type I (10 μg/cm2) 15 × 104 1.21* 26.2 (± 0.324)
ACM-1 (apical and basolateral), coating: collagen type I (10 μg/cm2) 15 × 104 1.64* 13.5 (± 0.614)
Mixture of ACM-2 and growth medium 20% FBS (1:1) (apical and
basolateral), coating: collagen type I (10 μg/cm2)
15 × 104 3.35 23.8 (± 0.572)
24-Well tissue culture inserts were from Greiner Bio-one® (transparent PET membrane, pore size 3.0 μm, 0.6 × 106 pores/cm2, n = 2–3). *Before first change
of medium.
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were 12.4 ± 0.155 × 10-6 cm/s and 9.68 ± 0.413 × 10-6 cm/s,
respectively (Figures 7A and B). Mean recoveries for Na-F
in all experiments were between 75% and 87% (Figure 7C).
For LY, mean recoveries were between 66% and 79%
(Figure 7D). According to Hubatsch et al. (2007), a
mass balance of at least 80% would be optimal to give
an acceptable approximation of the Papp value [44]. After
each experiment, TEER values were in the same range as
before the assay (or even higher) (Figures 3A-D), suggest-
ing that cell monolayers were robust during the experi-
ment and barrier integrity was maintained.
Evaluation of paracellular permeability through contact
co-cultures
Since lowest Papp values were obtained with hBMEC mono-
layers (Figures 7A and B), we established co-culture models
with SVG-A and HBPCT cells to further assess paracellular
permeability. Mean Papp values for Na-F through hBMEC81co-cultured with SVG-A and HBPCT cells were 7.43 ±
0.200 × 10-6 cm/s and 8.26 ± 0.893 × 10-6 cm/s, respectively
(compared to 5.08 ± 0.220 × 10-6 cm/s through hBMEC
mono-cultures). Since a culture medium supplemented
with growth factors may mask the potential BBB in-
ducing effect of astrocytes and pericytes, further ex-
periments were performed using culture medium without
growth factors. Mean Papp values for Na-F through
hBMEC monolayers cultured without growth factors was
5.11 ± 0.0487 × 10-6 cm/s (Figure 8). Through hBMEC
cells co-cultured with SVG-A or HBPCT cells using
medium deprived of growth factors, mean Papp values
were slightly higher (6.88 ± 0.516 × 10-6 cm/s and 7.22 ±
0.455 × 10-6 cm/s, respectively) (Figure 8). In all experi-
ments, mean recoveries were between 98% and 102%.
Discussion
There is a need for predictive assays amenable to medium
to high-throughput screening for the assessment of brain
Figure 7 Mean Papp values (A, B) and mean recoveries (C, D) for Na-F and LY through hCMEC/D3, hBMEC, and TY10 monolayers.
24-Well tissue culture inserts from Greiner Bio-oneW (transparent PET membrane, 3.0 μm pore size, 0.6 × 106 pores/cm2) were used (n = 3–5).
A, B: Lowest paracellular permeability of Na-F and LY was obtained through hBMEC monolayers (5.08 ± 0.220 × 10-6 cm/s and 5.39 ± 0.364 ×
10-6 cm/s, respectively). All experiments for Na-F permeability were carried out at the time indicated with a black arrow in Figures 3A-D.
For LY, permeability measurements were carried out at TEER values in the same range (graphs not shown). C, D: Mean recoveries of Na-F
in all experiments were in the range of 75% and 87%. For LY, mean recoveries varied between 66% and 79%. *cultured with initial
medium; **cultured with growth medium 20% FBS.
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talized human brain capillary endothelial cell lines have
been developed and used for the establishment of hu-
man in vitro BBB models [9]. The most extensively
characterized human cell line is the hCMEC/D3 cell line,
which has been reported to represent a promising in vitro
human BBB model for drug transport studies [45,46].
TY10 cell line, transduced with a temperature-sensitive
SV40 large-T antigen, has furthermore been reported to
be a promising and advantageous cell line with excel-
lent expression of TJ proteins such as claudin-5, occlu-
din, and ZO-1 [26]. Whereas at 33°C, TY10 cells can be
cultivated for more than 50 passages without undergoing
morphological changes, a temperature shift from 33°C to
37°C results in the exclusion of the SV40 large-T antigen
as a cancer gene [33,34].
However, monolayers of immortalized human brain
capillary endothelial cell lines are known to form only82moderately restrictive barriers, with TEER values in the
range of 20–200 Ωcm2 [17,20,21]. To increase barrier
tightness of four currently available human brain capil-
lary endothelial cell lines, hCMEC/D3, hBMEC, TY10,
and BB19 (Figure 1), we tested co-culture models with
immortalized human astrocytes (SVG-A cell line) and
pericytes (HBPCT cell line). Interestingly, we did not ob-
serve an increase of TJ resistance in immortalized hu-
man brain capillary endothelial cells under co-culture
conditions. All co-culture models produced TEER values
that were comparable or lower than those recorded
with mono-cultures (for hBMEC cell line, see Figures 6
and 8A). This suggested that the investigated endothelial
cell lines were unable to respond positively to stimuli from
immortalized astrocytic or pericytic cells.
These findings are in accord with previous reports in
which no additional benefit in terms of TEER was ob-
served when culturing hCMEC/D3 cells with ACM or
Figure 8 Mean TEER (A) and Papp (B) values for hBMEC cultured without growth factors in mono-cultures and contact co-cultures with
SVG-A and HBPCT cells. A: Mean TEER values recorded real-time by the CellZscope system for hBMEC cells cultured without growth factors
(w/o GF) in mono-cultures and co-cultures with SVG-A (black curve) or HBPCT cells (green curve). 24-Well tissue culture inserts from Greiner
Bio-oneW (transparent PET membrane, 3.0 μm pore size, 0.6 × 106 pores/cm2) were used (n = 3). Compared to co-cultures with SVG-A and HBPCT
cells, hBMEC mono-cultures produced higher TEER values in the range of 40 Ωcm2 (blue curve). CCL values were in the acceptable range of
0.5-5.0 μF/cm2 (data not shown), indicating that hBMEC cells were confluent. The black arrow indicates the time when the permeability assay with
Na-F was performed. B: Mean Papp values for Na-F through hBMEC cultured without growth factors through mono-cultures and co-cultures with
SVG-A or HBPCT cells. Lowest Papp values for Na-F (5.11 ± 0.0487 × 10
-6 cm/s) were obtained through hBMEC mono-cultures. Mean recoveries in
all experiments were between 98% and 102% (n = 3).
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trocytes, respectively [24,47]. In contrast, our results do
not support recent findings which showed that TJ resist-
ance of hCMEC/D3 and TY08 cells was significantly in-
creased in co-cultures with human brain astrocytes/
pericytes and HBPCT cells, respectively [29,48]. This di-
vergent effect might possibly be due to the difference of
culture conditions and the nature of cell types.
We observed that membrane material of inserts and
pore size had a significant impact on barrier tightness,
and we optimized mono-culture systems by systematic-
ally screening a large set of 24-well tissue culture inserts
from different providers for each cell line (Table 1).
Highest TEER values (28.4 ± 2.47 Ωcm2) were observed
with hBMEC mono-cultures on 24-well tissue culture
inserts from Greiner Bio-oneW with transparent PET
membrane and 3.0 μm pore size (Table 1). Our findings
clearly show that the selection of an appropriate tissue
culture insert is critical when establishing a BBB model
using these immortalized human brain capillary endo-
thelial cell lines, corroborating previous findings in
which a substantial impact of material characteristics on
the adherence of cells and barrier tightness was demon-
strated [31,32]. hCMEC/D3 and TY10 cells produced
TEER values in the range of 10 Ωcm2 (Table 1). BB19
cells were not included into the screening of tissue cul-
ture inserts, since these cells yielded extremely low
TEER values (around 5 Ωcm2, Figure 3E). These findings
are in agreement with previous studies suggesting that83the use of BB19 cells as an in vitro model of the human
BBB is limited due to a high sucrose permeability [49].
Surprisingly, we consistently observed lower TEER
values as compared to literature (hCMEC/D3 and hBMEC:
TEER ranging from 40–200 Ωcm2 [21,24,25], TY10: TEER
in the range of 40 Ωcm2 [26]). A possible explanation
may be that we used a different system (automated
CellZscope) for assessment of TEER [30]. Low TEER
values might also arise from a high concentration of
serum and growth factors in the growth medium, which
has been reported to prevent TJ formation between endo-
thelial cells [50]. However, hCMEC/D3 cells cultured with
growth medium containing 5% FBS instead of 20% FBS,
and hBMEC cells cultured in growth medium without
growth factor supplementation did not result in in-
creased TEER values or reduced paracellular permeability
(for hCMEC/D3, see Figures 3A, 3B, Figures 7A, and 7B,
for hBMEC see Figure 8). Furthermore, the selection of
the well format might affect TEER values. Because we
aimed to establish an in vitro BBB model suitable for
higher throughput, we miniaturized the assay to a 24-well
format that was selected previously for a bovine in vitro
BBB model [41].
Subsequent optimization of the hBMEC mono-culture
system resulted in TEER values in the range of 30–40
Ωcm2 (Table 2). We found that the cell seeding density
is critical, since highest TEER values were obtained
when hBMEC cells were seeded at a density ranging be-
tween 4.5 × 104 and 9.0 × 104 cells/cm2 onto coated
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cell growth and TJ development between adjacent cells
on the surface area of the Greiner Bio-oneW inserts
(0.336 cm2). As hBMEC cells are of human origin, we
moreover investigated the effect of HS on barrier tight-
ness. However, no increase in TEER could be observed
(Table 2). These results do not confirm previous findings
that the permeability of sucrose through hCMEC/D3
monolayers could significantly be reduced by HS supple-
mentation [45]. One may speculate that this could be
due to a different type of HS used in these experiments.
An individual HS batch as used for our experiments is
prone to higher batch-to-batch variation in soluble
factors and proteins than pooled HS from commercial
sources.
In the evaluation of paracellular permeability, mean
Papp values for Na-F and LY were significantly lower
with hBMEC monolayers (5.08 ± 0.220 × 10-6 cm/s
and 5.39 ± 0.364 × 10-6 cm/s, respectively) than with
hCMEC/D3 and TY10 monolayers (Figures 7A and B),
corroborating our measurements of TEER values. Perme-
ability values in the order of 10-6 cm/s were obtained pre-
viously in various in vitro BBB models [7,20,39,51].
In the biochemical and immunocytochemical characterization
of cellular junctions, VE-cadherin was detected in all cell
lines, albeit at varying levels (Figure 4). This confirmed
their endothelial lineage. Interestingly, the TJ protein
claudin-5 was expressed at similar levels as VE-cadherin,
confirming that VE-cadherin controls claudin-5 expres-
sion [52]. The cellular junction marker protein ZO-1
showed the same level of expression in hCMEC/D3 and
hBMEC cells, but was expressed only at very low levels in
BB19 and TY10 cells (Figure 4). Furthermore, white
arrows in Figure 5 point to ZO-1 signal at the leading
edge of migrating hBMEC cells, confirming findings
of previous studies [13].
We used an automated CellZscope system [30] in
order to obtain highly standardized data on-line. This
system has several advantages over other methods of
TEER measurement: TEER values are recorded in real-
time every hour in the incubator, thereby reducing work-
load and avoiding any damage of the cell layer during
growth. Also, a disruption of the cell layer is immedi-
ately visible from the recording. In addition, information
about confluency (CCL values) is obtained simultan-
eously, reducing the risk of false interpretation of TEER
values [53]. Experiments with Caco-2 cells on 24-well in-
serts demonstrated that the CellZscope is likewise an ef-
ficient tool for evaluating barrier tightness in other cell
lines, i.e. those used for the study of intestinal drug ab-
sorption. Again, independent of the membrane surface
area, TEER values of Caco-2 monolayers measured with
the CellZscope (24-well format) correlated to off-line
TEER values measured manually with an EVOM using a846-well format (data not shown). One limitation of the
CellZscope system may be its design which does not
allow the seeding of cells on the bottom of the plate. In-
vestigation of triple co-culture model systems is hence
not possible.
Conclusions
In the screening of four available immortalized human
brain capillary endothelial cell lines, hBMEC proved to
be the most suitable and promising cell line for a human
in vitro BBB model in terms of barrier tightness and
paracellular permeability in a 24-well mono-culture
system. hBMEC cells express P-gp [54], claudin-1 [55],
claudin-3 [56], occludin [55-57], ZO-1 [54-56,58], ß-
catenin [58], ICAM-1 [56], and VCAM-1 [56], some of
which were also shown under our experimental condi-
tions (VE-cadherin, ZO-1, and claudin-5, see Figures 4
and 5). Interestingly, although all three examined markers
were detected in hBMEC, the expression level of VE-
cadherin and claudin-5 was much lower than in hCMEC/
D3 and TY10 cells. As a next step, we are currently
validating the hBMEC model with the aid of a series
of compounds known to cross or not to cross the
BBB. After validation, the in vitro human BBB model
will be used for the screening of natural product de-
rived leads, such as GABAA receptor modulators [59],
regarding their ability to pass across the BBB.
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Abstract We recently established and optimized an immor-
talized human in vitro blood-brain barrier (BBB) model based
on the hBMEC cell line. In the present work, we validated this
mono-culture 24-well model with a representative series of
drug substances which are known to cross or not to cross the
BBB. For each individual compound, a quantitative UHPLC-
MS/MS method in Ringer HEPES buffer was developed and
validated according to current regulatory guidelines, with respect
to selectivity, precision, and reliability. Various biological and
analytical challenges were met during method validation,
highlighting the importance of careful method development.
The positive controls antipyrine, caffeine, diazepam, and pro-
pranolol showed mean endothelial permeability coefficients
(Pe) in the range of 17–70×10
−6 cm/s, indicating moderate
to high BBBpermeability when compared to the barrier integrity
marker sodium fluorescein (mean Pe 3–5 × 10
−6 cm/s).
The negative controls atenolol, cimetidine, and vinblastine
showed mean Pe values<10×10
−6 cm/s, suggesting low per-
meability. In silico calculations were in agreement with
in vitro data. With the exception of quinidine (P-glycoprotein
inhibitor and substrate), BBB permeability of all control com-
pounds was correctly predicted by this new, easy, and fast to
set up human in vitro BBBmodel. Addition of retinoic acid and
puromycin did not increase transendothelial electrical resistance
(TEER) values of the BBB model.
Keywords UHPLC-MS/MS .Method validation . FDA/
EMA . In vitro human blood-brain barrier (BBB)model .
Permeability coefficient . hBMEC cell line
Introduction
Central nervous system (CNS) drugs need to penetrate the
brain in order to reach their targets. Brain penetration is con-
trolled by the blood-brain barrier (BBB), a uniquely tight cel-
lular layer of endothelial cells lining the cerebral capillaries
which restricts the passage of molecules from the blood circu-
lation into the brain [1, 2]. Only 2 % of small molecule drugs
are able to reach the CNS [2]. Compounds targeted at the CNS
should, therefore, be screened already at an early stage of drug
development for BBB permeability, since low permeation
across the BBB can limit CNS exposure [3].
Numerous cell-based in vitro BBBmodels have been imple-
mented in academia and industry for early prediction of BBB
permeability of lead compounds [4, 5]. However, despite con-
siderable efforts in recent years, there is still a need for simple
and reliably predictive BBB permeation assays based on hu-
man cells [6]. Primary endothelial cells of animal brain origin
have repeatedly been shown to form relatively restrictive cellu-
lar barriers in vitro [7–10], but a limitation of suchmodels is the
species-dependent difference in expression of transporter pro-
teins and efflux pumps [11, 12]. Models using primary cultures
of human origin would avoid interspecies pharmacogenetic dif-
ferences, but the availability of such cells is restricted due to
ethical reasons. In addition, isolation, purification, and cultiva-
tion of primary cells are cumbersome and time-consuming;
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yields of cells are relatively low, and the lifespan of primary
cells is limited due to rapid de-differentiation and loss of phe-
notype. Because of these limitations, immortalized cerebral
capillary endothelial cells have been generated by transfection
with tumor genes (e.g., SV40 large-T antigen) [13–17]. Unlike
primary cells, immortalized cells are relatively easy to cultivate,
and they maintain their phenotype even after repeated passag-
ing. These properties render them highly suitable for standard-
ized BBB permeability assays. Among immortalized cell lines,
those derived from human brain tissues are of greatest interest.
However, currently available human brain capillary endothelial
cell lines often show deficiencies, such as low transendothelial
electrical resistance (TEER) values, relatively high paracellular
permeation of negative control compounds, and insufficient
expression of key transporter systems [18]. Therefore, careful
optimization of in vitro BBB models utilizing human cell lines
and, even more importantly, validation of these models are
needed prior to their application to permeability screenings of
compounds.
We recently established and optimized a human in vitro
BBB model, whereby four currently available immortalized
human brain capillary endothelial cell lines (hCMEC/D3,
hBMEC, BB19, and TY10) were compared regarding their
ability to produce endothelial cell layers with sufficient barrier
tightness [19]. The hBMEC cell line was found to be most
suited for that purpose [13, 19]. The aim of the present study
was to validate this 24-well model with a representative series
of drug substances that are known to permeate the BBB to a
different extent (antipyrine, caffeine, diazepam, and propran-
olol as positive controls; atenolol, cimetidine, quinidine, and
vinblastine as negative controls) (Fig. 1). In order to ensure
reliability of results, we developed for each compound a quan-
titative ultra-high-performance liquid chromatography
coupled to tandem mass spectrometry (UHPLC-MS/MS) as-
say in Ringer HEPES buffer (RHB) and validated the assays in
terms of selectivity, specificity, precision, accuracy, and reli-
ability according to the bioanalytical method validation guide-
lines of the US Food and Drug Administration (FDA) and
European Medicines Agency (EMA) [20, 21]. Finally, the
compounds were screened in the human in vitro BBB model,
and endothelial permeability coefficients (Pe) across hBMEC
monolayers were determined by means of the validated
UHPLC-MS/MS methods. Barrier tightness was assessed via
continuous on-line measurement of TEER values and with the
fluorescent barrier integritymarker sodium fluorescein (Na-F).
Materials and methods
Chemicals and reagents
Antipyrine, atenolol, caffeine, chloroquine, cimetidine,
nizatidine, propranolol, quinidine, Na-F, Tween 20, and
bovine serum albumin (BSA) were purchased from Sigma-
Aldrich (Steinheim, Germany). Vinblastine and vincristine
were obtained from Tocris (Bristol, UK). Diazepam and
temazepam were supplied by Lipomed (Arlesheim,
Switzerland). Acetonitrile, methanol, formic acid (FA),
trifluoroacetic acid (TFA), and ammonium formate were all
HPLC grade and were purchased from BioSolve
(Valkenswaard, the Netherlands). Dimethyl sulfoxide
(DMSO) was purchased from Scharlau (Scharlab AG,
Sentmenat, Spain). HPLC grade water was obtained by a
Milli-Q integral water purification system (Millipore Merck,
Darmstadt, Germany). Ringer HEPES buffer (RHB) (150mM
NaCl, 2.2 mM CaCl2, 0.2 mMMgCl2, 5.2 mM KCl, 2.8 mM
glucose, 5 mM HEPES, 6 mM NaHCO3) was prepared in-
house, adjusted to pH 7.4, filtered, and stored at 4 °C. 24-
well plates and inserts (transparent PET membrane, 3.0-μm
pore size, 0.6×106 pores/cm2) were obtained from Greiner
Bio-one (Frickenhausen, Germany). Immortalized human
brain microvascular endothelial cell line (hBMEC) [13] was
obtained from Profs. Kwang Sik Kim and Dennis Grab (Johns
Hopkins University, Baltimore, MD, USA).
Stock solutions, calibration standards, and quality
controls
Stock solutions of analytes and internal standards (IS) were
prepared separately by dissolving at least 2 mg of compound
in 10 mL of DMSO or high purity water (chloroquine).
Weightings were done on a micro analytical balance
(Sartorius, Switzerland). Working solutions (WS1) of analyte
and IS at a concentration of 10, 20, or 100 μg/mL in methanol
were prepared by further diluting the respective stock solu-
tions. For analytes, calibration standards (calibrators) and
quality controls (QCs) in RHB at low, medium, and high
concentrations (QCL, QCM, and QCH) were prepared by
serial dilution of the respective WS1 (range 2.00–200 ng/mL
for atenolol, propranolol, and quinidine; 5.00–500 ng/mL for
antipyrine, diazepam, and vinblastine; 10.0–1000 ng/mL for
caffeine and cimetidine). For vinblastine, a modified RHB
was used (RHB+0.2 % Tween 20). The first concentration
level of the calibrators was defined as lower limit of quantifi-
cation (LLOQ) and the last level as upper limit of quantifica-
tion (ULOQ). Calibrators and QCs were aliquoted into poly-
propylene tubes (or glass vials in the case of vinblastine) and
stored below −65 °C until analysis. For the IS, a second work-
ing solution (WS2) in methanol was prepared daily by further
diluting the respective WS1.
Sample extraction from Ringer HEPES buffer
RHB samples were extracted by means of protein precipita-
tion. Sample aliquots (200 μL) were spiked with 100 μL of
freshly prepared WS2 of the IS (chloroquine and propranolol
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200 ng/mL; caffeine 250 ng/mL; antipyrine 500 ng/mL; aten-
olol, nizatidine, and temazepam 1000 ng/mL; vincristine
2000 ng/mL). Subsequently, samples were spiked with
200 μL BSA solution (60 g/L) and then subjected to protein
precipitation with ice cold acetonitrile (1000 μL). After
vortexing and stirring for 10 min on an Eppendorf Mixmate
(Vaudaux-Eppendorf, Schönenbuch, Switzerland), the mix-
ture was centrifuged for 20 min at 16,168g (13,200 rpm)
(MiniSpin plus, Vaudaux-Eppendorf, Schönenbuch,
Switzerland). The supernatant was transferred into a 96-deep
well plate (96-DWP), dried under nitrogen (Evaporex EVX-
96, Apricot Designs, Monovia, CA, USA), and thereafter
reconstituted with corresponding injection solvent (200 μL)
(see Electronic Supplementary Material (ESM) Table S1). For
optimal reconstitution, the 96-DWP was stirred on an
Eppendorf Mixmate for 30 min at 2000 rpm and subsequently
centrifuged for 4 min at 2063g (3000 rpm) (Megafuge,
Heraeus Instruments AG, Switzerland). Samples were
injected into the UHPLC-MS/MS in full loop mode (injection
volumes see ESM Table S1) directly out of the 96-DWP or
transferred into glass vials in the case of vinblastine.
UHPLC-MS/MS settings
Method validation was performed on aWaters Acquity UPLC
system coupled to a Waters Acquity TQD (Waters, Milford,
MA, USA). The UPLC system consisted of a binary pump, a
cooling autosampler (set at 10 °C, protected from light), and a
column heater. Separation of analytes and IS was achieved
wi th an Acqu i ty UPLC HSS T3 co lumn (C18 ;
2.1×100 mm; 1.8-μm particle size) heated to 45 °C, and for
cimetidine, with an Acquity UPLC BEH column (C18;
2.1×50 mm; 1.7-μm particle size) heated to 70 °C (both col-
umns from Waters, Milford, MA, USA). Columns were
protected by an Acquity UPLC column in-line filter unit
(0.2 μm in-line frit). For antipyrine, atenolol, caffeine, and
diazepam, mobile phase Awas 0.1 % FA in water, and mobile
phase B was 0.1 % FA in acetonitrile (ESM Table S1). For
cimetidine, propranolol, and quinidine, mobile phase A was
5 mMammonium formate in water containing 0.05% FA, and
mobile phase B was 0.05 % FA in acetonitrile (ESM
Table S1). For vinblastine, mobile phase A was 10 mM am-
monium formate in water containing 0.1 % FA and mobile
Fig. 1 Compounds used for the
validation of the in vitro BBB
model and corresponding IS for
UHPLC-MS/MS quantitation
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phase B was 0.1 % FA in acetonitrile (ESM Table S1). Total
run time was 4 min for vinblastine, 5 min for cimetidine, and
6 min for all other analytes (ESM Table S1). The flow rate of
the mobile phase was set at 0.7 mL/min for cimetidine and at
0.4 mL/min for all other analytes (ESM Table S1). Gradients
for all analytes are listed in ESM Table S1. Weak wash solu-
tion was a mixture of acetonitrile and water (50/50, v/v) con-
taining 0.2 % TFA. Strong wash solution was a mixture of
acetonitrile, isopropanol, and acetone (40/30/30, v/v/v) con-
taining 0.2 % TFA. Seal wash solution was a mixture of ace-
tonitrile and water (10/90, v/v).
The TQD system was equipped with an electrospray ioni-
zation (ESI) interface and operated in positive ion mode (ESI+
) and in multiple reaction monitoring (MRM)mode. Nitrogen,
provided by a nitrogen generator N2-Mistral (Schmidlin AG,
Neuheim, Switzerland), was used both as desolvation gas and
as cone gas. Argon was used as collision gas. Source temper-
ature was set at 150 °C. MS/MS transitions and parameters
were generated using Waters IntelliStart software and subse-
quently optimized manually. MRM transitions, cone voltage,
and collision energy for analytes and IS are listed in Table 1.
Data were acquired with MassLynx V4.1 software and quan-
tification was done using QuanLynx software (Waters,
Milford, MA, USA).
Method validation
Method validation for the quantification of analytes by
UHPLC-MS/MS was performed according to the guidelines
of the FDA [20] and EMA [21]. Imprecision in all validation
tests was expressed by the coefficient of variation (CV %).
According to the guidelines, the CV % had to be below 15 %
(below 20 % at the LLOQ) of the nominal values at all con-
centration levels. Inaccuracy in all validation tests was
expressed by the relative error (RE %) and had to be within
±15 % (within ±20 % at the LLOQ) of the nominal values at
all concentration levels.
Calibration curve and regression parameters
Seven calibrators were injected with increasing concentration
after a blank sample (blank RHB) and a calibrator zero (RHB
only spiked with IS). Each validation run, performed on dif-
ferent days, consisted of a set of calibrators at the beginning
and at the end of the run. The calibration curve was validated
through six QCs (duplicates of QCL, QCM, and QCH), which
were inserted randomly into the analytical run. The weighting
factor was determined during the first run to obtain a consis-
tent dispersion of measure errors across the range. According
to the guidelines, a run was valid if at least 75 % of all cali-
brators were used to generate the calibration curve. For the
LLOQ and the ULOQ, at least one replicate had to be accept-
ed. For the six QCs, at least four replicates in total and at least
one replicate at each level had to be accepted [20, 21].
Carryover
To assess the carryover of both analyte and IS in each analyt-
ical run, blank samples were injected after the ULOQ. Peak
areas of analyte and IS in these blank samples were compared
to the peak areas at the LLOQ. Mean carryover in each ana-
lytical run, expressed in %, had to be below 20 % for analytes
and below 5 % for IS [21].
Specificity
A total of six blank samples (duplicates, three different
batches of RHB) without analyte and IS were injected into
the UHPLC-MS/MSwithin an analytical run. Peak areas were
assessed using a valid calibration curve, and they had not to
exceed 20 % of the mean peak areas of both replicates at the
LLOQ.
Selectivity
Six samples at the LLOQ (duplicates, three different batches
of RHB) were injected into the UHPLC-MS/MS within a
validation run. Concentrations were calculated using a valid
calibration curve. Selectivity imprecision (CV %) had to be
below 20% and inaccuracy (RE%) had to be within±20% of
the nominal values.
Table 1 Optimized MS/MS parameters in ESI positive mode for
analytes and corresponding ISs
Analyte
IS
MRM transitions Cone
voltage (V)
Collision
energy (eV)
Antipyrine
IS caffeine
189.00→ 56.00 28 22
195.00→ 138.06 38 20
Atenolol
IS propranolol
267.00→ 145.00 35 35
260.00→ 116.10 35 18
Caffeine
IS antipyrine
195.00→ 138.06 38 20
189.00→ 56.00 28 22
Cimetidine
IS nizatidine
252.80→ 159.05 22 14
331.80→ 155.05 22 18
Diazepam
IS temazepam
285.15→ 154.05 50 25
300.80→ 255.00 30 24
Propranolol
IS atenolol
260.10→ 116.05 34 19
267.13→ 55.95 32 30
Quinidine
IS chloroquine
324.95→ 80.90 40 34
319.70→ 247.05 35 20
Vinblastine
IS vincristine
811.00→ 355.10 60 38
825.00→ 765.20 68 38
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Within-run and between-run reproducibility
Six replicates at five concentration levels (LLOQ, QCL,
QCM, QCH, and ULOQ) were injected into the UHPLC-
MS/MS within three validation runs on three different days.
In each validation run, within-run imprecision (CV%) of each
level series had to be below 15 % (below 20 % at the LLOQ)
and within-run inaccuracy (RE %) had to be within±15 %
(within±20 % at the LLOQ) of the nominal values. Between-
run imprecision (CV%) and inaccuracy (RE%)were assessed
calculating the overall means and standard deviations (SD).
The acceptance criteria for between-run imprecision (CV %)
and inaccuracy (RE %) were the same as described above.
Dilution test
To assess the reliability of the method at concentration levels
outside the calibration ranges, dilution tests were performed.
From the WS1 of the analytes, a solution at a concentration
fivefold higher than the ULOQ was prepared. This solution
was first diluted to give a solution at a 10-fold lower concen-
tration, then further diluted to give a second solution at a 20-
fold (diazepam), 50-fold (cimetidine), or 100-fold (all other
compounds) lower concentration. Six replicates of both levels
were injected into the UHPLC-MS/MS system. For all repli-
cates of both QC series, the concentration was assessed using
a valid calibration curve and subsequently multiplied with the
corresponding dilution factor. Resulting mean concentrations,
imprecision, and inaccuracy were calculated. According to the
FDA/EMA guidances, the imprecision (CV %) had to be be-
low 15 % and the inaccuracy (RE %) had to be within±15 %
of the nominal values [20].
Extraction yield (recovery)
The extraction yield of the analytes was determined using six
replicates spiked with analyte at three different concentration
levels (QCL, QCM, and QCH) before extraction and spiked
with IS after extraction, compared to six replicates of blank
RHB samples spiked after extraction with analyte at three
different concentration levels (QCL, QCM, and QCH) and
with IS. The extraction yield of IS was determined using six
replicates spiked with IS before extraction and with analyte at
medium concentration after extraction, compared to six repli-
cates of blank RHB spiked after extraction with IS and analyte
at medium concentration. According to the FDA guidance, the
extent of recovery of the analyte and IS should be consistent,
precise, and reproducible [20].
Short-term stability tests
Freeze and thaw (F/T) stability Six replicates of QCL and
QCH were subjected to three freeze (below -65 °C) and
thaw (F/T) cycles, processed, and subsequently analyzed
using a valid calibration curve.
Benchtop stability at room temperature Six replicates of
QCL and QCH were stored for 4 h at room temperature
(RT), processed, and quantified using a valid calibration
curve.
Processed sample stability at autosampler conditions Six
replicates of QCL and QCH were injected into the UHPLC-
MS/MS after processing and quantified using a valid calibra-
tion curve. These 12 QCs were stored in the autosampler (set
at 10 °C, protected from light) for at least 24 h and reassessed
using a new calibration curve.
In all short-term stability tests, the imprecision (CV %) had to
be below 15 % and the inaccuracy (RE %) had to be within
±15 % of the nominal values at both concentration levels.
Long-term stability below −65 °C
Three replicates of QCL, QCM, and QCH were quantified
using a valid calibration curve at time zero (t=0), and three
replicates at the same concentration levels (QCL, QCM, and
QCH) were stored below −65 °C. After several days of stor-
age, the samples were processed and quantified using a valid
calibration curve generated by freshly prepared calibrators and
QCs. Results from samples stored below −65 °C were plotted
in function of results from time zero (t=0), and a curve was
fitted by linear regression (forced through zero). Samples were
considered as stable when the slope was within 1±0.15.
Stock solution stability
Fresh stock solutions for analytes and IS were prepared and
kept at RT for 4–6 h. Old stock solutions which were stored
below −65 °C for various time periods were thawed and sim-
ilarly kept at RT for 4–6 h. Subsequently, working solutions
for each compound at 5.00 μg/mL in respective injection sol-
vent (ESMTable S1) were prepared, injected six times into the
UHPLC-MS/MS system, and peak areas from old and fresh
stock solutions were compared. The eventual degradation had
to be below 5 %.
Human in vitro BBB model
The human mono-culture in vitro BBB model based on
hBMEC cell line was prepared as reported previously, with
minor modifications [19]. As culture medium, EBM-2 supple-
mented with Single-Quots (hydrocortisone, ascorbic acid, and
heparin), antibiotic-antimycotic solution, and 20 % fetal bo-
vine serum (heat inactivated at 56 °C for 30 min) was used
[19]. TEER values and cell layer capacitance (CCL) were
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monitored every hour using a 24-well CellZscope system
[22]. After 2.5–3 days of incubation of hBMEC monolayers
in the CellZscope (at a maximal TEER in the range of 20–
40 Ωcm2), the permeability assays for the compounds were
carried out. Briefly, the tissue culture inserts were transferred
into a 24-well plate containing 1200 μL of pre-warmed
(37 °C) RHB in each well (basolateral compartment).
Medium in inserts (apical compartment) was subsequently
replaced with 300 μL of a pre-warmed (37 °C) working solu-
tion containing the test compound (5 μM) and Na-F as barrier
integrity marker (10 μg/mL) in RHB containing 0.2 % BSA.
The 24-well plate was incubated at 37 °C on an orbital shaker
(ELMI DTS-2, Riga, Latvia) with moderate speed (300 rpm),
and aliquots of 250 μL of both apical and basolateral com-
partments were collected after several time points (15, 30, 60,
and 120 min) (one insert per time point) and stored below
−65 °C until analysis. Samples containing vinblastine were
stored in tubes pre-coated with 0.2 % Tween 20. All experi-
ments were performed at least in triplicate. Control experi-
ments were performed for all compounds, with and without
Na-F, to ensure that Na-F did not have an impact on the re-
sults. Na-F fluorescence was quantified with a Chameleon
microplate reader (Hidex, Turku, Finland), and quantification
of the test compounds was performed by means of the vali-
dated UHPLC-MS/MS methods.
Calculation of endothelial permeability coefficients (Pe)
Endothelial permeability coefficients (Pe) for each test sub-
stance and for Na-F were calculated as follows. For each rep-
licate (controls and samples), the cleared volume was calcu-
lated according to the following equation [23, 24]:
Clearance μLð Þ ¼ CBVB
CA
where CB and VB are the concentration and volume in the
basolateral compartments, respectively, and CA is the initial
concentration in the apical compartment. The cleared volume
was plotted as a function of time, and the slope was estimated
by linear regression analysis. Permeability-surface area prod-
ucts (PS) and Pe values were subsequently calculated accord-
ing to the following equations [23, 24]:
1
PStotal
−
1
PSfilter
¼ 1
PSe
PSe
A
¼ Pe
where PStotal is the slope of the clearance curve of cell mono-
layers with filter inserts, PSfilter is the slope of the clearance
curve of control filter inserts without cells, PSe is the slope of
the clearance curve for the endothelial cell monolayers, and A
is the surface area of the filter membrane (0.336 cm2).
Recovery (mass balance) was calculated according to the
following equation:
Recovery %ð Þ ¼ CAfVA þ Cb fVB
CA0VA
 100
where CAf and CBf are the final concentrations of the com-
pound in the apical and basolateral compartments, respective-
ly, CA0 is the initial concentration in the apical compartment,
and VA and VB are the volumes in the apical and basolateral
compartments, respectively. All results are expressed as
means±SEM.
In silico prediction of BBB permeability
Three-dimensional computer models of studied com-
pounds were built in Maestro modeling environment
[25]. The global minimum geometry was used as an
input for the QikProp application [26] to evaluate vari-
ous descriptors relevant for drug permeability. The polar
surface area (PSA) and the logarithm of partition and
distribution coefficient (LogP and LogD7.4, respective-
ly) descriptors were calculated using the Calculator
plugin of Chemaxon Marvin application [27].
Results
Method validation
Chromatographic performance
Calibration curves in the range of 2.00–200 ng/mL (atenolol,
propranolol, and quinidine), 5.00–500 ng/mL (antipyrine, di-
azepam, and vinblastine), and 10.0–1000 ng/mL (caffeine and
cimetidine) were fitted by least-squares quadratic regression,
and weighting factors of 1/X2 (caffeine and cimetidine) or 1/X
(all other compounds) were applied (ESM Table S2). The
mean coefficients of determination (R2) ranged from 0.9941
to 0.9986 (Table S2), fulfilling FDA/EMA acceptance criteria
(R2>0.96) [20, 21].
Carryover
Mean carryover in blank RHB samples injected after the
ULOQ was between 0.00 to 5.85 % for analytes and between
0.00 to 0.202 % for IS (Fig. 2, ESM Table S3). Acceptance
criteria were hence fulfilled (below 20 % for analyte, below
5 % for IS), demonstrating that carryover did not affect preci-
sion and accuracy of the methods [21].
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Specificity
Peak areas of the six blank samples (duplicates, three different
batches of RHB) were between 0.00 and 8.63 % of the mean
peak areas of the LLOQ for all quantification methods (data
not shown). Each UHPLC-MS/MS method was hence proved
to be specific for the corresponding analyte.
Selectivity
Selectivity imprecision (CV %) for the six samples at the
LLOQ (duplicates, three different RHB batches) was between
2.64 and 12.7 % (below 20 %), and inaccuracy (RE %) was
between −10.5 and 14.2 % (within ±20 %) for all quantifica-
tion methods (ESM Table S4). Hence, the quantification
methods were shown to be selective for the respective
analytes.
Within-run and between-run reproducibility
Within-run imprecision (CV%) was between 1.20 and 14.3%
(below 15 %) for all methods, and inaccuracy (RE %) was
between −12.1 and 9.86 % (within ±15 %) at all QC levels
(ESM Table S5). Between-run imprecision (CV %) ranged
Fig. 2 Typical MRM
chromatograms of RHB spiked at
1000 ng/mL (ULOQ) with
caffeine (a) and at 500 ng/mL
with IS antipyrine (b), of blank
RHB injected directly after the
ULOQ andmonitored for caffeine
(c) and for IS antipyrine (d), and
of RHB spiked at 10.0 ng/mL
(LLOQ) with caffeine (e) and at
500 ng/mL with IS antipyrine (f).
PA peak area
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from 1.98 to 8.79 % (below 15 %), and inaccuracy (RE %)
ranged from −15.7 to 3.70% at the LLOQ (within ±20 %) and
between −9.40 and 11.2 % at all other QC levels (within
±15 %) (Table 2). FDA/EMA acceptance criteria were ful-
filled, and the quantification methods proven to be precise,
accurate, and reproducible.
Dilution test
For both QC series, imprecision (CV %) was between 0.959
and 7.63 % (below 15 %) for both dilution factors, and
inaccuracy (RE %) was between −4.40 and 13.6 % (within
±15 %) for both dilution factors (ESM Table S6). It could
hence be demonstrated that dilution of samples up to 20-fold
(diazepam), 50-fold (cimetidine), or 100-fold (all other
analytes) did not affect the precision and accuracy of the
methods.
Extraction yield
Absolute recoveries were consistent at all levels (QCL, QCM,
and QCH) for all analytes and IS (ESM Table S7).
Freeze and thaw (F/T) stability
Atenolol, antipyrine, caffeine, diazepam, quinidine, and
vinblastine Imprecision (CV %) for the six replicates of
QCL and of QCH subjected to three successive F/T cycles
was between 0.660 and 10.5 % (below 15 %), and inaccuracy
(RE %) was between −12.9 and 6.44 % (within ±15 %) (ESM
Table S8). Hence, analytes were proven to be stable in RHB
after three F/T cycles below −65 °C.
Cimetidine and propranolol Imprecision (CV %) for the six
replicates of QCL and of QCH subjected to three F/T cycles
exceeded 15 % and inaccuracy (RE %) was outside ±15 % of
the nominal values (data not shown). This indicated that the
analytes were not stable after three successive F/T cycles be-
low −65 °C. Therefore, a new test with only two F/T cycles
was carried out. Imprecision (CV %) for the six replicates of
QCL and QCH was now between 0.990 and 4.10 % (below
15%), and inaccuracy (RE%) for both QC series was between
−4.43 and −0.622% (within ±15%) (ESMTable S8). The two
analytes were thus proven to be stable in RHB after two suc-
cessive F/T cycles below −65 °C.
Benchtop stability at room temperature
All analytes (except caffeine) Imprecision (CV%) for the six
replicates of QCL and QCH in RHB stored for 4 h at RTwas
between 1.65 and 9.86 % (below 15 %), and inaccuracy (RE
%) was between −9.57 and 3.33 % (within ±15 %) (ESM
Table S8). The analytes proved hence to be stable in RHB
when stored for 4 h at RT before sample extraction.
Benchtop stability at cold temperature
Caffeine Imprecision (CV %) for the six replicates of QCL
and QCH in RHB stored for 4 h at RT exceeded 15 % and
inaccuracy (RE %) was outside ±15 % of the nominal values
(data not shown). Therefore, samples in RHB were stored for
3 h at 4 °C (on ice). Imprecision (CV %) for QCL and QCH
was now 3.46 and 4.95 % (below 15 %), respectively, and
inaccuracy (RE %) for QCL and QCH was now −8.74 and
Table 2 Between-run imprecision (CV %) and inaccuracy (RE %) of
QCs, based on three series of six replicates for each level
Compound Nominal level (ng/mL)
2.00 6.00 100 160 200
Atenolol Mean 1.91 5.76 93.2 157 207
SD 0.106 0.217 5.28 5.86 13.9
CV % 5.56 3.78 5.66 3.73 6.73
RE % −4.62 −4.08 −6.77 −1.75 3.41
Propranolol Mean 1.69 5.44 102 166 210
SD 0.0922 0.299 6.80 6.17 7.03
CV % 5.47 5.51 6.65 3.73 3.35
RE % −15.7 −9.40 2.21 3.55 4.96
Quinidine Mean 2.01 6.16 103 163 206
SD 0.0749 0.188 2.85 4.85 6.10
CV % 3.73 3.05 2.77 2.97 2.95
RE % 0.536 2.68 3.18 2.05 3.17
5.00 15.0 250 400 500
Antipyrine Mean 4.99 14.3 249 404 532
SD 0.278 0.907 21.7 29.8 46.7
CV % 5.58 6.36 8.75 7.37 8.79
RE % −0.270 −4.96 −0.599 1.02 6.34
Diazepam Mean 5.02 16.7 254 389 489
SD 0.183 0.530 5.17 9.24 10.3
CV % 3.65 3.18 2.04 2.37 2.11
RE % 0.404 11.2 1.63 −2.65 −2.26
Vinblastine Mean 5.19 14.7 254 405 498
SD 0.407 0.843 8.93 12.6 15.3
CV % 7.84 5.75 3.52 3.12 3.08
RE % 3.70 −2.27 1.49 1.14 −0.464
10.0 30.0 500 800 1000
Caffeine Mean 9.69 27.8 498 783 1064
SD 0.455 1.26 22.5 19.8 35.4
CV % 4.69 4.51 4.53 2.53 3.32
RE % −3.10 −7.17 −0.477 −2.09 6.37
Cimetidine Mean 9.68 28.0 488 775 950
SD 0.287 0.554 25.6 48.6 43.9
CV % 2.97 1.98 5.24 6.28 4.62
RE % −3.23 −6.56 −2.32 −3.11 −4.98
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−4.15 % (within ±15 %), respectively (ESM Table S8).
Caffeine proved hence to be stable in RHB when stored for
3 h at 4 °C (on ice) prior to sample extraction.
Processed sample stability at autosampler conditions
Imprecision (CV%) for six replicates of QCL andQCH stored
after extraction from RHB at autosampler conditions (10 °C,
protected from light) was between 1.59 and 8.54 % (below
15%), and inaccuracy (RE%) was between −12.9 and 11.3 %
(within ±15 %) (ESM Table S8). Hence, processed samples
protected from light and kept at 10 °C proved to be stable for
1–7 days (antipyrine and caffeine for 24 h; atenolol for 36 h;
quinidine for 48 h; vinblastine for 3 days; cimetidine for
5 days; propranolol for 6 days; diazepam for 7 days) (ESM
Table S8).
Long-term stability below −65 °C
Slopes of the calculated linear regressions were between 0.872
and 1.01 (within 1±0.15) (ESM Table S9). Hence, stability of
samples in RHB could be confirmed for various days of stor-
age below −65 °C (atenolol and propranolol for 7 days; anti-
pyrine for 9 days; caffeine for 14 days; quinidine for 15 days;
vinblastine for 21 days; cimetidine for 39 days; diazepam for
55 days) (ESM Table S9).
Stock solution stability
For all compounds, the degradation expressed by the differ-
ence percentage was between −3.36 and 2.74 % (below 5 %),
showing that stock solutions in DMSO (water for chloro-
quine) were stable for the corresponding time periods (ESM
Table S10).
Validation of the immortalized human in vitro BBBmodel
Mean Pe values for the positive controls antipyrine, caffeine,
diazepam, and propranolol were between 16.8 and
69.8×10−6 cm/s (Fig. 3, Table 3). Mean Pe values for the
negative controls atenolol, cimetidine, and vinblastine were
between 6.43 and 9.78×10−6 cm/s (Fig. 3, Table 3). For the
negative control quinidine, the mean Pe value was 46.7
±2.14×10−6 cm/s, which is in a similar range as the positive
controls (Fig. 3, Table 3). For the fluorescent barrier integrity
marker Na-F, mean Pe values were between 2.78 and
5.35× 10−6 cm/s (Fig. 3, Table 3). Mean TEER values at
which permeability experiments were carried out were be-
tween 20.7 and 33.3Ωcm2 (Table 3). Mean TEER values after
the assay were in the same range, or even higher as before
(Table 3), suggesting that barrier integrity of hBMEC mono-
layers was maintained. Furthermore, CCL values were in the
range of 0.5–5.0 μF/cm2 in all experiments (data not shown),
confirming that hBMEC cell layers were confluent and that
TEER values were reliable [28]. Concentrations of analytes in
RHBwere in a similar range for samples with and without Na-
F (data not shown), indicating that Na-F did not have an im-
pact on the results.
In silico prediction of BBB permeability
Calculated values of descriptors relevant for BBB permeation
(Table 4) showed that antipyrine, caffeine, diazepam, propran-
olol, and quinidine had a PSA (ranging from 24 to 58 Å2)
below the recommended thresholds of 70 Å2 [29] and 90 Å2
[30], favoring their passive permeation across the BBB.
Furthermore, the sum of their donor and acceptor hydrogen
bonds (<7) as well as the number of rotatable bonds (≤6) were
low. On the other hand, the negative controls atenolol, cimet-
idine, and vinblastine showed PSAvalues (85 to 154 Å2) at or
above the limit allowing for passive BBB permeation (70 Å2
[29] or 90 Å2 [30]). Moreover, calculated LogD7.4 values for
atenolol (−1.8) and cimetidine (−0.22) did not fit into the
range of recommended LogP values (i.e., between 1 to 4),
while the molecular weight (MW) of vinblastine (811 g/
Mol) was clearly above the upper limit (450 g/Mol) recom-
mended for CNS drugs [30]. Compared to permeating com-
pounds, the three non-permeating control compounds (ateno-
lol, cimetidine, and vinblastine) had a larger sum of donor and
Fig. 3 Mean endothelial permeability coefficients (Pe) ± SEM values
across hBMEC monolayers for control compounds (blue bars) and the
fluorescent barrier integrity marker Na-F (yellow bars) screened in
parallel with each analyte (n = 3–4). The positive controls antipyrine,
caffeine, diazepam, and propranolol showed mean Pe values in the range
of 17–70× 10−6 cm/s, suggesting moderate to high BBB permeability
when compared to the mean Pe values of Na-F (3–5 × 10
−6 cm/s). The
negative controls atenolol, cimetidine, and vinblastine showed mean Pe
values < 10× 10−6 cm/s, indicating low permeability. Quinidine showed
an unexpectedly high mean Pe value of 46.7 ± 2.14× 10
−6 cm/s. Mean
recoveries were above 84 % for all compounds (except for propranolol:
62.6 ± 1.99 %) (Table 3)
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acceptor hydrogen bonds (>8) and a larger number of rotatable
bonds (≥7). LogBB values for all compounds were between
−1.15 and 0.19 (Table 4).
Discussion
There is a need for reliable human in vitro models for the
prediction of BBB permeability of drug leads that are amena-
ble to medium throughput screening. For that purpose, we
previously established and optimized an immortalized
mono-culture human in vitro BBB model based on the
hBMEC cell line [13, 19]. We here validated this 24-well
model with a representative series of structurally diverse drug
substances (Fig. 1) known to permeate the BBB to a different
extent. To ensure reliability of results, quantitative UHPLC-
MS/MS assays in RHB were developed and validated accord-
ing to FDA/EMA guidelines [20, 21].
During UHPLC-MS/MSmethod validation, biological and
analytical challenges were encountered, such as inaccurate
results due to the selection of unsuitable IS (data not shown),
interferences of co-eluting compounds during UHPLC-MS/
Table 3 Mean endothelial permeability coefficients (Pe) for analytes and Na-F (n = 3–4), mean recoveries for analytes (n = 12–18), and mean TEER
values for hBMEC monolayers before and after the permeability assays (n= 12–19)
Compound Transporta Mean Pe ± SEM
(×10−6 cm/s)
for analyte
Mean Pe ± SEM
(×10−6 cm/s)
for Na-F
Mean
recovery ± SEM
(%) for analyteb
Mean TEER±SEM
(Ωcm2) before assay
Mean TEER±SEM
(Ωcm2) after assay
Positive controls
Antipyrine Passive lipophilic 69.8 ± 4.96 4.01 ± 0.0437 104 ± 0.570 31.8 ± 0.524 32.9 ± 0.380
Caffeine Passive lipophilic, uptake:
adenine transporter
65.7 ± 1.64 4.07 ± 0.213 104 ± 1.31 33.3 ± 0.343 36.8 ± 0.482
Diazepam Passive lipophilic 50.0 ± 2.78 3.67 ± 0.142 95.5 ± 0.877 32.0 ± 0.328 36.9 ± 0.476
Propranolol Passive lipophilic 16.8 ± 1.42 5.35 ± 0.0811 62.6 ± 1.99 25.7 ± 0.199 28.4 ± 0.273
Negative controls
Atenolol Passive hydrophilic 9.78 ± 0.834 4.96 ± 0.192 84.7 ± 1.43 20.7 ± 0.230 21.7 ± 0.262
Cimetidine Efflux: P-gp, BCRP, OCT1-3 8.42± 0.314 4.38 ± 0.127 97.2 ± 0.747 32.2 ± 0.230 35.4 ± 0.543
Quinidine Efflux: P-gp, OCT1 46.7 ± 2.14 3.65 ± 0.155 87.2 ± 1.37 33.1 ± 0.404 35.2 ± 0.369
Vinblastine Efflux: P-gp, MRP1 and 2 6.43± 0.664 2.78 ± 0.114 102 ± 6.48 27.4 ± 0.590 33.4 ± 0.404
P-gp P-glycoprotein, BCRP breast cancer resistance protein,OCTorganic cation transporter,MRPmultidrug resistance-associated protein,Na-F sodium
fluorescein (negative fluorescent barrier integrity marker; screened in parallel to each positive and negative control)
a Nakagawa et al. [7] and McCall et al. [48]
b Recoveries were assessed with the experimental concentrations of the working solutions
Table 4 In silico calculation of BBB permeation for test compounds
Compound QikProp descriptors (3D) ChemAxon Marvin (2D) Rotatable bonds
MW DonorHBa AccptHBb PSA (Å2) LogPo/w Human oral
absorption (%)
LogBBc PSA (Å2) LogPo/w LogD7.4
Positive controls
Antipyrine 188.2 0.0 4.0 35 0.38 91.8 0.12 24 1.22 1.22 1
Caffeine 194.2 0.0 5.0 74 −0.07 80.7 −0.27 58 −0.55 −0.55 0
Diazepam 284.7 0.0 4.0 47 2.99 100.0 0.19 33 3.08 3.08 1
Propranolol 259.3 2.0 3.9 38 3.09 100.0 0.06 41 2.58 0.36 6
Negative controls
Atenolol 266.3 4.0 6.5 93 0.174 55.7 −1.15 85 0.43 −1.8 8
Cimetidine 252.3 3.0 5.5 91 0.45 77.0 −0.95 89 −0.11 −0.22 7
Quinidine 324.4 1.0 5.5 44 3.44 100.0 0.18 46 2.51 0.86 4
Vinblastine 811.0 2.0 12.3 141 5.814 39.1 −0.55 154 4.18 1.81 10
DonorHB donor hydrogen bonds, AccptHB acceptor hydrogen bonds, LogBB predicted brain/blood partition coefficient (for 95 % of known drugs
values range between −3.0 and 1.2)
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MS analysis (data not shown), non-specific adsorption of
compounds to surfaces, and analyte instability in RHB after
short-term and long-term storages. If not addressed properly,
such issues lead to an incorrect determination of analyte con-
centrations in the matrix. Thus, appropriate measures were
taken to overcome these problems.
Caffeine proved to be unstable in RHB when stored for 4 h
at RT. In a subsequent validation test, samples were therefore
stored for 3 h on ice. Under these conditions, benchtop stability
of the compound in RHB could be confirmed (ESMTable S8),
and study samples were treated accordingly. Furthermore,
short-term stability issues were met during F/T stability assess-
ment of cimetidine and propranolol. These analytes proved to
be unstable in RHB when subjected to three successive F/T
cycles below −65 °C. In a subsequent validation test, stability
could be demonstrated when samples were subjected to only
two cycles (ESM Table S8), and study samples were thus
thawed only up to two times prior to UHPLC-MS/MS
analysis. Processed sample stability at autosampler conditions
was carried out to ensure that samples could be reinjected if
technical incidents during UHPLC-MS/MS analysis occurred.
At least 24 h of sample stability was thus needed. In the case of
technical issues, samples were therefore reinjected only during
the time period for which stability was proven (between 1 and
7 days) (ESM Table S8).
In general, all analytes showed relatively limited long-term
stabilities (between 7–55 days) in RHB when stored below
−65 °C (ESM Table S9). Hence, study samples were assessed
within the time period for which stability of the compound
was confirmed. An additional challenge was encountered for
vinblastine. During UHPLC-MS/MS method development,
non-specific adsorption of the compound to various surfaces
was observed, resulting in unacceptable calibration curves
(data not shown). We resolved this problem by using tubes
(overnight) pre-coated with 0.2 % Tween 20 for study sam-
ples, and by spiking RHB with 0.2 % Tween 20 for the prep-
aration of calibrators and QCs [31]. We observed no differ-
ences in calibration curves generated by calibrators in pre-
coated tubes compared to curves generated by calibrators in
spiked RHB (data not shown). As the latter procedure was
more convenient and time-efficient, we decided to prepare
calibrators and QCs in this way (calibration curves see ESM
Table S2).
Extraction yields (recoveries) for diazepam were slightly
lower (between 70.3 and 76.5 %) than recoveries for the other
compounds (between 80.6 and 109 %) (ESM Table S7). This
finding might possibly be due to compound loss during pro-
tein precipitation. According to the FDA guidance, the recov-
ery of the analyte does not need to be 100 %, but the extent of
recovery of an analyte and of IS should be consistent, precise,
and reproducible [20]. Since recoveries for diazepam were
similar at each concentration level (between 70.3 and
76.5 %), acceptance criteria were thus fulfilled.
Culture conditions for the in vitro BBB model using the
hBMEC cell line were previously optimized in a comprehen-
sive study [19]. As part of the present work, further optimiza-
tions were carried out by evaluating the effect of retinoic acid
(RA) and puromycin on the barrier tightness of hBMEC
monolayers. RA had been previously found to increase
TEER values in a human stem cell-based BBB model [32],
and puromycin was reported to decrease the permeability of
the negative marker mannitol through Caco-2 cell monolayers
[33]. In the hBMEC model, however, no increase of TEER
values could be observed when cells were cultured with media
containing RA or puromycin at different concentrations (ESM
Fig. S1).
For the positive controls antipyrine, caffeine, and diazepam
meanPe values were in the range of 50–70×10
−6 cm/s (Fig. 3,
Table 3). Compared to the mean Pe values of the negative
control Na-F (3–5×10−6 cm/s), these values were consider-
ably higher and were thus indicating high BBB permeation.
The positive control propranolol showed a lower mean Pe
value (16.8±1.42×0−6 cm/s) than the other positive controls.
An explanation for this finding might be the low recovery of
propranolol (62.6±1.99 %) (Table 3), possibly due to com-
pound accumulation and/or metabolization in the endothelial
cells resulting in an underestimation of BBB permeability for
this compound [34]. Nevertheless, propranolol could be clas-
sified as a permeable compound (mean Pe value of 16.8
±1.42×10−6 cm/s) when compared to the mean Pe values of
Na-F (3–5×10−6 cm/s).
Mean Pe values for the negative controls atenolol, cimeti-
dine, and vinblastine ranged from 6 to 10×10−6 cm/s (Fig. 3,
Table 3). These values were in a similar range than the mean
Pe values for Na-F and were thus indicative of limited BBB
permeability. The negative control quinidine, however,
showed an unexpectedly high mean Pe value (46.7
± 2.14×10−6 cm/s). Quinidine is an inhibitor and substrate
of P-glycoprotein (P-gp), and the high BBB permeability
might be due to low expression of P-gp by hBMEC cells
and/or saturation of P-gp, enabling the compound to easily
permeate the monolayer [33, 35]. According to calculated
descriptor values (Table 4), quinidine should be able to per-
meate the BBB. A detailed study of expression and functional
activity of P-gp in hBMEC cells would be necessary to clarify
this apparently contradictory experimental finding.
In silico LogBB values (logarithm of total brain-to-plasma
ratio) for the compounds were between −1.15 and 0.19
(Table 4). For the positive control caffeine, the negative
LogBB value (−0.27) seemed not to correlate with the high
Pe value (65.7 ± 1.64× 10
−6 cm/s) observed in the in vitro
BBB model (Tables 3 and 4). Also, literature LogBB values
for caffeine and antipyrine were negative (−0.055 and −0.097,
respectively) [36–38] and appeared not to be in agreement
with observed Pe values. However, LogBB values are a mea-
sure of the extent of brain penetration (i.e., of the distribution
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of a drug between plasma and brain, which is influenced by
multiple factors such as plasma protein and brain tissue bind-
ing), while Pe values predict the rate of brain penetration (i.e.,
BBB permeability by passive diffusion, active uptake, and/or
efflux) [39, 40]. The two parameters thus describe different
aspects of brain drug penetration and are not necessarily in
agreement [40, 41].
The TEER values of hBMEC cell monolayers were
rather low (20–40 Ωcm2) (Table 3) [19], when compared
to TEER values reported for in vitro BBB models using
primary animal cells, where TEER values in the range of
400–1500 Ωcm2 can be reached [7–10]. However, mean
Pe values for Na-F were in a similar range as those mea-
sured in other primary animal in vitro BBB models (0.5–
6 × 10−6 cm/s) [7, 8]. Also, mean Pe values for the nega-
tive controls atenolol, cimetidine, and vinblastine obtain-
ed in our model (6–10 × 10−6 cm/s) were similar to those
from a primary triple-culture rat in vitro model (Pe values
between 2 and 3 × 10−6 cm/s) [7]. Interestingly, observed
Pe values for the positive controls selected for this study
were considerably lower than those observed in several
other in vitro models (170–2000 × 10−6 cm/s) [7, 42].
Nevertheless, our model was able to discriminate between
permeable and non-permeable compounds (mean Pe
values in the range of 17–70 × 10−6 cm/s for permeable
compounds; mean Pe values around 6–10 × 10
−6 cm/s for
non-permeable compounds). Also, BBB permeability data
from our immortalized human model were in agreement
with data from two well-established animal primary
models for the natural products (E,Z)-3-(4-hydroxy-3,5-
dimethoxybenzylidene)indolin-2-one [43], tryptanthrin
(unpublished data), and several phenolic compounds (un-
published data). A limitation of the model may be the fact
that discrimination between passive diffusion and active
efflux of compounds is not possible, as the case of quin-
idine showed. Specific assays to evaluate possible inter-
action with efflux pumps may thus be recommended.
Despite this limitation, the hBMEC model is a promising
tool for early BBB permeability assessment of lead can-
didates in drug discovery, as it is easy and fast to set up,
and is amenable to moderate throughput screening.
Conclusions
We successfully validated an immortalized human mono-
culture in vitro BBB model (24-well format) based on the
hBMEC cell line with a representative series of structurally
diverse drugs that are known to cross the BBB to a different
extent. For each compound, a quantitative UHPLC-MS/MS
method in RHB was developed and validated according to
current regulatory guidelines [20, 21]. During UHPLC-MS/
MS method validation, various biological and analytical
challenges were met, indicating that major precautions for
sample analysis need to be taken before quantification. The
human in vitro BBB model correctly predicted the BBB per-
meability of control compounds, with the exception of one
negative control (quinidine, a small lipophilic P-gp inhibitor
and substrate). We are currently screening selected natural
product-derived leads, such as GABAA receptor modulators,
for their ability to cross the BBB [44–47].
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Fig. S1 TEER values recorded real-time by the CellZscope system for hBMEC monolayers cultured with media 
containing different concentrations of (a) retinoic acid (RA) and (b) puromycin (n = 1). Treatment with RA (at 1, 
2, 5, 7.5, and 10 µM) and puromycin (1, 1.5, 2, and 3 µM) did not result in increased TEER values of hBMEC 
monolayers.  *Change of medium 
  
102
3 
 
Table S1 Optimized UHPLC parameters for compounds 
Compound 
Total 
run 
time 
(min) 
Eluents Gradient Injection 
solvent 
Injection 
volume 
(µL) 
Column 
Column 
temperature 
(˚C) 
Flow rate 
(mL/min) 
Antipyrine 6.00 A1 + B1 2–90% B1 in 3.5 min I 5 A 45 0.4 
Atenolol 6.00 A1 + B1 2–90% B1 in 3.5 min I 5 A 45 0.4 
Caffeine 6.00 A1 + B1 2–90% B1 in 3.5 min I 10 A 45 0.4 
Cimetidine 5.00 A2 + B2 0–100% B2 in 2.5 min I 10 B 70 0.7 
Diazepam 6.00 A1 + B1 2–90% B1 in 3.5 min I 10 A 45 0.4 
Propranolol 6.00 A2 + B2 2–90% B2 in 3.5 min I 10 A 45 0.4 
Quinidine 6.00 A2 + B2 10–70% B2 in 3.5 min II 10 A 45 0.4 
Vinblastine 4.00 A3 + B1 20–80% B1 in 2.5 min III 2 A 45 0.4 
A1: high purity water + 0.1% FA acid; A2: 5 mM ammonium formate in high purity water + 0.05% FA; A3: 10 mM 
ammonium formate in high purity water + 0.1% FA; B1: acetonitrile + 0.1% FA; B2: acetonitrile + 0.05% FA 
Injection solvent I: 65% A1 + 35% B1; Injection solvent II: 65% A2 + 35% B2; Injection solvent III: 65% A3 + 35% B1 
Column A: Waters Acquity UPLC HSS T3 (C18; 2.1 x 100 mm; 1.8 µm particle size) 
Column B: Waters Acquity UPLC BEH (C18; 2.1 x 50 mm; 1.7 µm particle size) 
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Table S2 Calibrators and calibration curve parameters for analytes. Response: A x Conc.2 + B x Conc. + C, quadratic regression, weighting factor 1/X (exception caffeine and 
cimetidine: 1/X2), origins: included 
Compound  Nominal level (ng/mL) Regression parameters 
  2.00 10.0 20.0 40.0 80.0 160 200 A B C R2 
Atenolol Mean 1.99 10.5 21.0 40.1 77.7 158 203 -0.0108 8.05 2.10 0.9980 
 S.D. 0.114 0.781 1.30 2.19 3.87 6.61 7.19 0.000968 0.775 - - 
 CV % 5.75 7.45 6.21 5.47 4.98 4.18 3.54 - - - - 
 RE % -0.650 4.79 5.12 0.292 -2.88 -1.16 1.68 - - - - 
Propranolol Mean 2.03 9.90 19.9 40.4 80.4 157 202 -0.00000342 0.00603 0.000297 0.9974 
 S.D. 0.117 0.462 1.57 2.06 2.77 12.0 8.94 0.00000119 0.000455 - - 
 CV % 5.78 4.67 7.88 5.08 3.45 7.61 4.43 - - - - 
 RE % 1.60 -0.951 -0.615 1.07 0.496 -1.66 0.924 - - - - 
Quinidine Mean 1.97 10.1 21.2 39.9 77.6 162 200 -0.00000938 0.00729 0.000712 0.9978 
 S.D. 0.0773 0.343 1.15 1.52 3.12 9.17 14.1 0.000000570 0.000392 - - 
 CV % 3.93 3.41 5.43 3.81 4.02 5.64 7.03 - - - - 
 RE % -1.59 0.615 5.80 -0.287 -2.95 1.55 0.0820 - - - - 
  5.00 25.0 50.0 100 200 400 500 A B C R2 
Antipyrine Mean 4.97 26.2 51.5 98.9 198 397 506 -0.00000418 0.00766 0.00369 0.9986 
 S.D. 0.165 1.14 2.56 4.59 10.0 11.2 24.9 0.000000304 0.000365 - - 
 CV % 3.32 4.35 4.97 4.64 5.06 2.81 4.93 - - - - 
 RE % -0.542 4.65 2.97 -1.13 -1.20 -0.699 1.19 - - - - 
Diazepam Mean 5.21 24.4 48.7 98.9 205 396 501 0.0000000929 0.000262 0.0000594 0.9978 
 S.D. 0.445 1.86 3.39 7.24 12.4 13.1 14.4 0.00000000963 0.0000154 - - 
 CV % 8.55 7.62 6.96 7.32 6.04 3.30 2.87 - - - - 
 RE % 4.22 -2.23 -2.52 -1.13 2.47 -0.929 0.270 - - - - 
Vinblastine Mean 5.17 24.8 49.6 102 198 401 500 -0.000000587 0.00705 0.00168 0.9980 
 S.D. 0.390 1.67 1.96 5.51 11.9 15.7 19.9 0.000000380 0.00102 - - 
 CV % 7.55 6.73 3.96 5.40 6.04 3.92 3.98 - - - - 
 RE % 3.38 -0.794 -0.754 2.08 -1.16 0.139 0.0389 - - - - 
  10.0 50.0 100 200 400 800 1000 A B C R2 
Caffeine Mean 10.3 50.9 97.1 195 394 799 1016 -0.000000204 0.00221 0.00149 0.9941 
 S.D. 0.800 2.70 4.41 14.1 26.9 60.3 64.0 0.000000179 0.000333 - - 
 CV % 7.75 5.31 4.54 7.22 6.82 7.55 6.29 - - - - 
 RE % 3.28 1.71 -2.85 -2.60 -1.43 -0.170 1.64 - - - - 
Cimetidine Mean 10.1 50.7 100 197 382 801 1042 -0.000000766 0.00331 0.000990 0.9964 
 S.D. 0.531 3.47 4.95 12.3 15.4 42.0 54.1 0.000000180 0.000200 - - 
 CV % 5.23 6.84 4.92 6.26 4.05 5.25 5.19 - - - - 
 RE % 1.49 1.41 0.431 -1.33 -4.56 0.102 4.21 - - - - 
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Table S3 Carry-over assessment for both analytes and I.S. (n = 7–10) 
Compound Mean carry-over (%) 
Atenolol 
I.S. Propranolol 
0.00 
0.0137 
Propranolol 
I.S. Atenolol 
0.0730 
0.00117 
Quinidine 
I.S. Chloroquine 
0.00 
0.00 
Antipyrine 
I.S. Caffeine 
0.915 
0.202 
Diazepam 
I.S. Temazepam 
0.00 
0.00 
Vinblastine 
I.S. Vincristine 
0.00 
0.00 
Caffeine 
I.S. Antipyrine 
5.85 
0.0181 
Cimetidine 
I.S. Nizatidine 
0.164 
0.0189 
 
 
Table S4 Selectivity test at the LLOQ, based on 3 different RHB batches (n = 6) 
Compound Nominal level (ng/mL) 2.00 
Atenolol Mean 2.14 
 
S.D. 0.0830 
 
CV % 3.89 
 
RE % 6.86 
Propranolol Mean 2.12 
 
S.D. 0.158 
 
CV % 7.44 
 
RE % 6.20 
Quinidine Mean 1.96 
 
S.D. 0.0517 
 
CV % 2.64 
 
RE % -2.17 
 Nominal level (ng/mL) 5.00 
Antipyrine Mean 5.09 
 
S.D. 0.358 
 
CV % 7.04 
 
RE % 1.72 
Diazepam Mean 4.99 
 
S.D. 0.285 
 
CV % 5.71 
 
RE % -0.227 
Vinblastine Mean 4.47 
 
S.D. 0.567 
 
CV % 12.7 
 
RE % -10.5 
 Nominal level (ng/mL) 10.0 
Caffeine Mean 11.4 
 
S.D. 0.383 
 
CV % 3.35 
 
RE % 14.2 
Cimetidine Mean 9.62 
 
S.D. 0.748 
 
CV % 7.78 
 
RE % -3.83 
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Table S5 Within-run imprecision (CV %) and inaccuracy (RE %) of QCs (n = 6) 
Compound  Nominal level (ng/mL) 
  2.00 6.00 100 160 200 
Atenolol Mean 1.87 5.75 92.2 156 203 
 
S.D. 0.0847 0.168 4.32 5.62 10.9 
 
CV % 4.53 2.91 4.68 3.61 5.37 
 
RE % -6.57 -4.14 -7.80 -2.80 1.48 
Propranolol Mean 1.76 5.79 106 165 213 
 
S.D. 0.100 0.311 9.11 7.31 13.1 
 
CV % 5.69 5.37 8.55 4.42 6.16 
 
RE % -12.1 -3.50 6.48 3.28 6.34 
Quinidine Mean 2.11 6.48 106 167 209 
 
S.D. 0.0732 0.197 2.67 5.68 9.54 
 
CV % 3.46 3.04 2.51 3.40 4.57 
 
RE % 5.68 8.06 6.18 4.20 4.39 
 
 5.00 15.0 250 400 500 
Antipyrine Mean 5.07 14.0 245 408 539 
 
S.D. 0.189 1.13 16.4 22.1 76.9 
 
CV % 3.73 8.09 6.68 5.42 14.3 
 
RE % 1.38 -6.95 -1.90 1.95 7.86 
Diazepam Mean 4.98 16.5 257 391 490 
 
S.D. 0.197 0.425 3.08 11.7 11.9 
 
CV % 3.96 2.58 1.20 3.00 2.44 
 
RE % -0.363 9.86 2.67 -2.30 -2.06 
Vinblastine Mean 5.23 14.5 246 397 486 
 
S.D. 0.425 1.06 7.94 10.4 7.15 
 
CV % 8.12 7.29 3.23 2.63 1.47 
 
RE % 4.55 -3.35 -1.77 -0.754 -2.84 
 
 10.0 30.0 500 800 1000 
Caffeine Mean 9.96 28.3 489 784 1071 
 
S.D. 0.502 1.52 17.1 23.5 31.5 
 
CV % 5.04 5.37 3.49 3.00 2.94 
 
RE % -0.443 -5.66 -2.17 -1.96 7.14 
Cimetidine Mean 9.58 27.5 470 794 1015 
 
S.D. 0.268 0.693 24.3 25.7 51.1 
 
CV % 2.80 2.52 5.17 3.23 5.04 
 
RE % -4.21 -8.22 -5.98 -0.730 1.46 
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Table S6 Dilution test (n = 6) 
Compound Nominal level (ng/mL) 1000 
 Dilution factor 10X 100X 
Atenolol Mean 1035 1136 
 
S.D. 25.3 28.2 
 
CV % 2.44 2.49 
 
RE % 3.55 13.6 
Propranolol Mean 1117 1139 
 
S.D. 33.6 33.0 
 
CV % 3.01 2.89 
 
RE % 11.7 13.9 
Quinidine Mean 992 1033 
 
S.D. 27.7 9.91 
 
CV % 2.80 0.959 
 
RE % -0.812 3.31 
 Nominal level (ng/mL) 2500 
 Dilution factor 10X 100X 
Antipyrine Mean 2491 2631 
 
S.D. 108 137 
 
CV % 4.34 5.22 
 
RE % -0.341 5.23 
Vinblastine Mean 2598 2744 
 
S.D. 78.4 209 
 
CV % 3.02 7.63 
 
RE % 3.91 9.76 
 Dilution factor 10X 20X 
Diazepam Mean 2773 2765 
 
S.D. 69.0 102 
 
CV % 2.49 3.68 
 
RE % 10.9 10.6 
 Nominal level (ng/mL) 5000 
 Dilution factor 10X 100X 
Caffeine Mean 5533 5613 
 
S.D. 180 280 
 
CV % 3.25 4.99 
 
RE % 10.7 12.3 
 Dilution factor 10X 50X 
Cimetidine Mean 4780 5105 
 
S.D. 96.3 104 
 
CV % 2.02 2.04 
 
RE % -4.40 2.10 
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Table S7 Absolute extraction yield of analytes and I.S. (n = 6) 
Analyte Nominal level (ng/mL) 6.00 100 160 
Atenolol Absolute recovery (%) 107 104 101 
 
CV % 7.40 1.62 3.07 
 
S.D. 7.91 1.68 3.10 
I.S. Nominal level (ng/mL) 86.67   
I.S. Propranolol Absolute recovery (%) 86.5 - - 
 
CV % 2.35 - - 
 
S.D. 2.03 - - 
Analyte Nominal level (ng/mL) 6.00 100 160 
Propranolol Absolute recovery (%) 89.1 92.2 98.1 
 
CV % 3.42 2.17 2.64 
 
S.D. 3.05 2.00 2.59 
I.S. Nominal level (ng/mL) 433.33   
I.S. Atenolol Absolute recovery (%) 101 - - 
 
CV % 1.88 - - 
 
S.D. 1.90 - - 
Analyte Nominal level (ng/mL) 6.00 100 160 
Quinidine Absolute recovery (%) 93.2 100 105 
 
CV % 2.28 1.45 1.86 
 
S.D. 2.13 1.46 1.95 
I.S. Nominal level (ng/mL) 86.67   
I.S. Chloroquine Absolute recovery (%) 85.2 - - 
 
CV % 2.80 - - 
 
S.D. 2.39 - - 
Analyte Nominal level (ng/mL) 15.0 250 400 
Antipyrine Absolute recovery (%) 91.7 85.9 86.3 
 
CV % 11.9 7.51 7.26 
 
S.D. 10.9 6.45 6.26 
I.S. Nominal level (ng/mL) 108.33   
I.S. Caffeine Absolute recovery (%) 89.5 - - 
 
CV % 6.25 - - 
 
S.D. 5.60 - - 
Analyte Nominal level (ng/mL) 15.0 250 400 
Diazepam Absolute recovery (%) 70.3 70.7 76.5 
 
CV % 15.8 6.54 9.11 
 
S.D. 11.1 4.62 6.97 
I.S. Nominal level (ng/mL) 433.33   
I.S. Temazepam Absolute recovery (%) 87.2 - - 
 
CV % 5.99 - - 
 
S.D. 5.22 - - 
Analyte Nominal level (ng/mL) 15.0 250 400 
Vinblastine Absolute recovery (%) 89.3 85.5 83.5 
 
CV % 8.85 3.24 3.12 
 
S.D. 7.90 2.77 2.61 
I.S. Nominal level (ng/mL) 866.67   
I.S. Vincristine Absolute recovery (%) 80.6 - - 
 
CV % 3.50 - - 
 
S.D. 2.82 - - 
Analyte Nominal level (ng/mL) 30.0 500 800 
Caffeine Absolute recovery (%) 93.1 98.7 98.4 
 
CV % 6.77 1.91 3.19 
 
S.D. 6.30 1.89 3.14 
I.S. Nominal level (ng/mL) 216.67   
I.S. Antipyrine Absolute recovery (%) 105 - - 
 
CV % 7.32 - - 
 
S.D. 7.69 - - 
Analyte Nominal level (ng/mL) 30.0 500 800 
Cimetidine Absolute recovery (%) 109 106 103 
 
CV % 3.29 1.04 1.15 
 
S.D. 3.58 1.11 1.18 
I.S. Nominal level (ng/mL) 433.33   
I.S. Nizatidine Absolute recovery (%) 85.9 - - 
 
CV % 6.03 - - 
 
S.D. 5.18 - - 
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Table S8 Short-term stabilities during storage at various conditions expressed as CV % and RE % (n = 6)  
  CV % RE % 
Compound Nominal level (ng/mL) 6.00 160 6.00 160 
Atenolol 3 successive F/T cycles below -65°C 3.43 4.90 2.38 -1.15 
 
Stored samples at RT for 4 hours  2.80 2.03 2.69 0.121 
 
Processed samples at 10°C for 36 hours 3.02 2.19 8.30 -4.62 
Propranolol 2 successive F/T cycles below -65°C 4.10 1.86 -3.83 -0.622 
 
Stored samples at RT for 4 hours 4.11 2.25 -6.37 1.12 
 
Processed samples at 10°C for 6 days 2.36 2.74 0.142 3.13 
Quinidine 3 successive F/T cycles below -65°C 2.76 0.660 6.44 -6.69 
 
Stored samples at RT for 4 hours 3.33 2.09 -7.34 -9.57 
 
Processed samples at 10°C for 48 hours 2.81 3.94 -2.95 -12.9 
 Nominal level (ng/mL) 15.0 400 15.0 400 
Antipyrine 3 successive F/T cycles below -65°C 5.28 7.93 -12.9 -4.93 
 
Stored samples at RT for 4 hours  9.86 5.27 -2.76 -5.88 
 
Processed samples at 10°C for 24 hours 5.24 8.54 -7.45 -11.5 
Diazepam 3 successive F/T cycles below -65°C 7.46 1.50 4.93 -6.73 
 
Stored samples at RT for 4 hours  4.24 3.53 3.33 -3.57 
 
Processed samples at 10°C for 7 days 6.43 2.40 3.37 3.41 
Vinblastine 3 successive F/T cycles below -65°C 10.5 1.95 -3.63 -2.55 
 
Stored samples at RT for 4 hours 6.91 2.40 -1.99 2.00 
 
Processed samples at 10°C for 3 days 5.39 3.06 11.3 12.2 
 Nominal level (ng/mL) 30.0 800 30.0 800 
Caffeine 3 successive F/T cycles below -65°C 3.30 5.92 -9.67 2.44 
 
Stored samples at 4°C (on ice) for 3 hours 3.46 4.95 -8.74 -4.15 
 
Processed samples at 10°C for 24 hours 3.87 1.59 -6.38 -8.51 
Cimetidine 2 successive F/T cycles below -65°C 1.54 0.990 -4.43 -3.45 
 
Stored samples at RT for 4 hours 2.16 1.65 -5.76 -9.37 
 
Processed samples at 10°C for 5 days 2.51 2.49 1.41 -2.26 
 
 
 
Table S9 Long-term stabilities expressed as difference (%) between t=0 and t=last and slopes (n = 3) 
Compound Nominal level (ng/mL) 6.00 100 160 Slope 
Atenolol Stored samples below -65°C for 7 days -10.4 -10.9 -13.2 0.872 
Propranolol Stored samples below -65°C for 7 days -0.843 -2.56 2.04 1.01 
Quinidine Stored samples below -65°C for 15 days 1.51 -2.68 -12.2 0.894 
 Nominal level (ng/mL) 15.0 250 400 Slope 
Antipyrine Stored samples below -65°C for 9 days 1.04 1.69 -8.49 0.941 
Diazepam Stored samples below -65°C for 55 days -12.3 0.249 -5.31 0.961 
Vinblastine Stored samples below -65°C for 21 days -3.90 0.231 -0.411 0.997 
 Nominal level (ng/mL) 30.0 500 800 Slope 
Caffeine Stored samples below -65°C for 14 days -3.90 1.92 -9.06 0.935 
Cimetidine Stored samples below -65°C for 39 days -7.24 -4.09 -8.77 0.925 
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Table S10 Stock solution stability of compounds  
Compound Solvent Long-term stability below -65°C (days) 
Hours kept at 
RT (h) Difference (%) 
Atenolol DMSO 206 6 2.74 
Propranolol DMSO 206 6 -1.09 
Antipyrine DMSO 88 6 0.113 
Caffeine DMSO 88 6 -2.05 
Cimetidine DMSO 148 6 0.546 
Nizatidine DMSO 148 6 -2.40 
Quinidine DMSO 39 6 0.0984 
Chloroquine Water 39 6 0.393 
Vinblastine DMSO 74 6 -3.36 
Vincristine DMSO 74 6 -2.23 
Diazepam DMSO 182 4 1.95 
Temazepam DMSO 138 4 -3.25 
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The alkaloid piperine from black pepper (Piper nigrum L.), and several synthetic piperine analogs 
were previously identified as positive allosteric modulators of γ-aminobutyric acid type A (GABAA) 
receptors. To evaluate their potential to penetrate the brain, we screened the compounds in our recently 
validated immortalized human in vitro BBB model, in a human stem cell in vitro BBB model, and in a 
primary bovine endothelial/rat astrocytes co-culture in vitro BBB model. In addition, in silico data for 
BBB permeability were calculated. For each compound, a quantitative UHPLC-MS/MS assay in the 
corresponding matrix was developed, and permeability coefficients in each model were determined. In 
vitro predictions from the two human models were in good agreement, while permeability data from 
the animal model differed to some extent. In all three models, piperine and the semisynthetic analog 
SCT-64 displayed highest BBB permeation, which was corroborated by in silico prediction data. For 
the other piperine analogs (SCT-66, SCT-29, LAU397, and LAU399), BBB permeability was low to 
moderate in the two human models, and moderate to high in the animal model. Efflux ratios (ER) 
calculated from bidirectional permeability experiments indicated that the compounds were not 
substrates of active efflux. 
 
 
 
 
 
 
 
 
My contributions to this publication: development of UHPLC-MS/MS quantification methods, 
cultivation of cells, preparation of the immortalized human in vitro BBB models, design and 
performance of permeability experiments, sample preparation and analysis, recording and analysing 
data, writing the manuscript draft, and preparation of figures and tables. 
 
Daniela Elisabeth Eigenmann 
111
Manuscript: In vitro blood-brain barrier permeability predictions for GABAA receptor modulating piperine analogs 
 
1 
 
 
MANUSCRIPT 1 
 2 
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS 3 
 4 
In vitro blood-brain barrier permeability predictions for GABAA receptor modulating piperine analogs  5 
 6 
Daniela Elisabeth Eigenmann
a
, Carmen Dürig
a
, Evelyn Andrea Jähne
a
, Martin Smieškob, Maxime Culotc, Fabien 7 
Gosselet
c
, Romeo Cecchelli
c
, Hans Christian Cederberg Helms
d
, Birger Brodin
d
, Laurin Wimmer
e
, Marko D. 8 
Mihovilovic
e
, Matthias Hamburger
a
, and Mouhssin Oufir
a,* 
 9 
 10 
a
Pharmaceutical Biology, Department of Pharmaceutical Sciences, University of Basel, Klingelbergstrasse 50, 11 
CH-4056 Basel, Switzerland  12 
b
Molecular Modeling, Department of Pharmaceutical Sciences, University of Basel, Klingelbergstrasse 50, CH-13 
4056 Basel, Switzerland 14 
c
Univ. Artois, EA 2465, Laboratoire de la Barrière Hémato-Encéphalique (LBHE), F-62300 Lens Cedex, France 15 
d
Drug Transporters in ADME, Department of Pharmacy, Faculty of Health and Medical Sciences, University of 16 
Copenhagen, Universitetsparken 2, DK-2100 Copenhagen, Denmark 17 
e
Institute of Applied Synthetic Chemistry, TU Wien, Getreidemarkt 9, A-1060 Vienna, Austria 18 
 19 
*Corresponding author. Pharmaceutical Biology, Department of Pharmaceutical Sciences, University of Basel, 20 
Klingelbergstrasse 50, CH-4056 Basel, Switzerland. Tel: +41 61 2671425; fax: +41 61 2671474. 21 
E-mail address: mouhssin.oufir@unibas.ch (M. Oufir). 22 
 23 
Keywords: Piperine, GABAA receptor, in vitro blood-brain barrier (BBB) model, primary cells, immortalized 24 
cell line, human stem cells, UHPLC-MS/MS, permeability coefficient 25 
 26 
Abbreviations: BBB, blood-brain barrier; BLEC, human brain-like endothelial cells; BSA, bovine serum 27 
albumin; CCL, cell layer capacitance; CNS, central nervous system; CV, coefficient of variation; DMEM, 28 
Dulbecco’s Modified Eagle Medium; ER, efflux ratio; FA, formic acid; FBS, fetal bovine serum; GABAA 29 
receptor, γ-aminobutyric acid type A receptor; hBMEC, human brain microvascular endothelial cell line; I.S., 30 
internal standard; LLOQ, lower limit of quantification; MRM, multiple reaction monitoring; Na-F, sodium 31 
fluorescein; Papp, apparent permeability coefficient; Pe, endothelial permeability coefficient; P-gp, P-32 
glycoprotein; QC, quality control; RE, relative error; RHB, Ringer HEPES buffer; TEER, transendothelial 33 
electrical resistance; TFA, trifluoroacetic acid; TRPV1, transient receptor potential vanilloid 1; UHPLC-MS/MS, 34 
ultra-high performance liquid chromatography tandem mass spectrometry; ULOQ, upper limit of quantification; 35 
WS, working solution. 36 
 37 
 38 
 39 
 40 
112
Manuscript: In vitro blood-brain barrier permeability predictions for GABAA receptor modulating piperine analogs 
 
2 
 
 
 41 
 42 
Abstract 43 
The alkaloid piperine from black pepper (Piper nigrum L.) and several synthetic piperine analogs were recently 44 
identified as positive allosteric modulators of γ-aminobutyric acid type A (GABAA) receptors. In order to reach 45 
their target sites of action, these compounds need to enter the brain by crossing the blood-brain barrier (BBB). 46 
We here evaluated piperine and five selected analogs (SCT-66, SCT-64, SCT-29, LAU397, and LAU399) 47 
regarding their BBB permeability. Data were obtained in three in vitro BBB models, namely a recently 48 
established human model with immortalized hBMEC cells, a human brain-like endothelial cells (BLEC) model, 49 
and a primary animal (bovine endothelial/rat astrocytes co-culture) model. For each compound, quantitative 50 
UHPLC-MS/MS methods in the range of 5.00–500 ng/mL in the corresponding matrix were developed, and 51 
permeability coefficients in the three BBB models were determined. In vitro predictions from the two human 52 
BBB models were in good agreement, while permeability data from the animal model differed to some extent, 53 
possibly due to high protein binding of the screened compounds. In all three BBB models, piperine and SCT-64 54 
displayed the highest BBB permeation potential. This was corroborated by data from in silico prediction. For the 55 
other piperine analogs (SCT-66, SCT-29, LAU397, and LAU399), BBB permeability was low to moderate in the 56 
two human BBB models, and moderate to high in the animal BBB model. Efflux ratios (ER) calculated from 57 
bidirectional permeability experiments indicated that the compounds were not substrates of active efflux 58 
transporters. 59 
 60 
  61 
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1 Introduction 62 
The alkaloid piperine, the major pungent component of black pepper (Piper nigrum L.), was recently identified 63 
as a positive allosteric γ-aminobutyric acid type A (GABAA) receptor modulator. The compound showed 64 
anxiolytic-like activity in behavioral mouse models, and was found to interact with the GABAA receptors at a 65 
binding site that was independent of the benzodiazepine binding site [1,2]. Given that the compound complied 66 
with Lipinski’s “rule of five” [1], it represented a new scaffold for the development of novel GABAA receptor 67 
modulators [1–3].  68 
 69 
Given that  piperine also activates the transient receptor potential vanilloid 1 (TRPV1) receptors [4] which are 70 
involved in pain signaling and regulation of the body temperature [5,6], structural modification of the parent 71 
compound was required to dissect GABAA and TRPV1 activating properties. 72 
 73 
In a first step, the piperidine ring of piperine was replaced by a N,N-diisobutyl residue, resulting in a non-TRPV1 74 
activating derivative (designated as SCT-66) (Fig. 1) [2]. Compared to piperine, SCT-66 increased chloride 75 
currents through GABAA receptors more potently and efficiently, and showed a stronger anxiolytic effect in 76 
mice [7]. Based on these findings, a library of 76 piperine analogs with modifications at the amide functionality 77 
and at the linker region was synthesized [7]. In this compound series, SCT-64 and SCT-29 (Fig. 1) showed the 78 
strongest modulation and highest potency, respectively, at GABAA receptors expressed in Xenopus laevis 79 
oocytes [7]. Both analogs were devoid of TRPV1 receptor activating properties in vitro, exerted pronounced 80 
anxiolytic effects in mice, and appeared in significant concentration in mouse plasma after intraperitoneal 81 
application [7]. However, all compounds synthesized up to that point contained the metabolically liable 1,3-82 
benzodioxole group [8]. Hence, a set of 15 aryl-modified piperine analogs was synthesized bearing the non-83 
natural dibutylamide function [9]. Of these, the analogs LAU397 and LAU399 (Fig. 1) were significantly more 84 
efficient at the GABAA receptor than piperine while being devoid of in vitro TRPV1 receptor interaction [9]. 85 
 86 
For drugs acting on the central nervous system (CNS), brain penetration is required. This process is controlled 87 
by the blood-brain barrier (BBB), a tight layer of endothelial cells lining the brain capillaries that limits the 88 
passage of molecules from the blood circulation into the brain [10]. Since low BBB permeability can reduce 89 
CNS exposure [11], lead compounds should be evaluated at an early stage of the drug development process for 90 
their ability to permeate the BBB [12]. 91 
 92 
In the present study, we assessed the BBB permeability of piperine and five selected piperine analogs (Fig. 1) in 93 
three in vitro cell-based human and animal BBB models [13–16]. Permeability coefficients across the 94 
monolayers were determined by means of UHPLC-MS/MS, whereby quantitative UHPLC-MS/MS assays in the 95 
corresponding matrices were developed for each compound. In addition, we calculated descriptors relevant for 96 
BBB permeation and compared them with the in vitro data from the BBB models.  97 
 98 
 99 
 100 
 101 
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2 Materials and methods 102 
2.1 Chemicals and reagents 103 
The piperine analogs (2E,4E)-5-(benzo[d][1,3]dioxol-5-yl)-N,N-diisobutylpenta-2,4-dienamide (SCT-66), 104 
(2E,4E)-5-(benzo[d][1,3]dioxol-5-yl)-N,N-dipropylpenta-2,4-dienamide (SCT-64), (2E,4E)-5-(benzo[d][1,3]-105 
dioxol-5-yl)-N,N-dibutylpenta-2,4-dienamide (SCT-29), (2E,4E)-N,N-dibutyl-5-(4-methoxyphenyl)penta-2,4-106 
dienamide (LAU397; compound 6 in reference [9]), and (2E,4E)-N,N-dibutyl-5-(thiophen-3-yl)penta-2,4-107 
dienamide (LAU399; compound 16 in reference [9]) were synthesized at TU Wien as described elsewhere 108 
[2,7,9]. Piperine, Tween 20, bovine serum albumin (BSA), Dulbecco’s Modified Eagle Medium (DMEM) high 109 
glucose, and sodium fluorescein (Na-F) were purchased from Sigma-Aldrich (Steinheim, Germany). Fetal 110 
bovine serum (FBS) was from Pan-Biotech (Aidenbach, Germany). Immortalized human brain microvascular 111 
cell line (hBMEC) [17] was received from Prof. Kwang Sik Kim and Prof. Dennis Grab (Johns Hopkins 112 
University, Baltimore, MD, USA). Acetonitrile, methanol, formic acid (FA), trifluoroacetic acid (TFA), and 113 
ammonium formate were all HPLC grade and were obtained from BioSolve (Valkenswaard, the Netherlands). 114 
Dimethyl sulfoxide (DMSO) was purchased from Scharlau (Scharlab AG, Sentmenat, Spain). HPLC grade water 115 
was obtained by a Milli-Q integral water purification system (Millipore Merck, Darmstadt, Germany). Ringer 116 
HEPES buffer (RHB) (150 mM NaCl, 2.2 mM CaCl2, 0.2 mM MgCl2, 5.2 mM KCl, 2.8 mM glucose, 5 mM 117 
HEPES, 6 mM NaHCO3) was prepared in-house, adjusted to pH 7.4, filtered, and stored at 4°C.  118 
 119 
2.2 Stock solutions, calibration standards, and quality controls 120 
Stock solutions of each compound were prepared in DMSO. Weighings were done on a 1 µg precision 121 
microbalance (Sartorius, Switzerland). Working solutions (WS1) of analytes and corresponding I.S. (Table 1) at 122 
a concentration of 10 µg/mL in methanol were subsequently prepared by diluting the respective stock solutions. 123 
For all compounds, calibration standards (calibrators) in the range of 5.00–500 ng/mL (5.00, 25.0, 50.0, 100, 124 
200, 400, and 500 ng/mL) and quality controls (QCs) at low, middle, and high concentration (QCL = 15.0 125 
ng/mL, QCM = 250 ng/mL, and QCH = 400 ng/mL) were prepared in modified RHB (RHB + 0.2% Tween 20) 126 
and modified DMEM (DMEM + 10% FBS for piperine, LAU397, and LAU399; DMEM + 10% FBS + 0.2% 127 
Tween 20 for the other analogs) by serial dilution of the respective WS1. The first concentration level of the 128 
calibrators was defined as lower limit of quantification (LLOQ), and the last level as upper limit of 129 
quantification (ULOQ). Calibrators and QCs were aliquoted into polypropylene tubes and stored below -65°C 130 
until analysis. For the I.S., a second working solution (WS2) in methanol was freshly prepared on the day of 131 
each analytical run by further diluting the corresponding WS1. 132 
 133 
2.3 Sample extraction  134 
Prior to sample injection into the UHPLC-MS/MS system, analytes and I.S. were extracted from the matrices by 135 
means of protein precipitation. 136 
Samples in modified RHB: Sample aliquots in modified RHB (100 µL; exception LAU399: 200 µL) were 137 
spiked with a freshly prepared WS2 (between 200–1000 ng/mL) of the corresponding I.S. (100 µL) (Table 1). 138 
Samples were subsequently spiked with 200 µL BSA solution (60 g/L) and subjected to protein precipitation 139 
with ice cold acetonitrile (1000 µL). After vortexing and stirring for 10 min on an Eppendorf Mixmate 140 
(Vaudaux-Eppendorf, Schönenbuch, Switzerland), the mixture was centrifuged for 20 min at 13200 rpm 141 
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(MiniSpin plus, Vaudaux-Eppendorf). The supernatant (1200 µL) was transferred into a 96-deep well plate (96-142 
DWP), dried under nitrogen (Evaporex EVX-96, Apricot Designs, Monovia, CA, USA) and reconstituted with 143 
injection solvent (65% mobile phase A and 35% mobile phase B, v/v). Prior to injection (5 µL) into the UHPLC 144 
and for optimal reconstitution, the 96-DWP was stirred on an Eppendorf Mixmate for 30 min at 2000 rpm and 145 
then centrifuged for 4 min at 3000 rpm (Megafuge, Heraeus Instruments AG, Switzerland).  146 
Samples in modified DMEM: Sample aliquots in modified DMEM (100 µL) were spiked with a freshly 147 
prepared WS2 (between 200–1000 ng/mL) of the corresponding I.S. (100 µL) (Table 1) and directly subjected to 148 
protein precipitation by the addition of ice cold acetonitrile (1000 µL). After vortexing and stirring for 10 min on 149 
an Eppendorf Mixmate, the mixture was centrifuged for 20 min at 13200 rpm. The supernatant (1000 µL) was 150 
thereafter transferred into a 96-DWP. The subsequent procedure was the same as described above. 151 
 152 
2.4 UHPLC-MS/MS settings 153 
Method development was performed on a 1290 Infinity UHPLC system coupled to a 6460 Triple Quadrupole 154 
(QQQ) mass spectrometer (all Agilent, Waldbronn, Germany). Data were acquired with MassHunter software 155 
version B.07.00 (Agilent). The UHPLC system included a binary pump, a degasser, a cooling multisampler (set 156 
at 10°C), and a column heater. Separation was performed on a Kinetex PFP column (particle size 1.7 µm, 2.1 x 157 
50 mm) (Phenomenex, Torrance, CA, USA) heated to 55°C. The column was protected by an UHPLC column 158 
in-line filter unit (0.2 µm in-line frit). Mobile phase A was 10 mM ammonium formate containing 0.05% FA, 159 
and mobile phase B was acetonitrile containing 0.05% FA. The flow rate was set at 0.5 mL/min. The gradient 160 
started at 1 min with 40% of B and increased to 70% of B within 3.00 min, followed by a column washing step 161 
with 100% of B for 1 min. Needle wash solution was a mixture of acetonitrile and water (50/50, v/v) containing 162 
0.2% TFA, and seal wash solution was a mixture of methanol, isopropanol, and water (60/20/20, v/v). 163 
 164 
The QQQ was equipped with an Agilent Jet Stream source, and measurements were performed in electrospray 165 
ionization positive ion mode (ESI+) and multiple reaction monitoring (MRM) mode. MS/MS parameters were 166 
optimized using Agilent Optimizer software and were as follows: drying gas (nitrogen) temperature and flow 167 
rate were 320°C and 10 L/min, respectively, nebulizer pressure was 20 psi, sheath gas (nitrogen) temperature 168 
was 400°C, and flow rate was 11 L/min. Capillary voltage was 2500 V. For samples containing LAU399 in 169 
modified DMEM, sheath gas temperature and flow rate were 300°C and 6 L/min, respectively, and capillary 170 
voltage was 3500 V. MRM transitions, fragmentor voltage, and collision energy for each compound are listed in 171 
Table 1. Quantification was done using MassHunter Quantitative Analysis software version B.07.00 (Agilent).  172 
 173 
2.5 Analytical runs  174 
2.5.1 Calibration curve and regression analysis 175 
Each analytical run consisted of a set of seven calibrators injected with increasing concentration after a blank 176 
sample (blank matrix) and a calibrator zero (blank matrix only spiked with I.S.) at the beginning and at the end 177 
of the run. A calibration curve was considered valid if the coefficient of determination (R
2
) was higher than 0.96 178 
and if at least 75% of all calibrators were used to generate the calibration curve. The back calculated 179 
concentrations of the calibrators had to be within ± 15% of the nominal values at all concentration levels 180 
(exception LLOQ: within ± 20%). For the LLOQ and the ULOQ, at least one replicate had to be accepted. The 181 
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calibration curve was validated through six QCs (duplicates of QCL, QCM, and QCH), which were inserted 182 
randomly into the analytical run. The back calculated concentrations had to be within ± 15% of the nominal 183 
values at all QC levels. For the six QCs, at least four replicates in total and at least one replicate at each 184 
concentration level had to be accepted. Imprecision in all analytical runs was expressed by the coefficient of 185 
variation (CV %), and had to be below 15% (below 20% at the LLOQ) of the nominal values at all concentration 186 
levels. Inaccuracy was expressed by the relative error (RE %), and had to be within ± 15% (within ± 20% at the 187 
LLOQ) of the nominal values at all concentration levels [18,19]. 188 
 189 
2.5.2 Carry-over 190 
To assess the carry-over of both analyte and I.S. in each analytical run, blank samples were injected after both 191 
replicates of the ULOQ. Peak areas of analyte and I.S. in these blank samples were then compared to the peak 192 
areas at the LLOQ. Mean carry-over in each analytical run, expressed in %, had to be below 20% for analytes, 193 
and below 5% for I.S. [19]. 194 
 195 
2.5.3 Between-run reproducibility 196 
Between-run reproducibility was assessed by calculating the imprecision (CV %) and inaccuracy (RE %) at five 197 
concentration levels (LLOQ, QCL, QCM, QCH, and ULOQ) of two replicates injected within three analytical 198 
runs on three different days (n = 6). 199 
 200 
2.6 Immortalized in vitro human BBB model (based on hBMEC cell line) 201 
The immortalized human mono-culture in vitro BBB model (24-well format) based on hBMEC cell line was 202 
prepared as reported previously [13,14], with minor modifications. As cell culture medium for hBMEC cells, 203 
EBM-2 supplemented with Single-Quots (hydrocortisone, ascorbic acid, and heparin), antibiotic-antimycotic 204 
solution, and 20% FBS (heat inactivated at 56°C for 30 min) was used. Cells were seeded at a density of 60000 205 
cells/cm
2
 onto rat tail collagen I-coated 24-well tissue culture inserts (0.336 cm
2
, transparent PET membrane, 3.0 206 
µm pore size, Greiner Bio-one, Frickenhausen, Germany), and transferred into a 24-well module of a CellZscope 207 
device [20]. Transendothelial electrical resistance (TEER) and cell layer capacitance (CCL) values were recorded 208 
in real-time every hour by the CellZscope system (NanoAnalytics, Münster, Germany) inside the incubator 209 
(37°C and 5% CO2). The permeability experiments were carried out after 2.5–3 days of incubation of hBMEC 210 
monolayers. Pre-warmed (37°C) RHB was added to the receiver compartments (1200 µL in empty wells of a 24-211 
well plate for transport from apical-to-basolateral (A→B), and 300 µL in inserts for transport from basolateral-212 
to-apical (B→A)). Working solution containing the test compound (2 µM) and Na-F (10 µg/mL) in RHB + 0.1% 213 
BSA was added to the donor compartments (300 µL in inserts for A→B, and 1200 µL in empty wells for B→A). 214 
The 24-well plates were incubated on an orbital shaker at 37°C and 300 rpm (ELMI DTS-2, Riga, Latvia), and 215 
aliquots of apical and basolateral compartments were collected after several time points (15, 30, 60, and 120 216 
min) (one insert per time point) and stored below -65°C until analysis. The experiments were performed at least 217 
in triplicate, and control experiments without cells were performed. Na-F fluorescence was quantified with a 218 
Chameleon microplate reader (Hidex, Turku, Finland), and quantification of test compounds was carried out by 219 
UHPLC-MS/MS. Before UHPLC-MS/MS analysis, samples were diluted with an equal volume of 0.4% Tween 220 
20 in order to avoid non-specific adsorption to surfaces. 221 
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2.7 In vitro human brain-like endothelial cells (BLEC) BBB model  222 
The human in vitro BBB model derived from hematopoietic stem cells (12-well format) was prepared as 223 
described previously [15]. Tissue culture inserts were from Corning (1.12 cm
2
, polycarbonate membrane, 0.4 µm 224 
pore size, Corning, New York, USA), and were coated with matrigel. Prior to the permeability experiments, 225 
buffered Ringer’s solution was added to the receiver compartments (1500 µL in empty wells of a 12-well plate 226 
for A→B transport, and 500 µL in inserts for B→A transport). Working solution containing the test compound 227 
(2 µM) and Na-F (10 µg/mL) in RHB + 0.1% BSA was added to the donor compartments (500 µL in inserts for 228 
A→B, and 1500 µL in empty wells for B→A), and the 12-well plates were incubated on an orbital shaker at 229 
37°C and 60 rpm (Polymix, Kinematica). After 15, 30, and 60 min for A→B transport, inserts were transferred 230 
into a new receiver plate filled with transport buffer. After 15, 30, 60, and 120 min for A→B transport, or after 231 
two hours incubation for B→A, an aliquot from each donor and receiver compartment and working solution was 232 
withdrawn and stored below -65°C until analysis. Control inserts without cells were assayed for each test 233 
compound. Experiments were performed in triplicate. The amount of fluorescent tracer (Na-F) was analyzed 234 
with a fluorescence counter (Synergy H1, Biotek). Quantification of test compounds was carried out as described 235 
above.  236 
 237 
2.8 In vitro primary bovine endothelial/rat astrocytes co-culture BBB model  238 
The bovine endothelial/rat astrocytes co-culture model was prepared as described previously [21]. Tissue culture 239 
inserts were from Corning (1.12 cm
2
, polycarbonate membrane, 0.4 µm pore size, Corning, New York, USA), 240 
and were coated with collagen/fibronectin. Experiments were performed in triplicate. Transcellular transport 241 
studies were performed directly in the culture medium (DMEM + 10% FBS) after 6 days of co-culture. TEER 242 
was measured after equilibration to RT prior to all experiments, using an Endohm-12 cup electrode chamber 243 
(World Precision Instruments, Sarasota, Florida, USA) connected to a Millicell-ERS device (Millipore, 244 
Massachusetts, USA). Cells were equilibrated to 37°C, and transport was started by addition of a working 245 
solution containing the test compound (5 µM) and Na-F (10 µg/mL) in DMEM + 10% FBS to the donor 246 
compartments (500 µL for A→B and 1000 µL for B→A). The cells were placed on a temperature-controlled 247 
shaking table at 37°C and 90 rpm. Aliquots (100 μL from the apical and 200 μL from the basolateral 248 
compartments) were withdrawn from the receiver compartments after 15, 30, 60, and 120 min, and from the 249 
donor compartment after 120 min. Withdrawn samples were replaced with pre-warmed (37°C) medium. Na-F 250 
signal was immediately measured in a NOVOstar plate reader (BMG Labtech GmbH, Offenburg, Germany), and 251 
Na-F concentration in the samples was calculated by comparison to a standard curve. Samples were 252 
subsequently stored at -20°C until UHPLC-MS/MS-analysis.  253 
 254 
2.9 Calculation of permeability coefficients  255 
For the two human in vitro BBB models, endothelial permeability coefficients (Pe) for each test compound and 256 
for Na-F were calculated as follows. For each replicate (control inserts without cells and inserts with cells), the 257 
clearance was calculated according to the following equation [22,23]: 258 
Clearance (µL) = CRVR/CD                 (1) 259 
where CR and VR are the concentration and volume in the receiver compartments, respectively, and CD is the 260 
initial concentration in the donor compartment. The mean cleared volume was plotted as a function of time (15, 261 
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30, 60, and 120 min), and the slope was estimated by linear regression analysis. Permeability-surface area 262 
products (PS) and Pe values were subsequently calculated according to the following equations [22,23]: 263 
1/PStotal – 1/PSfilter = 1/PSe                (2) 264 
PSe/A = Pe (cm/s)                    (3) 265 
where PStotal is the slope of the clearance curve of cell monolayers with filter inserts, PSfilter is the slope of the 266 
clearance curve of control filter inserts without cells, PSe is the slope of the clearance curve of the endothelial 267 
monolayers, and A is the surface area of the filter membrane. 268 
 269 
For all three models, apparent permeability coefficients (Papp) were calculated according to the following 270 
equations [24,25]: 271 
Papp (cm/s) = J/(ACD)                                                        (4) 272 
where J is the rate of appearance of the compounds in the receiver compartment, A is the surface area of the 273 
filter membrane, and CD is the initial concentration in the donor compartment. 274 
 275 
Furthermore, efflux ratios (ER) were calculated: 276 
ER = Papp (B→A)/Papp (A→B)                       (5) 277 
where Papp (B→A) and Papp (A→B) are the Papp values in the direction basolateral-to-apical and apical-to-basolateral, 278 
respectively. A high ER indicates a potentially significant role for efflux transporters in the passage of a 279 
compound across cell monolayers. Compounds with a ER > 2 are thus usually categorized as efflux transporter 280 
substrates [26,27]. 281 
 282 
Recovery (mass balance) of each compound was calculated according to the following equation: 283 
Recovery (%) = (NDf + NRf)/NDi x 100                                   (6) 284 
where NDf and NRf are the final amounts of the compounds in the donor and receiver compartments, respectively, 285 
and NDi is the initial amount in the donor compartment. All results are expressed as means ± standard deviation 286 
(SD). 287 
 288 
2.10 In silico prediction of BBB permeability 289 
Three-dimensional computer models of studied compounds were built in Maestro modeling environment [28]. 290 
The global minimum geometry was used as an input for the QikProp application [29] to evaluate various 291 
descriptors relevant for compound permeability through the BBB. The polar surface area (PSA) and the 292 
logarithm of partition and distribution coefficient (LogP and LogD7.4, respectively) descriptors were calculated 293 
using the Calculator plugin of Chemaxon Marvin application [30].  294 
 295 
3 Results 296 
3.1 UHPLC-MS/MS 297 
3.1.1 Chromatographic performance 298 
Calibration curves in the range of 5.00–500 ng/mL for each analyte were fitted by least-squares quadratic 299 
regression, and a weighting factor of 1/X was applied. The mean coefficients of determination (R
2
) ranged from 300 
0.9945 to 0.9996 (Tables S1 and S2).  301 
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3.1.2 Carry-over 302 
Mean carry-over in blank matrix samples (modified RHB and modified DMEM) injected after the ULOQ were 303 
between 0.00% to 4.27% for analytes (below 20%), and between 0.00% and 0.0597% for I.S. (below 5%) (Table 304 
S3), indicating that carry-over did not have an impact on the results. 305 
 306 
3.1.3 Between-run reproducibility 307 
Between-run imprecision (CV %) was between 1.17% and 14.9% (below 15%), and between-run inaccuracy (RE 308 
%) was between -8.15% and 10.0% (within ± 15%) at all calibration levels in both matrices (modified RHB and 309 
modified DMEM) (Tables 2 and 3), indicating that the methods were accurate, precise, and reproducible. 310 
 311 
3.2 Immortalized in vitro human BBB model (based on hBMEC cell line) 312 
In the immortalized in vitro human BBB model [13,14], piperine showed a mean Pe (A→B) value of 53.7 ± 4.47 x 313 
10
-6 
cm/s, indicating significant BBB permeability when compared to the mean Pe (A→B) value of the negative 314 
control Na-F (6.51 ± 0.163 x 10
-6 
cm/s) (Fig. 2A, Table 4). SCT-64 and LAU399 showed lower mean Pe (A→B) 315 
values (26.4 ± 1.48 x 10
-6 
cm/s and 21.6 ± 9.52 x 10
-6 
cm/s, respectively) than piperine (Fig. 2A, Table 4), but 316 
were still significantly higher than those for Na-F (4.50 and 4.83 x 10
-6 
cm/s), respectively). Compounds SCT-317 
66, SCT-29, and LAU397 showed mean Pe (A→B) values between 4.29 and 9.32 x 10
-6 
cm/s (Fig. 2A, Table 4), 318 
suggesting low BBB permeability when compared to Na-F. The compounds could be ranked based on their Pe 319 
(A→B) values in the following order: piperine > SCT-64/LAU399 > SCT-66 > LAU397/SCT-29. ER values for 320 
the compounds (except SCT-29) were between 0.750 and 1.92 (Table S4), suggesting that permeability of the 321 
compounds was not affected by active efflux transporters [26,27].  322 
 323 
Mean TEER values were between 20–40 Ωcm2 for the BBB drug permeability experiments, and were in the 324 
same range after the assays (Fig. S1). Mean CCL values were in the range of 0.5–5.0 µF/cm
2
 (Fig. S1), indicating 325 
cell confluency of hBMEC monolayers and validating TEER values [31]. During the permeability assays, Papp 326 
values for Na-F were constant, indicating that barrier integrity of hBMEC monolayers was maintained 327 
throughout the experiments.  328 
 329 
3.3 In vitro human brain-like endothelial cells (BLEC) BBB model  330 
In the in vitro human BLEC model [15], piperine, SCT-66, and SCT-64 showed mean Pe (A→B) values between 331 
26.7 and 97.8 x 10
-6 
cm/s (Fig. 2B, Table 5) that were indicative of moderate to high BBB permeability when 332 
compared to the mean Pe (A→B) values for Na-F (9.99–12.0 x 10
-6 
cm/s). The analogs SCT-29, LAU397, and 333 
LAU399 showed mean Pe (A→B) values between 4.61 and 12.4 x 10
-6 
cm/s (Fig. 2B, Table 5), suggesting low 334 
permeability when compared to Na-F. The compounds could be ranked regarding their Pe (A→B) values as 335 
follows: piperine > SCT-66/SCT-64 > LAU397 > LAU399/SCT-29.  336 
 337 
For all compounds (except piperine), mean recoveries were rather low (between 55.7% and 68.5%) (Table 5), 338 
also in the absence of cells (data not shown). This was indicative of a possible non-specific binding of analytes 339 
to plastic surfaces and/or coating material of the inserts and transwell plates. Thus, Pe (A→B) values might be 340 
underestimated.  341 
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ER values for all compounds were between 0.406 and 0.804 (Table S5), suggesting that the compounds were not 342 
substrates of active efflux. Mean TEER values, at which permeability experiments were carried out, were 343 
between 150–200 Ωcm2 [15].  344 
 345 
3.4 In vitro primary bovine endothelial/rat astrocytes co-culture BBB model  346 
In the primary bovine endothelial/rat astrocytes co-culture in vitro BBB model, the compounds showed mean 347 
Papp (A→B) values between 20.9 and 81.3 x 10
-6 
cm/s (Fig. 2C, Table 6). Compared to the mean Papp (A→B) values of 348 
Na-F (2.15–5.07 x 10-6 cm/s) (Table 6), these values were considerably higher, indicating high BBB permeability 349 
for all compounds. The compounds could be ranked based on their Papp (A→B) values in the following order: 350 
piperine > SCT-64 > LAU399/LAU397 > SCT-66/SCT-29.  351 
 352 
However, the mean Papp (A→B) values for Na-F in presence of the test compounds (2.15–5.07 x 10
-6 
cm/s, Table 6) 353 
were up to five times higher than those usually obtained in the model (below 1 x 10
-6
 cm/s). Mean Papp values in 354 
the direction B→A for Na-F in presence of the compounds, on the other hand, were in this expected range 355 
(below 1 x 10
-6
 cm/s, Table S6). Hence, a polarized opening of the paracellular space may have occurred when 356 
the compounds were applied on the apical side (but not on the basolateral side). For piperine, we further 357 
investigated this junctional effect by applying the compound to the apical and basolateral side of the inserts (at 5 358 
µM), and measuring TEER as a function of incubation time. Throughout a two hour incubation period, the TEER 359 
was relatively stable for control cell monolayers and for cell monolayers to which piperine was applied on the 360 
basolateral side (Fig. 3). However, TEER values decreased from 1261 to 268 cm2 for cell monolayers to which 361 
piperine was added on the apical side (Fig. 3), supporting the hypothesis of a polarized paracellular opening.  362 
 363 
ER values for all compounds were between 0.340 and 0.584 (Table S6), indicating no involvement of active 364 
efflux transporters. TEER values, at which experiments were performed, were in the range of 1900–2500 Ωcm2. 365 
 366 
3.5 In silico prediction of BBB permeability 367 
The analysis of descriptors relevant for the BBB permeation showed that the compounds had a PSA (26.9–48.1 368 
Å
2
) (Table 7) below the recommended thresholds of 70 Å
2
 [32] and 90 Å
2
 [33], which favors their passive 369 
permeation across the BBB. Similarly, their molecular weight (MW) was below the recommended value of 450 370 
g/mol for CNS drugs (between 285 and 329 g/mol) (Table 7) [33]. All compounds had a low effective number of 371 
H-bond acceptors (< 5) and no H-bond donors (Table 7), which facilitates their desolvation before entering into 372 
the lipophilic phase of the cell membranes. The QikProp model for brain/blood partitioning predicted favorable 373 
LogBB parameters (between -0.51 and -0.12) for all compounds (for 95% of known drugs, values range between 374 
-3.0 and 1.2), and the predicted permeability across Madin-Darby Canine Kidney (MDCK) and Caco-2 cells was 375 
very high (> 2000 nm/s) (Table 7). LogP values for the compounds ranged from 3.27 to 5.34 (recommended 376 
values for CNS drugs are between 1–4), and the total numbers of rotatable bonds were between 3 and 10 (Table 377 
7) (less than 6 rotatable bonds recommended for CNS drugs [34]).  378 
 379 
 380 
 381 
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4 Discussion 382 
The alkaloid piperine was recently identified as a promising lead compound for the development of positive 383 
allosteric GABAA receptor modulating drugs interacting at an up to now poorly characterized binding site [1]. 384 
However, the compound concomitantly activates TRPV1 receptors [4], which is undesirable for a lead structure 385 
as unwanted side effects might possibly occur. A large series of semisynthetic and fully synthetic piperine 386 
analogs was therefore synthesized, with the objective to obtain compounds with improved GABAA receptor 387 
activity and reduced TRPV1 receptor interaction [2,7,9]. Among these, the analogs SCT-66, SCT-64, SCT-29, 388 
LAU397, and LAU399 (Fig. 1) modulated GABAA receptors more potently and/or efficiently than piperine, 389 
while being devoid of TRPV1 interaction [1,2,7,9]. 390 
 391 
Drugs acting on the CNS such as GABAA receptor modulators need to penetrate the brain by crossing the BBB 392 
in order to reach their target sites. In this study, we aimed thus at early screening piperine and five promising 393 
analogs (SCT-66, SCT-64, SCT-29, LAU397, and LAU399) for their ability to cross the BBB, in order to 394 
evaluate their potential as lead structures for the development of new GABAA receptor modulating drugs, and to 395 
select the most promising candidate molecule for further in vivo testing or for the next cycle of medicinal 396 
chemistry optimization. 397 
 398 
For comparative purposes, we initially decided to select three human BBB models including immortalized, 399 
primary, and stem cell-derived human cell phenotypes. However, getting access to post-mortem human brains 400 
was critical, and we therefore utilized a highly tight animal BBB model. The compounds were thus screened in 401 
our previously established and validated immortalized human mono-culture in vitro BBB model based on 402 
hBMEC cell line [13,14], in a recently developed in vitro human BLEC BBB model [15], and in a well-403 
established tight primary animal (bovine endothelial/rat astrocytes co-culture) in vitro BBB model [21]. For each 404 
compound, a specific quantitative UHPLC-MS/MS assay in the corresponding matrix was developed, and 405 
permeability coefficients across the endothelial monolayers were determined. For each model, we reported the 406 
permeability coefficients that are usually calculated for screened compounds (i.e. Pe for the two human models 407 
[14,15], and Papp for the animal model [21]). 408 
 409 
During UHPLC-MS/MS method development, non-specific adsorption of the compounds in RHB to various 410 
surfaces was observed, leading to unacceptable calibration curves (data not shown). This problem was resolved 411 
by spiking RHB with 0.2% Tween 20 for the preparation of calibrators and QCs [35], and valid calibration 412 
curves could be obtained (Table S1). For compounds in modified DMEM, the addition of Tween 20 was only 413 
necessary for SCT-66, SCT-64, and SCT-29. For the other analogs, the presence of FBS (10%) in the matrix 414 
(DMEM) seemed to be sufficient to avoid non-specific adsorption to surfaces. However, the permeability assays 415 
could not be carried out using RHB spiked with Tween 20 since the detergent could affect the integrity of the 416 
endothelial barrier. Thus, samples were diluted after the assays with an equal volume of RHB containing 0.4% 417 
Tween 20 directly in the tubes for optimal desorption.  418 
 419 
In the two human in vitro BBB models, piperine and SCT-64 displayed moderate to high BBB permeability, 420 
while SCT-29 and LAU397 displayed low BBB permeability (Fig. 2A and 2B, Tables 4 and 5). The derivative 421 
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SCT-66 showed moderate BBB permeability in the human BLEC BBB model (but low permeability in the 422 
immortalized model), while LAU399 showed moderate BBB permeation in the immortalized model (but low 423 
permeability in the human BLEC model) (Fig. 2A and 2B, Tables 4 and 5). With the exception of this minor 424 
difference, both human models provided a similar ranking of the compounds based on their Pe (A→B) values. 425 
 426 
Results from the primary animal in vitro BBB model were not in complete agreement with permeability data 427 
from the two human models. In the animal model, all compounds showed high BBB permeability, while in the 428 
human models, two analogs (SCT-29 and LAU397) showed low BBB permeation (Fig. 2, Tables 4–6). These 429 
data discrepancies were most likely due to the different matrices used for the permeability screenings. In the 430 
animal model, transport experiments were carried out directly in cell culture medium containing 10% FBS. The 431 
presence of proteins in the receiver compartment thus created an additional sink, increasing the permeability for 432 
the lipophilic piperine analogs across the BBB due to a high protein binding [36].  433 
 434 
According calculated descriptor values relevant for BBB permeation (i.e. PSA, MW, H-bond acceptors and 435 
donors, LogBB) (Table 7), all compounds should be able to permeate the BBB by passive diffusion. However, a 436 
closer consideration of two further descriptor values, namely LogP and number of rotatable bonds, may provide 437 
a further explanation for the low permeability observed for SCT-29 and LAU397 in the human BBB models. 438 
According to Brito-Sánchez et al. (2015), the total number of rotatable bonds should not exceed 6 to facilitate the 439 
permeation of a compound across the BBB [34]. For SCT-29 and LAU397, the total number of rotatable bonds 440 
of the compounds was rather high (9 and 10, respectively; counting according to Veber rules) (Table 7). 441 
Furthermore, SCT-29 and LAU397 showed relatively high LogP values (4.70 and 5.34, respectively) (Table 7) 442 
which are above the recommended range of 1–4 for CNS drugs. Compounds SCT-66 and SCT-64 also showed 443 
relatively high LogP values (4.59 and 3.96, respectively). However, their total number of rotatable bonds was 444 
lower (7). In case of LAU399, the high number of rotatable bonds (9) and non-optimal lipophilicity (LogP of 445 
5.21) were probably compensated by its extremely small PSA (26.9 Å
2
). Piperine showed moderate lipophilicity 446 
(LogP of 3.27), a low number of rotatable bonds (3), and was thus best suited for BBB permeation. In 447 
conclusion, it seemed that for the human models, BBB permeation of this series of compounds depended mainly 448 
on their number of rotatable bonds. 449 
 450 
In the animal in vitro BBB model, mean Papp (A→B) values for Na-F in presence of the compounds were up to five 451 
times higher than those normally observed in this model (below 1 x 10
-6
 cm/s). However, mean Papp values in the 452 
direction B→A for Na-F in presence of the compounds were in this expected range (below 1 x 10-6 cm/s, Table 453 
S6). Thus, a polarized opening of the paracellular space may have occurred when the compounds were applied 454 
on the apical side (but not on the basolateral side). Therefore, mean Papp values in the direction B→A for the 455 
compounds may give a better estimation of their BBB permeability in a situation where there is no barrier 456 
opening. 457 
 458 
For piperine, the polarized junctional effect was further investigated by applying the compound on the apical and 459 
basolateral side of the inserts (5 µM), and measuring the TEER as a function of incubation time. Throughout an 460 
incubation period of two hours, the TEER was relatively stable for control cell monolayers and for cell 461 
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monolayers to which piperine was applied on the basolateral side (Fig. 3). However, TEER values decreased 462 
from 1261 to 268 cm2 for cell monolayers to which piperine was added on the apical side (Fig. 3), supporting 463 
the hypothesis of a polarized paracellular opening. The apparent junctional opening could be caused by TRPV1 464 
activation in brain endothelial cells, as has previously been demonstrated in anesthetized rats [38]. TRPV1 465 
activation has been shown to decrease TEER and to cause occludin redistribution in a rat submandibular gland 466 
cell line (SMG-C6) [39], and may have caused similar effects in the bovine endothelial cells, which would imply 467 
an apical localization of TRPV1 receptors in the endothelial cells. The five tested piperine analogs were reported 468 
not to act on rat TRPV1 receptors [2,9], but affinities for the bovine form of the receptor may differ. However, 469 
more detailed studies to clarify these issues would be necessary. An opening of the barrier could not be observed 470 
in the human models with compounds at 2 μM, as Pe values for Na-F in both directions (Pe (A→B) see Table 7; Pe 471 
(B→A) data not shown) were in a similar range as usually obtained in the two models, indicating that barrier 472 
integrity was maintained throughout the experiments.  473 
 474 
In previous studies, piperine and the analogs SCT-66, SCT-64, and SCT-29 were reported to exhibit anxiolytic 475 
effects in mice [2,7]. However, SCT-66 and SCT-29 did not cross the BBB significantly in the in vitro human 476 
models, while crossing the BBB in the in vitro bovine/rat model. As discussed above, the high permeability of 477 
the compounds in the animal model was likely due to the presence of FBS in the transport matrix, which created 478 
sink conditions in the receiver compartment, and thus improved Papp values due to a high protein binding of the 479 
compounds. To evaluate whether the compounds are able to reach the brain in vivo, further studies to assess 480 
protein binding and the in vivo extent of brain penetration (e.g. total brain-to-plasma ratio) of the compounds are 481 
therefore necessary, and are currently in progress in our laboratory. Also, free brain drug concentration in vivo of 482 
the compounds should be determined. 483 
 484 
Finally, by performing bidirectional permeability experiments we did not evidence any effect of active efflux 485 
transporters on compound permeation across the BBB (ER below 2, Tables S4–S6). However, piperine has been 486 
reported to inhibit P-glycoprotein (P-gp) and phase I and II metabolism enzymes [40–42]. Thus, possible 487 
inhibition of P-gp and CYPs by the compounds needs to be assessed. Also, an evaluation of the metabolic 488 
stability is needed, especially for compounds containing the metabolically critical 1,3-benzodioxole group 489 
(piperine, SCT-66, SCT-64, and SCT-29) (Fig. 1). 490 
 491 
5 Conclusions 492 
Piperine and five selected piperine analogs with positive GABAA receptor modulatory activity were screened in 493 
three in vitro cell-based human and animal BBB models for their ability to cross the BBB. Data from the three 494 
models differed to some extent, possibly due to high protein binding of the piperine analogs. In all three models, 495 
piperine and SCT-64 displayed the highest BBB permeation potential, which could be corroborated by in silico 496 
prediction data. For the other piperine analogs (SCT-66, SCT-29, LAU397, and LAU399), BBB permeability 497 
was low to moderate in the two human models, and moderate to high in the animal model. ER calculated from 498 
bidirectional permeability experiments indicated that the compounds were not substrates of active efflux. We 499 
conclude that further in vivo experiments are necessary to evaluate the extent of brain penetration of the 500 
compounds. In addition, pharmacokinetic properties and drug metabolism of the compounds should be assessed. 501 
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Several studies are currently in progress in our laboratory, and will serve to select the most promising candidate 502 
molecule for further development or for the next cycle of medicinal chemistry optimization. 503 
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FIGURES 620 
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Fig. 1 Piperine and analogs analyzed in the in vitro BBB models. Selection and optimization process, and 623 
structures of compounds [1,2,7,9]. 624 
 625 
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 629 
Fig. 2 Mean endothelial permeability coefficients (Pe (A→B)) ± SD for piperine and five analogs in (A) the 630 
immortalized in vitro human BBB model (hBMEC cell line-based), (B) the in vitro human BLEC BBB model, 631 
and (C) mean apparent permeability coefficients (Papp (A→B)) ± SD in the in vitro primary bovine endothelial/rat 632 
astrocytes co-culture BBB model. 633 
 634 
 635 
 636 
 637 
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 638 
Fig. 3 Mean TEER ± SD values in the primary bovine endothelial/rat astrocytes co-culture in vitro BBB model 639 
for endothelial cell monolayers as a function of incubation time (n = 2). TEER values were relatively stable for a 640 
two hour incubation time for control cell monolayers, and for cell monolayers when piperine (5 µM) was applied 641 
on the basolateral side (Piperine B-to-A). However, TEER values of cell monolayers decreased from 1261 to 268 642 
cm2 when piperine (5 µM) was applied on the apical side (Piperine A-to-B), suggesting a polarized opening of 643 
the paracellular space. 644 
 645 
 646 
 647 
 648 
 649 
 650 
 651 
 652 
 653 
 654 
 655 
 656 
 657 
 658 
 659 
 660 
 661 
 662 
 663 
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TABLES 666 
 667 
Table 1 Optimized MS/MS parameters (MRM transitions, fragmentor voltage, and collision energy) in ESI 668 
positive mode for analytes and corresponding I.S. 669 
Analyte 
I.S. 
MRM transitions Fragmentor voltage (V) Collision energy (V) 
Piperine (Quantifier) 
Piperine (Qualifier) 
I.S. SCT-64 
286.15 → 115.00 
286.15 → 143.00 
302.18 → 115.00 
117 
117 
117 
54 
34 
58 
SCT-66 (Quantifier) 
SCT-66 (Qualifier) 
I.S. SCT-64 
330.21 → 201.10 
330.21 → 115.10 
302.18 → 115.00 
127 
127 
117 
22 
62 
58 
SCT-64 (Quantifier) 
SCT-64 (Qualifier) 
I.S. SCT-66 
302.18 → 115.00 
302.18 → 143.00 
330.21 → 201.10 
117 
117 
127 
58 
34 
22 
SCT-29 (Quantifier) 
SCT-29 (Qualifier) 
I.S. SCT-64 
330.21 → 201.00 
330.21 → 115.00 
302.18 → 115.00 
177 
177 
117 
22 
62 
58 
LAU397 (Quantifier) 
LAU397 (Qualifier) 
I.S. LAU399 
316.23 → 187.00 
316.23 → 144.00 
292.18 → 163.00 
205 
205 
205 
18 
38 
18 
LAU399 (Quantifier) 
LAU399 (Qualifier) 
I.S. SCT-64 
292.18 → 163.00 
292.18 → 91.10 
302.18 → 115.00 
205 
205 
117 
18 
54 
58 
 670 
Table 2 Between-run imprecision (CV %) and inaccuracy (RE %) of QCs in modified RHB, based on 3 series of 671 
2 replicates for each level (n = 18). 672 
Compound  Nominal concentration (ng/mL) 
  5.00 15.0  250  400  500  
Piperine Mean 5.03 14.3 257 384 507 
 S.D. 0.214 2.12 12.2 28.5 16.7 
 CV % 4.25 14.9 4.76 7.43 3.29 
 RE % 0.549 -4.97 2.81 -4.08 1.44 
SCT-66 Mean 4.85 15.9 261 389 500 
 S.D. 0.120 1.00 17.8 7.20 20.2 
 CV % 2.47 6.27 6.80 1.85 4.04 
 RE % -2.94 5.76 4.52 -2.65 -0.0419 
SCT-64 Mean 4.88 14.5 241 374 493 
 S.D. 0.424 1.62 24.9 11.1 22.0 
 CV % 8.69 11.2 10.3 2.98 4.46 
 RE % -2.47 -3.65 -3.59 -6.51 -1.48 
SCT-29 Mean 5.20 16.5 244 397 494 
 S.D. 0.296 1.37 22.0 36.3 12.6 
 CV % 5.70 8.30 9.04 9.13 2.55 
 RE % 4.06 9.98 -2.59 -0.735 -1.11 
LAU397 Mean 5.05 15.2 256 398 501 
 S.D. 0.446 0.918 11.0 7.98 26.3 
 CV % 8.84 6.05 4.31 2.01 5.25 
 RE % 0.961 1.25 2.54 -0.605 0.138 
LAU399 Mean 4.83 16.0 264 403 499 
 S.D. 0.0960 1.39 12.3 41.5 21.3 
 CV % 1.99 8.68 4.65 10.3 4.27 
 RE % -3.50 6.81 5.63 0.851 -0.227 
 673 
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Table 3 Between-run imprecision (CV %) and inaccuracy (RE %) of QCs in modified DMEM, based on 3 series 674 
of 2 replicates for each level (n = 18). 675 
Compound  Nominal concentration (ng/mL) 
  5.00  15.0  250  400  500  
Piperine Mean 4.81 15.9 247 393 503 
 S.D. 0.250 1.09 22.1 8.64 7.42 
 CV % 5.20 6.83 8.93 2.20 1.48 
 RE % -3.90 6.17 -1.17 -1.73 0.600 
SCT-66 Mean 4.94 16.4 253 384 506 
 S.D. 0.180 1.23 20.3 17.0 10.7 
 CV % 3.65 7.54 8.05 4.42 2.12 
 RE % -1.21 9.13 1.03 -3.95 1.12 
SCT-64 Mean 4.92 13.8 230 375 502 
 S.D. 0.250 0.658 9.41 6.79 11.3 
 CV % 5.08 4.75 4.10 1.81 2.24 
 RE % -1.53 -7.72 -8.15 -6.14 0.354 
SCT-29 Mean 4.88 16.4 269 394 501 
 S.D. 0.256 0.566 12.1 22.5 15.1 
 CV % 5.24 3.46 4.50 5.71 3.02 
 RE % -2.34 9.11 7.77 -1.40 0.108 
LAU397 Mean 4.72 16.5 242 379 507 
 S.D. 0.144 1.22 14.8 9.78 5.93 
 CV % 3.06 7.41 6.11 2.58 1.17 
 RE % -5.64 9.77 -3.35 -5.37 1.38 
LAU399 Mean 5.24 16.5 254 408 506 
 S.D. 0.234 0.431 10.1 13.7 7.69 
 CV % 4.46 2.61 4.00 3.36 1.52 
 RE % 4.89 10.0 1.42 1.97 1.25 
 676 
 677 
 678 
 679 
 680 
 681 
 682 
 683 
 684 
 685 
 686 
 687 
 688 
 689 
 690 
 691 
 692 
 693 
 694 
 695 
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Table 4 Mean endothelial permeability coefficients (Pe (A→B)) for analytes and Na-F, and mean recoveries for 696 
analytes obtained in the immortalized in vitro human BBB model based on hBMEC cell line (n = 3–4). 697 
Compound 
Mean Pe ± SD (x 10
-6
 
cm/s) 
Na-F: Mean Pe ± SD (x 
10
-6
 cm/s) 
Mean recovery ± SD for 
analyte (%)* 
Direction A→B  A→B  A→B 
Piperine 53.7 ± 4.47 6.51 ± 0.163 107 ± 5.59 
SCT-66 9.32 ± 2.82 7.01 ± 0.0817 86.7 ± 15.3 
SCT-64 26.4 ± 1.48 4.50 ± 0.387 70.4 ± 4.55 
SCT-29 4.29 ± 1.25 4.99 ± 0.205 88.2 ± 8.73 
LAU397 4.49 ± 1.07 5.45 ± 0.0609 88.2 ± 3.41 
LAU399 21.6 ± 9.52 4.83 ± 0.188 97.5 ± 13.3 
*Recoveries were assessed with the experimental concentrations of the working solutions. 698 
 699 
Table 5 Mean endothelial permeability coefficients (Pe (A→B)) for analytes and Na-F, and mean recoveries for 700 
analytes obtained in the in vitro human BLEC BBB model (n = 3). 701 
Compound 
Mean Pe ± SD (x 10
-6
 
cm/s) 
Na-F: Mean Pe ± SD (x 
10
-6
 cm/s) 
Mean recovery ± SD for 
analyte (%)* 
Direction A→B  A→B  A→B 
Piperine 97.8 ± 24.1 9.99 ± 1.41 97.0 ± 8.02 
SCT-66 29.4 ± 7.79 12.0 ± 1.47 68.5 ± 9.49 
SCT-64 26.7 ± 13.8 10.5 ± 1.32 61.2 ± 5.83 
SCT-29 4.61 ± 1.29 12.7 ± 1.38 56.1 ± 10.4 
LAU397 12.4 ± 9.91 10.6 ± 1.05 55.7 ± 2.54 
LAU399 7.79 ± 2.64 14.8 ± 3.57 60.1 ± 1.55 
*Recoveries were assessed with the experimental concentrations of the working solutions. 702 
 703 
Table 6 Mean apparent permeability coefficients (Papp (A→B)) for analytes and Na-F, and mean recoveries for 704 
analytes obtained in the primary bovine endothelial/rat astrocytes co-culture in vitro BBB model (n = 3). 705 
Compound 
Mean Papp ± SD (x 10
-6
 
cm/s) 
Na-F: Mean Papp ± SD (x 
10
-6
 cm/s) 
Mean recovery ± SD for 
analyte (%)* 
Direction A→B  A→B  A→B 
Piperine 81.3 ± 2.04 3.00 ± 1.12 120 ± 5.70 
SCT-66 27.9 ± 2.90 3.88 ± 0.573 78.4 ± 6.50 
SCT-64 69.4 ± 7.40 3.39 ± 0.530 96.6 ± 3.20 
SCT-29 20.9 ± 3.48 5.07 ± 2.81 68.4 ± 2.80 
LAU397 38.0 ± 8.44 3.42 ± 3.19 125 ± 9.70 
LAU399 44.8 ± 12.3 2.15 ± 1.58 118 ± 3.70 
*Recoveries were assessed with the experimental concentrations of the working solutions. 706 
 707 
 708 
 709 
 710 
 711 
 712 
 713 
 714 
 715 
 716 
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Table 7 In silico calculation of BBB permeation for piperine and analogs. 717 
 
QikProp descriptors (3D based) Marvin descriptors 
 
Compound MW donorHBa accptHBb PSA (Å2) 
LogP  
(o/w) 
Human Oral Absorption (%) LogBBc 
QPPCacod 
(nm/s) 
QPPMDCKe 
(nm/s) 
PSA (Å2) LogP Rotatable bondsf 
Piperine 285.3 0 4.5 48.1 3.27 100 -0.12 3996 2211 38.8 2.78 3 
SCT-66 329.4 0 4.5 43.6 4.59 100 -0.25 5441 3087 38.8 4.42 7 
SCT-64 301.4 0 4.5 45.5 3.96 100 -0.29 4893 2753 38.8 3.69 7 
SCT-29 329.4 0 4.5 45.3 4.70 100 -0.42 4923 2772 38.8 4.57 9 
LAU397 315.5 0 3.75 35.1 5.34 100 -0.51 4869 2739 29.5 4.79 10 
LAU399 291.5 0 3 26.9 5.21 100 -0.30 4877 5545 20.3 4.72 9 
a
donorHB: donor hydrogen bonds; 
b
accptHB: acceptor hydrogen bonds; 
c
LogBB: Predicted brain/blood partition coefficient (for 95% of known drugs, values range between -3.0 718 
and 1.2); 
d
QPPCaco: predicted apparent Caco-2 cell permeability in nm/s (< 25 poor, > 500 great); 
e
QPPMDCK: predicted apparent Madin-Darby Canine Kidney (MDCK) cell 719 
permeability in nm/s (< 25 poor, > 500 great); 
f
Counting according to Veber rules. 720 
 721 
 722 
 723 
 724 
 725 
 726 
 727 
 728 
 729 
 730 
 731 
 732 
 733 
 734 
 735 
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ELECTRONIC SUPPLEMENTARY MATERIAL  736 
 737 
SUPPLEMENTARY FIGURES 738 
 739 
 740 
 741 
Fig. S1 Mean TEER ± SD values (black curve) and mean cell layer capacitance (CCL) ± SD values (blue curve) 742 
recorded in real-time by the CellZscope system of hBMEC cell monolayers grown on 24-well tissue culture 743 
inserts (n = 14). CCL values in the range of 0.5–5.0 µF/cm
2
 indicate cell confluency and validate TEER values. 744 
*Permeability assay with SCT-64. **CellZscope transferred back into incubator (37°C, 5% CO2) for barrier 745 
integrity control.  746 
 747 
 748 
 749 
 750 
 751 
 752 
 753 
 754 
 755 
 756 
 757 
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SUPPLEMENTARY TABLES 758 
Table S1 Calibrators and calibration curve parameters for analytes in modified RHB. Response: A x Conc.
2
 + B x Conc. + C, quadratic regression, weighting factor 1/X, origin: 759 
included (n = 4–6). 760 
Compound  Nominal concentration (ng/mL) Regression parameters 
  5.00 25.0 50.0 100 200 400 500 A B C R2 
Piperine Mean 5.03 24.8 49.9 99.7 204 392 507 -0.0000429 0.141 -0.00451 0.9970 
 S.D. 0.214 1.34 1.53 5.75 13.1 31.2 16.7 0.0000318 0.0228 - - 
 CV % 4.25 5.42 3.07 5.76 6.45 7.97 3.29 - - - - 
 RE % 0.549 -0.871 -0.140 -0.259 1.81 -2.11 1.44 - - - - 
SCT-66 Mean 4.85 25.8 48.7 99.6 199 401 500 0.000000456 0.00854 0.00587 0.9977 
 S.D. 0.120 1.44 2.78 5.86 7.69 17.9 20.2 0.000000519 0.00468 - - 
 CV % 2.47 5.59 5.72 5.88 3.87 4.46 4.04 - - - - 
 RE % -2.94 3.18 -2.67 -0.412 -0.457 0.162 -0.0419 - - - - 
SCT-64 Mean 4.88 25.6 51.0 97.5 197 413 493 0.000000141 0.00116 -0.000231 0.9945 
 S.D. 0.424 1.84 3.60 6.88 10.4 34.7 22.0 0.000000375 0.000348 - - 
 CV % 8.69 7.17 7.05 7.06 5.29 8.40 4.46 - - - - 
 RE % -2.47 2.55 2.07 -2.48 -1.60 3.17 -1.48 - - - - 
SCT-29 Mean 5.20 24.6 48.2 99.6 201 407 494 0.00000112 0.0242 -0.00513 0.9987 
 S.D. 0.296 1.28 1.94 3.41 4.52 17.1 12.6 0.00000201 0.00461 - - 
 CV % 5.70 5.22 4.02 3.42 2.25 4.21 2.55 - - - - 
 RE % 4.06 -1.66 -3.51 -0.446 0.349 1.74 -1.11 - - - - 
LAU397 Mean 5.05 25.2 48.7 101 201 399 501 0.000000221 0.0102 0.0000172 0.9953 
 S.D. 0.446 2.40 3.40 7.54 17.4 31.6 26.3 0.00000122 0.00246 - - 
 CV % 8.84 9.53 6.99 7.49 8.64 7.93 5.25 - - - - 
 RE % 0.961 0.617 -2.70 0.716 0.671 -0.372 0.138 - - - - 
LAU399 Mean 4.83 24.8 51.9 102 193 403 499 0.00000313 0.0127 0.000294 0.9972 
 S.D. 0.0960 1.40 3.58 8.01 13.9 9.28 21.3 0.00000351 0.00166 - - 
 CV % 1.99 5.64 6.88 7.86 7.18 2.30 4.27 - - - - 
 RE % -3.50 -0.701 3.89 1.96 -3.47 0.774 -0.227 - - - - 
 761 
 762 
 763 
 764 
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Table S2 Calibrators and calibration curve parameters for analytes in modified DMEM. Response: A x Conc.
2
 + B x Conc. + C, quadratic regression, weighting factor 1/X, 765 
origin: included (n = 4–6). 766 
Compound  Nominal concentration (ng/mL) Regression parameters 
  5.00 25.0 50.0 100 200 400 500 A B C R2 
Piperine Mean 4.81 26.1 51.3 102 195 399 503 -0.00000140 0.00329 0.00150 0.9993 
 S.D. 0.250 1.78 1.09 3.73 4.80 11.4 7.42 0.000000268 0.000188 - - 
 CV % 5.20 6.81 2.13 3.68 2.46 2.87 1.48 - - - - 
 RE % -3.90 4.55 2.61 1.61 -2.37 -0.247 0.600 - - - - 
SCT-66 Mean 4.94 24.8 50.0 105 198 394 506 -0.00000231 0.0132 -0.0000265 0.9982 
 S.D. 0.180 0.845 3.20 9.55 9.78 9.61 10.7 0.00000164 0.00178 - - 
 CV % 3.65 3.41 6.39 9.12 4.93 2.44 2.12 - - - - 
 RE % -1.21 -0.966 -0.0246 4.81 -0.794 -1.58 1.12 - - - - 
SCT-64 Mean 4.92 25.3 50.0 100 200 398 502 0.000000117 0.000971 0.000155 0.9993 
 S.D. 0.250 1.03 1.60 4.57 5.32 6.62 11.3 0.0000000466 0.000153 - - 
 CV % 5.08 4.08 3.20 4.54 2.66 1.66 2.24 - - - - 
 RE % -1.53 1.10 -0.0164 0.481 -0.0658 -0.585 0.354 - - - - 
SCT-29 Mean 4.88 25.9 50.4 100 199 400 501 0.00000855 0.0815 0.0253 0.9990 
 S.D. 0.256 0.701 1.22 3.05 3.48 14.5 15.1 0.00000607 0.0147 - - 
 CV % 5.24 2.71 2.42 3.07 1.75 3.63 3.02 - - - - 
 RE % -2.34 3.41 0.778 -0.418 -0.323 -0.0902 0.108 - - - - 
LAU397 Mean 4.72 25.8 50.8 101 199 392 507 -0.000000531 0.00389 0.000852 0.9996 
 S.D. 0.144 0.990 0.865 1.91 3.28 1.73 5.93 0.000000351 0.000345 - - 
 CV % 3.06 3.84 1.70 1.88 1.65 0.440 1.17 - - - - 
 RE % -5.64 3.26 1.55 1.16 -0.608 -2.04 1.38 - - - - 
LAU399 Mean 5.24 24.6 48.4 103 204 390 506 0.000000955 0.00264 -0.00201 0.9988 
 S.D. 0.234 3.01 2.22 3.08 4.58 8.13 7.69 0.000000116 0.000274 - - 
 CV % 4.46 12.3 4.59 2.98 2.25 2.09 1.52 - - - - 
 RE % 4.89 -1.70 -3.18 3.10 1.82 -2.58 1.25 - - - - 
 767 
 768 
 769 
 770 
 771 
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Table S3 Carry-over assessment for analytes and corresponding I.S. (n = 4–6). 772 
Compound 
Mean carry-over (%)  
in modified RHB 
Mean carry-over (%)  
in modified DMEM 
Piperine 
I.S. SCT-64 
0.928 
0.00 
4.27 
0.0501 
SCT-66 
I.S. SCT-64 
0.266 
0.00 
1.61 
0.0444 
SCT-64 
I.S. SCT-66 
0.00 
0.0130 
0.355 
0.0139 
SCT-29 
I.S. SCT-64 
2.03 
0.00 
3.35 
0.0140 
LAU397 
I.S. LAU399 
0.747 
0.00 
3.74 
0.0597 
LAU399 
I.S. SCT-64 
0.00 
0.00 
3.70 
0.0152 
 773 
 774 
 775 
 776 
 777 
 778 
 779 
 780 
 781 
 782 
 783 
 784 
 785 
 786 
 787 
 788 
 789 
 790 
 791 
 792 
 793 
 794 
 795 
 796 
 797 
 798 
 799 
 800 
 801 
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Table S4 Mean apparent permeability coefficients (Papp (A→B) and Papp (B→A)) for analytes and Na-F, and efflux 802 
ratios (ER) for analytes obtained in the immortalized in vitro human BBB model based on hBMEC cell line (n = 803 
3–4). 804 
Compound Mean Papp ± SD (x 10
-6
 cm/s)  
Na-F:  
Mean Papp ± SD (x 10
-6
 cm/s)  
ER 
Direction A→B  B→A  A→B  B→A  - 
Piperine 26.1 ± 0.986 34.2 ± 2.20 5.74 ± 0.0406 6.53 ± 0.703 1.31 
SCT-66 7.25 ± 1.70 13.9 ± 2.59 6.28 ± 0.0369 6.28 ± 0.197 1.92 
SCT-64 15.6 ± 0.480 11.7 ± 1.59 4.20 ± 0.372 4.84 ± 0.0928 0.750 
SCT-29 3.38 ± 0.856 7.30 ± 0.675 4.51 ± 0.217 4.51 ± 0.0859 2.16 
LAU397 3.55 ± 0.769 4.14 ± 1.43 4.91 ± 0.0298 4.59 ± 0.0287 1.16 
LAU399 14.0 ± 4.90 16.8 ± 2.16 4.42 ± 0.135 5.07 ± 0.312 1.20 
Na-F: sodium fluorescein; A: apical; B: basolateral 805 
 806 
Table S5 Mean apparent permeability coefficients (Papp (A→B) and Papp (B→A)) for analytes and Na-F, and efflux 807 
ratios (ER) for analytes obtained in the in vitro human BLEC BBB model (n = 3).  808 
Compound Mean Papp ± SD (x 10
-6
 cm/s)  
Na-F:  
Mean Papp ± SD (x 10
-6
 cm/s)  
ER 
Direction A→B  B→A  A→B  B→A  - 
Piperine 25.1 ± 0.931 19.5 ± 3.08 8.53 ± 0.615 9.01 ± 0.483 0.777 
SCT-66 11.7 ± 0.806 5.59 ± 0.331 9.44 ± 0.644 8.53 ± 0.132 0.478 
SCT-64 11.2 ± 1.87 9.03 ± 0.590 8.02 ± 0.465 7.79 ± 0.254 0.804 
SCT-29 3.31 ± 0.891 1.37 ± 0.153 9.86 ± 0.478 8.36 ± 0.438 0.414 
LAU397 3.44 ± 1.03 1.40 ± 0.174 8.33 ± 0.356 8.29 ± 0.177 0.406 
LAU399 5.69 ± 0.822 2.81 ± 0.202 9.87 ± 1.02 7.87 ± 0.614 0.493 
Na-F: sodium fluorescein; A: apical; B: basolateral 809 
 810 
Table S6 Mean apparent permeability coefficients (Papp (A→B) and Papp (B→A)) for analytes and Na-F, and efflux 811 
ratios (ER) for analytes obtained in the primary bovine endothelial/rat astrocytes co-culture in vitro BBB model 812 
(n = 3). 813 
Compound Mean Papp ± SD (x 10
-6
 cm/s) 
Na-F:  
Mean Papp ± SD (x 10
-6
 cm/s) 
ER 
Direction A→B B→A A→B B→A - 
Piperine 81.3 ± 2.04 32.2 ± 1.64 3.00 ± 1.12 0.731 ± 0.00699 0.396 
SCT-66 27.9 ± 2.90 13.7 ± 0.830 3.88 ± 0.573 0.501 ± 0.0235 0.490 
SCT-64 69.4 ± 7.40 27.9 ± 1.53 3.39 ± 0.530 0.779 ± 0.0207 0.402 
SCT-29 20.9 ± 3.48 12.2 ± 1.54 5.07 ± 2.81 0.864 ± 0.0399 0.584 
LAU397 38.0 ± 8.44 17.3 ± 1.00 3.42 ± 3.19 0.610 ± 0.0517 0.460 
LAU399 44.8 ± 12.3 15.2 ± 0.440 2.15 ± 1.58 0.738 ± 0.239 0.340 
Na-F: sodium fluorescein; A: apical; B: basolateral 814 
 815 
 816 
 817 
 818 
 819 
 820 
 821 
 822 
138
3.4  Development and validation of a LC-MS/MS method for assessment of an 
anti-inflammatory indolinone derivative by in vitro blood-brain barrier models 
 
Evelyn A. Jähne, Daniela E. Eigenmann, Maxime Culot, Roméo Cecchelli, Fruzsina R. Walter, 
Mária A. Deli, Robin Tremmel, Gert Fricker, Martin Smieško, Matthias Hamburger, Mouhssin Oufir 
 
Journal of Pharmaceutical and Biomedical Analysis 98 (2014) 235–246 
DOI: 10.1016/j.jpba.2014.05.026 
 
The anti-inflammatory and anti-allergic compound (E,Z)-3-(4-hydroxy-3,5-dimethoxybenzylidene)-
indolin-2-one (indolinone) (Figure 1) from woad (Isatis tinctoria L., Brassicaceae) was screened in 
our previously established immortalized human in vitro BBB model and in two well-established 
animal in vitro BBB models. For this purpose, a quantitative LC-MS/MS method for the compound in 
modified Ringer HEPES buffer was developed and validated according to FDA and EMA guidelines. 
In vitro data from the three models showed good correlation and indicated a high BBB permeation 
potential of indolinone, corroborated by in silico prediction data. P-glycoprotein interaction of the 
compound was assessed with the aid of a calcein-AM uptake assay and bidirectional permeability 
experiments. Both assays suggested that no active mediated transport mechanism was involved for the 
compound.  
 
 
Figure 1 (E,Z)-3-(4-hydroxy-3,5-dimethoxybenzylidene)indolin-2-one (indolinone) 
 
 
 
 
 
My contributions to this publication: cultivation of cells, preparation of the immortalized human in 
vitro BBB model, permeability experiments with indolinone, and contribution to writing of the 
manuscript.  
Daniela Elisabeth Eigenmann 
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a  b  s  t  r  a  c  t
The  compound  (E,Z)-3-(4-hydroxy-3,5-dimethoxybenzylidene)indolin-2-one  (indolinone)  was  identi-
ﬁed  from  lipophilic  woad  extracts  (Isatis  tinctoria  L., Brassicaceae)  as  a compound  possessing  potent
histamine  release  inhibitory  and  anti-inﬂammatory  properties  [1]. To  further  evaluate  the potential  of
indolinone  in  terms  of  crossing  the  blood–brain  barrier  (BBB),  we  screened  the  compound  in  several
in  vitro  cell-based  human  and  animal  BBB  models.  Therefore,  we developed  a quantitative  LC–MS/MS
method  for  the compound  in modiﬁed  Ringer  HEPES  buffer  (RHB)  and validated  it  according  to FDA  and
EMA  guidelines  [2,3]. The  calibration  curve  of indolinone  in  the  range  between  30.0  and  3000  ng/ml  was
quadratic,  and  the  limit  of quantiﬁcation  was 30.0 ng/ml.  Dilution  of  samples  up  to 100-fold  did  not  affect
precision  and accuracy.  The  carry-over  was  within  acceptance  criteria.  Indolinone  proved  to  be  stable  in
RHB  for  3 h at room  temperature  (RT),  and  for three  successive  freeze/thaw  cycles.  The  processed  sam-
ples  could  be  stored  in the  autosampler  at 10 ◦C  for at least  28  h. Moreover,  indolinone  was stable  for  at
least  16  days  in  RHB  when  stored  below  −65 ◦C. This validation  study  demonstrates  that  our  method  is
speciﬁc,  selective,  precise,  accurate,  and  capable  to  produce  reliable  results.
In  the  immortalized  human  BBB  mono-culture  model,  the  apparent  permeability  coefﬁcient  from  apical
to  basolateral  (Papp A→B),  and the  Papp from  basolateral  to apical  (Papp B→A) were  19.2 ±  0.485  ×  10−6 cm/s
and  21.7  ±  0.326  ×  10−6 cm/s,  respectively.  For  the  primary  rat/bovine  BBB  co-culture  model  a Papp A→B of
−627.1  ±  1.67  ×  10 cm/s  was  determined.  In  the primary  rat  BBB  triple  co-culture  model,  the  Papp A→B and
the  Papp B→A were  56.2 ± 3.63  ×  10−6 cm/s  and  34.6 ± 1.41 × 10−6 cm/s,  respectively.  The  data  obtained
with  the  different  models  showed  good  correlation  and  were  indicative  of  a high  BBB  permeation  poten-
tial  of  indolinone  conﬁrmed  by  in silico  prediction  calculations.  P-glycoprotein  (P-gp)  interaction  for
indolinone  was  studied  with  the  aid  of a calcein-AM  uptake  assay,  and  by calculation  of  the  efﬂux ratio
(ER)  from  the  bidirectional  permeability  assays.  For  both  bidirectional  BBB  models  an ER below  2  was
calculated,  indicating  that  no  active  mediated  transport  mechanism  is involved  for indolinone.  In porcine
Abbreviations: BBB, blood–brain barrier; BSA, bovine serum albumin; BBEC, primary bovine brain capillary endothelial cells; Cal, calibrator; cLogP, calculated logarithm of
artitioning coefﬁcient; Calcein-AM, calcein-acetoxymethylester; CCl, cell layer capacitance; Conc., concentration; CNS, central nervous system; CV%, coefﬁcient of variation;
PT-cAMP, 8-(4-chlorophenylthio)-adenosine-3′ ,5′-cyclic monophosphate, sodium salt; DMEM, Dulbecco’s modiﬁed Eagle’s medium; DMSO, dimethyl sulfoxide; DNase I,
eoxyribonuclease type I; 96-DWP, 96-deep well plate; EMA, European Medicines Agency; ER, efﬂux ratio; ESI, electrospray ionization; FBS, fetal bovine serum; FDA, Food
nd  Drug Administration; hBMEC, immortalized human brain microvascular endothelial cell line; HEPES, 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid; HPLC, high-
erformance liquid chromatography; I.S., internal standard; KRB, Krebs–Ringer buffer; LLOQ, lower limit of quantiﬁcation; LTS, long-term stability; MRM,  multiple reaction
onitoring; MW,  molecular weight; Na-F, sodium ﬂuorescein; NMR, nuclear magnetic resonance; PBCEC, porcine brain capillary endothelial cells; PBS, phosphate buffered
aline; Papp, apparent permeability coefﬁcient; P-gp, P-glycoprotein; PSA, polar surface area; QC, quality control; QCH, quality control high; QCL, quality control low; QCM,
uality control medium; RBEC, primary rat brain capillary endothelial cell; RE%, relative error; RHB, Ringer HEPES buffer; Rpm, revolutions per minute; RT, room temperature;
D,  standard deviation; S.E.M., standard error of the mean; SS, stock solution; TEER, transendothelial electrical resistance; TFA, triﬂuoroacetic acid; TQD, tandem quadrupole
etector; ULOQ, upper limit of quantiﬁcation; UPLC–MS/MS, ultra performance liquid chromatography with tandem mass spectrometric detection; v/v, volume per volume;
S,  working solution.
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brain  capillary  endothelial  cells  (PBCECs),  the calcein-AM  uptake  assay  demonstrated  that  indolinone  is
neither a P-gp  substrate  nor  a  P-gp  inhibitor  and  is  accumulated  into  cells  at high  extent.
© 2014  Elsevier  B.V.  All  rights  reserved.
1
a
I
d
p
a
a
a
d
t
a
c
c
p
m
p
U
h
S
i
s
a
i
p
e
a
s
o
c
L
v
w
m
b
c
c
b
t
f
2
2
h
w
s
f
s
L
i
t
m
g
(
a column heater set at 45 ◦C, which was  coupled to an Acquity. Introduction
In the course of an investigation of anti-inﬂammatory and
nti-allergic compounds in the ancient anti-inﬂammatory plant
satis tinctoria [1,4–20] we identiﬁed (E,Z)-3-(4-hydroxy-3,5-
imethoxybenzylidene)indolin-2-one (indolinone) as the com-
ound responsible for the inhibition of histamine release from
ctivated mast cells [1]. The compound was a potent inhibitor of
ntigen-induced histamine release by stabilizing mast cells [1] by
 molecular mode of action that is not yet fully understood but
ifferent from known compounds. The compound was shown not
o act via targets upstream of the histamine containing granules
nd, hence, is thought to interact with the membrane of histamine-
ontaining granules [1]. Given the new mechanism of action, low
ytotoxicity, anti-allergic potency, and drug-like physicochemical
roperties [21], indolinone is a promising lead for the develop-
ent of new anti-allergic drugs. For further assessment of the
otential of indolinone we recently developed and validated an
PLC–MS/MS method for quantiﬁcation of indolinone in lithium
eparinized rat plasma for a preliminary pharmacokinetic study in
prague-Dawley male rats [22]. To further evaluate the potential of
ndolinone in terms of blood–brain barrier (BBB) permeability, we
creened the compound in several in vitro cell-based human and
nimal BBB models.
Blood–brain  barrier (BBB) penetration is necessary for drugs act-
ng on the central nervous system (CNS). High passive membrane
ermeability and low P-glycoprotein (P-gp) interaction favor CNS
xposure [23]. On the other hand, low BBB penetration is desir-
ble for drugs aimed at peripheral targets to minimize CNS-related
ide effects. Hence, regardless of the therapeutic area, assessment
f BBB penetration is required at an early phase of the drug dis-
overy process [24]. For this purpose, we developed a quantitative
C–MS/MS assay for indolinone in Ringer HEPES buffer (RHB) and
alidated it according to international guidelines [2,3]. Indolinone
as screened in several cell-based in vitro human and animal BBB
odels [25–27], and the permeability of indolinone was  assessed
y LC–MS/MS. P-gp interaction was studied with the aid of a
alcein-AM uptake assay in porcine brain capillary endothelial
ells (PBCECs), and by calculation of the efﬂux ratio (ER) from the
idirectional permeability assays [25,27]. To further explore the
ransporter mechanism of indolinone, an uptake assay was per-
ormed in PBCECs.
. Materials and methods
.1. In silico prediction of blood–brain barrier permeability
Three-dimensional computer models of both (E)- and (Z)-3-(4-
ydroxy-3,5-dimethoxybenzylidene)indolin-2-one (indolinone)
ere built in Maestro modeling environment (Maestro, ver-
ion 9.3, Schrödinger, LLC, New York, NY, 2012), and the most
avorable conformers were identiﬁed by the conformational
earch in MacroModel (MacroModel, version 9.9, Schrödinger,
LC, New York, NY, 2012) using the OPLS-2005 force-ﬁeld,
mplicit solvent conditions (water), and 1000 iterations of
he mixed serial/low mode sampling method. For each iso-
er, the conformers within 5 kcal/mol from the corresponding
lobal minimum were used as input for the QikProp application
QikProp, version 3.5, Schrödinger, LLC, New York, NY, 2012), to
141Fig. 1. Chemical structures of (E,Z)-3-(4-hydroxy-3,5-dimethoxybenzylidene)-
indolin-2-one (indolinone) (A) and internal standard, (E,Z)-3-(benzylidenyl)-
indolin-2-one (B) [22].
evaluate various descriptors relevant for drug permeability. For
comparison, the polar surface area (PSA) and the logarithm of
partition coefﬁcient (cLogP) descriptors were calculated also
using the Calculator plugin of Chemaxon Marvin web-application
(http://www.chemaxon.com/marvin/sketch/index.php, accessed
on February 12, 2014) requiring only the 2D structural formula as
input.
2.2. LC–MS/MS analysis
2.2.1. Chemicals and reagents
(E,Z)-3-(4-Hydroxy-3,5-dimethoxybenzylidene)indolin-2-one
(indolinone)  (Fig. 1A) and the internal standard (I.S.) (E,Z)-3-
(benzylidenyl)-indolin-2-one (Fig. 1B) were synthesized according
to a general protocol for indolinones [28]. Both compounds showed
a purity of ≥99% as determined by HPLC–UV–ESI-MS and 1H and
13C NMR  [29]. The ratio of E to Z isomers for indolinone and I.S. was
assessed by 1H NMR  and HPLC as 71:29 and 75:25, respectively
[22]. Preparative separation of isomers failed because of slow
spontaneous isomerization at RT [9,28]. All used solvents were
of HPLC grade. Acetonitrile and dimethyl sulfoxide (DMSO) were
supplied by Scharlau (Barcelona, Spain). Methanol was  from Lab-
Scan (Gliwice, Poland). Formic acid and triﬂuoroacetic acid (TFA)
were purchased from BioSolve (Valkenswaard, Netherlands), and
albumin from bovine serum (BSA) was supplied by Sigma–Aldrich
(Steinheim, Germany). HPLC grade water was  obtained by an
EASYpure II (Barnstead, Dubuque, IA, USA) water puriﬁcation
system. Ringer HEPES buffer (RHB) (150 mM NaCl, 2.2 mM CaCl2,
0.2 mM MgCl2, 5.2 mM KCl, 2.8 mM glucose, 5 mM HEPES, 6 mM
NaHCO3, 0.2% BSA) was  prepared in-house, adjusted to pH 7.4, and
stored at 4 ◦C.
2.2.2. LC–MS/MS instrument and chromatographic conditions
Method validation was performed on an Acquity UPLC system
consisting of a binary pump, an autosampler set at 10 ◦C, andTQD (all Waters Corp., Milford, MA,  USA). Separation of analyte
(indolinone) and I.S. ((E,Z)-3-(benzylidenyl)-indolin-2-one) was
achieved with a UPLC HSS T3 column (100 mm × 2.1 mm;  1.8 m
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article size) (Waters Corp., Milford, MA,  USA). The mobile phase
onsisted of water containing 0.1% formic acid (Eluent A) and
cetonitrile containing 0.1% formic acid (Eluent B). Chromato-
raphic separation was performed at a ﬂow rate of 0.5 ml/min
ith the following gradient: 0–0.5 min, B 2%; 0.5–2 min, B 2–100%;
–2.5 min, B 100%; 2.5–2.6 min, B 100–2%; 2.6–4 min, B 2%. The
otal run time was 4 min. As injection solvent a mixture of 35%
ater containing 0.1% formic acid and 65% methanol containing
.1% formic acid was used (35:65, v/v). Weak and strong wash sol-
ents were water–acetonitrile (50:50, v/v) containing 0.2% TFA,
nd acetonitrile–isopropanol–acetone (40:40:30, v/v/v) contain-
ng 0.2% TFA, respectively. The seal wash solvent consisted of a
ater–acetonitrile mixture (90:10, v/v).
MS detection was performed with electrospray ionization in
ositive ion mode (ESI+). Nitrogen, generated by a nitrogen gener-
tor N2-Mistral (Schmidlin AG, Neuheim, Switzerland), was  used
oth as desolvation and nebulization gas. Argon was  used as
ollision gas. MS/MS  parameters were generated using Waters
ntelliStart software followed by manual optimization.
MRM  transitions were 297.7 > 265.0 for indolinone, and
21.8 > 194.0 for I.S. ((E,Z)-3-(benzylidenyl)-indolin-2-one). The
apillary voltage was 3.5 kV. Cone voltage was 46 V, and collision
nergy was 21 eV for both indolinone and I.S. Source temperature
as set at 150 ◦C, and the desolvation temperature was  400 ◦C.
he ﬂow rates for desolvation gas and cone gas were 900 l/h and
0 l/h, respectively. The dwell time was automatically set at 69 ms.
ata were acquired with MassLynx V4.1 software and quantiﬁed
y means of QuanLynx software (Waters Corp., Milford, MA,  USA).
.2.3. Standards and stock solutions
Stock solutions (SS) of analyte and I.S. were prepared by weigh-
ng pure compounds on an analytical balance (Mettler-Toledo,
witzerland) and dissolving them in DMSO. The working solu-
ions (WS1) of analyte and I.S. were freshly prepared in methanol
y further diluting the corresponding SS to obtain a concentra-
ion of 100 g/ml for indolinone, and 10 g/ml for the I.S. For the
.S., a daily second working solution (WS2) at a concentration of
000 ng/ml was freshly prepared by diluting WS1  (10 g/ml) with
ethanol. All SS and WS  (except WS2, which was  discarded after
se) were stored below −65 ◦C until analysis.
.2.4. Preparation of calibration and quality control samples
Seven  calibration samples (calibrators) in the range of
0.0–3000 ng/ml and quality controls (QCs) at low, middle and high
evels (QCL = 90.0 ng/ml, QCM = 1500 ng/ml, QCH = 2400 ng/ml)
ere prepared in RHB by serial dilution of the WS of indolinone
100 g/ml). After dilution, all samples were vortexed, aliquoted
nto polypropylene tubes, and stored below −65 ◦C until analysis.
.2.5. Sample extraction in Ringer HEPES buffer
To 200 l of RHB containing indolinone, 100 l of I.S. at
000 ng/ml, 200 l of BSA solution (60 g/l), and 1000 l of ice
old acetonitrile were added. The mixture was brieﬂy vortexed,
ixed for 10 min  at room temperature (RT) in an Eppendorf Ther-
omixer (1400 rpm), and centrifuged for 20 min  at 13 200 rpm at
0 ◦C (Centrifuge 5415R, Eppendorf, Schoenenbuch, Switzerland).
he supernatant (1300 l) was transferred into a 96-deep well plate
DWP), dried under nitrogen gas ﬂow (Evaporex EVX-96, Apri-
ot Designs, Monovia, CA, USA), and reconstituted with 200 l of
njection solvent (35% solvent A + 65% solvent B, A: water + 0.1%
ormic acid, B: methanol + 0.1% formic acid). Afterwards, the 96-
WP was shaken for 45 min  at RT in an Eppendorf Mixmate and
entrifuged for 2 min  at 3000 rpm (Megafuge, Heraeus Instruments
G, Switzerland). Due to nonspeciﬁc adsorption of I.S. onto the 96-
WP, each sample was transferred into a 300 l glass insert of a
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HPLC vial before injection into the UPLC–MS/MS system in full loop
mode (5 l).
2.3. Method validation
The method was  validated according to the guidelines of the
US Food and Drug Administration (FDA) [2] and the European
Medicines Agency (EMA) [3].
2.3.1. Chromatographic performance
The calibration curve was  generated by seven calibrators ran-
ging from 30.0 to 3000 ng/ml. To meet requirements of the FDA
guidance, the coefﬁcient of determination (R2) has to be higher than
0.96 and at least 75% of all calibrators should be valid. Furthermore,
for both levels: LLOQ and ULOQ, only one value could be omitted.
2.3.2.  Regression parameters
Two  sets of seven calibrators (ranging from 30.0 to 3000 ng/ml)
were injected at the beginning and at the end of each analytical run,
starting from the lower limit of quantiﬁcation (LLOQ = 30.0 ng/ml)
to the upper limit of quantiﬁcation (ULOQ = 3000 ng/ml). The cali-
bration curve was validated by six QCs (duplicates of QCL, QCM and
QCH), which were inserted randomly into the analytical run.
2.3.3.  Carry-over
To  evaluate the carry-over of analyte and I.S. in each analyt-
ical run, an extracted RHB blank was injected immediately after
the ULOQ (3000 ng/ml) of both sets of calibrators. Mean carry-over
(n = 2) in the blank sample following the ULOQ should not exceed
20% of the signal of the LLOQ (30.0 ng/ml) for indolinone and 5% for
I.S.
2.3.4. Selectivity
Six  QC samples of indolinone at the LLOQ (duplicates, three
different batches of RHB) were extracted and injected within a vali-
dation run into the UPLC–MS/MS system. Selectivity imprecision
(CV%) had to be below 20% and inaccuracy (RE%) had to be within
±20% of the nominal values. Moreover, only one QC sample of each
RHB batch was allowed to have an inaccuracy of more than ±20%.
2.3.5. Speciﬁcity
A  total of six blank samples (duplicates, three different batches
of RHB) without the addition of indolinone and I.S. were injected
into the UPLC–MS/MS within an analytical run and quantiﬁed by
means of a valid calibration curve. For all three batches of RHB,
the peak areas evaluated in the blank samples were not allowed to
exceed 20% of the mean LLOQ peak area.
2.3.6. Intra-run and inter-run repeatability
Six replicates of QCs at ﬁve concentration levels (30.0, 90.0,
1500, 2400, 3000 ng/ml) were processed and injected into the
UPLC–MS/MS. To ensure the reproducibility, these sets of QCs were
tested within three validation runs on three different days. In each
run, intra-run imprecision (CV%) of each QC series had to be below
15% (20% at the LLOQ) and intra-run inaccuracy (RE%) had to be
within ±15% of the nominal values (±20% at the LLOQ). At the
end of the three series, inter-run imprecision and inaccuracy were
assessed by calculating the overall mean and standard deviation
(SD) for each QC level. The acceptance criteria for imprecision (CV%)
and inaccuracy (RE%) were the same as described above.
2.3.7.  Extraction yield
The  absolute recovery of the analyte was  calculated using six
replicates of indolinone at low (90.0 ng/ml), medium (1500 ng/ml),
and high concentration (2400 ng/ml) which were spiked with I.S.
after extraction compared to six blank RHB samples which were
2 al and
s
a
s
i
s
a
2
c
r
p
t
s
c
c
t
c
i
l
i
2
2
(
(
t
A
1
v
2
o
4
t
i
2
S
p
w
l
p
i
h
2
m
q
c
−
q
t
o
p
t
t
f
s
2
n38 E.A. Jähne et al. / Journal of Pharmaceutic
piked with indolinone at three concentration levels (90.0, 1500,
nd 2400 ng/ml) and I.S. after extraction.
The extraction yield of I.S. was calculated by comparison of
ix processed samples containing I.S. which were spiked with
ndolinone at medium level (1500 ng/ml) after extraction versus
ix replicates of blank RHB samples which were spiked with I.S.
nd indolinone (1500 ng/ml) after extraction.
.3.8.  Dilution test
In  order to demonstrate that the dilution of samples at higher
oncentration levels than the ULOQ (3000 ng/ml) did not affect the
eliability of the method, a dilution test was performed. For this pur-
ose, the matrix was spiked with the WS  of indolinone (100 g/ml)
o obtain a ﬁnal concentration of 15 000 ng/ml (i.e. 5× ULOQ). This
olution was further serially diluted to give six replicates at a con-
entration of 1500 ng/ml (10-fold dilution) and six replicates at a
oncentration of 150 ng/ml (100-fold dilution). Concentrations of
he replicates of each dilution level were calculated using a valid
alibration curve. Furthermore, the resulting mean concentration,
mprecision, and inaccuracy were calculated. According to guide-
ines [2,3], the imprecision (CV%) had to be below 15% and the
naccuracy had to be within ±15% of the nominal value.
.3.9.  Short-term stabilities of indolinone in Ringer HEPES buffer
.3.9.1.  Freeze and thaw cycles below −65 ◦C. Six replicates of QCL
90.0 ng/ml) and QCH (2400 ng/ml) were exposed to three freeze
below −65 ◦C, storage time > 24 h) and thaw (at RT) cycles before
hey were processed and quantiﬁed using a valid calibration curve.
t both concentration levels, the imprecision (CV%) had to be below
5% and the inaccuracy (RE%) had to be within ±15% of the nominal
alue.
.3.9.2. Biological sample stability on benchtop at RT. Six replicates
f QCL (90.0 ng/ml) and QCH (2400 ng/ml) were stored at RT for
 h and quantiﬁed using a valid calibration curve. At both concen-
ration levels, the imprecision (CV%) had to be below 15% and the
naccuracy (RE%) had to be within ±15% of the nominal value.
.3.9.3.  Processed sample stability in the autosampler at 10 ◦C.
ix replicates of QCL (90.0 ng/ml) and QCH (2400 ng/ml) were
rocessed and quantiﬁed using a valid calibration curve. All QCs
ere stored for 28 h in the autosampler (set at 10 ◦C, protected from
ight) before they were re-injected and re-analyzed with freshly
repared calibrators and QCs. At both concentration levels, the
mprecision (CV%) had to be below 15% and the inaccuracy (RE%)
ad to be within ±15% of the nominal value.
.3.10. Long-term stability below −65 ◦C
Three replicates of RHB samples freshly prepared at low,
edium and high concentration (90.0, 1500, 2400 ng/ml) were
uantiﬁed at time zero (t = 0). Three other replicates at the same
oncentration levels (90.0, 1500, 2400 ng/ml) were stored below
65 ◦C. After 16 days of storage, the samples were processed and
uantiﬁed by means of a valid calibration curve which consisted of
wo sets of freshly prepared calibrators and QCs. The mean values
f each concentration level at 16 days were calculated and com-
ared to the mean values of the appropriate concentration from
he ﬁrst day (t = 0) of the long-term stability test. The results of
 = 16 days were plotted in function of t = 0 and a linear regression,
orced through zero, was performed. To conﬁrm the stability of the
amples, the slope had to be within 1 ± 0.15.
.3.11. Stock solutions stability test
According to the FDA guideline, the eventual degradation should
ot exceed the threshold of 5% for both compounds [2].
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2.4. Blood–brain barrier permeability screening
2.4.1. Immortalized mono-culture human in vitro BBB model
Indolinone was screened in a human in vitro BBB model
which we  previously established using immortalized human brain
microvascular endothelial cells (hBMEC cell line) [25,30]. Culture
medium for hBMEC cells was  EBM-2 supplemented with hydro-
cortisone, ascorbic acid, heparin, antibiotic-antimycotic solution,
and 20% fetal bovine serum (FBS).
For the in vitro BBB model, hBMEC cells were seeded at
a density of 6.0 × 104 cells/cm2 on the apical side of collagen-
coated ﬁlter membranes of 24-well tissue culture inserts from
Greiner Bio-one® (transparent PET membrane, 3.0 m pore size,
0.6 × 106 pores/cm2). The tissue culture inserts were transferred
into a 24-well cell module of a CellZscope system (NanoAn-
alytics, Münster, Germany) [31], incubated at 37 ◦C (5% CO2),
and transendothelial electrical resistance (TEER) values were
recorded in real-time every hour. After 50 h, at a TEER value of
40.8 ± 0.884  cm2 (Fig. 4), the permeability assay for indolinone
was carried out as follows. The tissue culture inserts were trans-
ferred into a 24-well plate containing 1200 l of pre-warmed
(37 ◦C) RHB in each well (basolateral compartment). Medium
in inserts (apical compartment) was subsequently replaced
with 300 l of a pre-warmed (37 ◦C) WS  containing indolinone
(5 M)  and sodium ﬂuorescein (Na-F) as integrity control marker
(10 g/ml) in RHB. The 24-well plate was incubated at 37 ◦C on
an orbital shaker (ELMI DTS-2, Riga, Latvia) with moderate speed
(100 rpm) and aliquots of 250 l of both apical and basolateral
compartments were collected after 1 hour. Quantiﬁcation of Na-F
ﬂuorescence was  carried out using a Chameleon microplate reader
(Hidex, Turku, Finland). Quantiﬁcation of indolinone was done by
LC–MS/MS. All experiments were performed bidirectionally and in
triplicate.
2.4.2. Animal in vitro BBB models
2.4.2.1. Primary co-culture rat/bovine in vitro BBB model. The
method of Dehouck et al. [32] was  used with minor modiﬁcations.
Bovine brain capillary endothelial cells (BBECs) isolated from cap-
illary fragments were co-cultured with primary mixed glial cells
from newborn Sprague-Dawley rats. The glial cells were isolated
according to the method of Booher and Sensenbrenner [33] and
cultured for 3 weeks, plated on the bottom of cell culture clusters
containing six wells each. The BBECs were seeded onto collagen-
coated 6-well tissue culture inserts which were placed in the wells
containing glial cells. The medium used for the co-culture was
Dulbecco’s modiﬁed Eagle’s medium (DMEM, Life technologies,
Saint Aubin, France) supplemented with 10% (v/v) newborn calf
serum (Integro b.v., Zaandam, Netherlands), 10% (v/v) horse serum
(Life technologies), 2 mM glutamine (Sigma Aldrich), 50 g/ml gen-
tamycin, and 1 ng/ml of basic ﬁbroblast growth factor (bFGF, Sigma
Aldrich). The medium was  changed every second day. Under these
conditions, BBECs formed a conﬂuent monolayer after 5 days. The
permeability assay for indolinone was carried out 7 days after
conﬂuency by transferring BBEC monolayers to six-well plates
containing 2.5 ml  of RHB per well. The solution containing 5 M
indolinone and 1 M Na-F, used as integrity control marker, in RHB
was added to the cell monolayer (1.5 ml  for 6-well plate ﬁlters), and
the plates were placed on an orbital shaker. After 1 hour, aliquots
were taken from both compartments. Quantiﬁcation of Na-F ﬂu-
orescence was carried out using a Synergy H1 multiplates reader
(BioTek Instruments, Vinooski, USA). Quantiﬁcation of indolinone
was done by LC–MS/MS. All experiments were performed in
triplicate. The mean TEER value after 7 days in co-culture with
rat primary glial cells was  in the range of 350–400  cm2
[34].
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.4.2.2. Primary triple co-culture rat in vitro BBB model. Primary
at brain capillary endothelial cells (RBECs) were isolated from
-week-old Wistar rats, similarly as described earlier [35,36]. Fore-
rains were collected in sterile phosphate buffered saline (PBS)
n ice, and meninges were removed using heat sterilized ﬁlter
aper. Gray matter was cut by scalpels into 1 mm3 pieces which
ere digested in Dulbecco’s modiﬁed Eagle’s medium (DMEM, Life
echnologies, Gibco, USA) with 1 mg/ml  collagenase (Worthington,
SA) and deoxyribonuclease type I (DNase I, Roche, USA) for 50 min
t 37 ◦C. Microvessels were separated by a gradient centrifugation
n 20% BSA–DMEM (1000 × g, 20 min) from myelin, and this step
as repeated three times. The isolated and pooled fraction was  fur-
her digested with 1 mg/ml  collagenase–dispase (Roche, USA) and
Nase I in DMEM for 30 min. From the digested cell suspension,
rain endothelial cell clusters were separated on a 33% Percoll gra-
ient (Sigma Aldrich, USA) (1000 × g, 10 min), collected and washed
wice in cell culture medium before plating on 60 mm Petri dishes
Orange, Belgium) coated with collagen type IV and ﬁbronectin
Sigma Aldrich, USA). RBECs were cultured in DMEM/F12 supple-
ented with 15% plasma-derived bovine serum (First Link, UK),
 ng/ml basic ﬁbroblast growth factor (bFGF, Roche, USA), insulin
5 g/ml), transferrin (5 g/ml), sodium selenite (5 ng/ml) (insulin-
ransferrin-sodium selenite media supplement, Sigma Aldrich,
SA), 100 g/ml heparin (Sigma Aldrich, USA) and 50 g/ml gen-
amicin (Sigma Aldrich, USA). In the ﬁrst 4 days, cell culture medium
ontained puromycin (3 g/ml, Sigma Aldrich, USA) to selectively
liminate P-gp negative contaminating cell types [37]. When cul-
ures reached 90% conﬂuency (fourth day in dish), the puromycin
reated RBECs were passaged to the apical side of the collage type IV
nd ﬁbronectin coated ﬁlter membranes of 24-well tissue culture
nserts from Greiner Bio-one® (transparent PET membrane, 3.0 m
ore size) at a cell number of 2.5 × 104 cells/insert and used for
he permeability experiments. To induce BBB characteristics, RBECs
ere co-cultured with rat cerebral glial cells and rat pericytes [27].
Primary cultures of rat mixed glial cells were obtained from 1-
ay-old Wistar rats [35,36]. Meninges were removed by forceps
n a small drop of PBS, then cortical pieces were mechanically
issociated by pressing the tissue through a nylon mesh (40 m,
illipore, USA) in DMEM containing 10% FBS (Lonza, Switzerland)
nd 50 g/ml gentamicin. Dissociated cell clusters were plated on
 g/ml poly-l-lysine (Sigma Aldrich, USA) coated 24-well plates
rom Greiner Bio-One® and cultured for at least 2 weeks before use.
n conﬂuent glia cultures 89% of cells were positively stained for the
stroglia cell marker glial ﬁbrillary acidic protein (GFAP), while the
emaining 11% were positive for CD11b, a microglia marker.
Cultures  of rat brain microvessel pericytes were prepared by
 3-week long culture of isolated rat brain capillary fragments
hich contained a high number of pericytes besides endothelial
ells. The same microvessel isolation yielded RBECs, and pericytes
f puromycin-treatment was omitted. Cell survival and prolifera-
ion were helped by selective culture conditions using uncoated
ishes and DMEM (Life Technologies, Gibco, low glucose) supple-
ented with 10% FBS and antibiotics. Culture medium was  changed
very 3 days. Rat brain microvessel pericyte cultures were positive
or -smooth muscle actin, NG2 and PDGFRß immunostaining, and
egative for von Willebrand factor and GFAP markers [38].
To  assemble the BBB model from the three cell-types, Greiner
io-one® tissue culture inserts were put into 24-well plates con-
aining glia at the bottom of the wells. Pericytes at passage number
 were seeded on the bottom side of the inserts (basolateral) and
BECs were passaged to the upper side of the coated inserts (apical)
ith endothelial culture medium in both compartments [27]. After days of co-culturing, 550 nM hydrocortisone (Sigma Aldrich, USA)
as added to the culture medium [39]. Before experiments, cells
ere treated with 8-(4-chlorophenylthio)-adenosine-3′,5′-cyclic
onophosphate (CPT-cAMP, 250 M,  Sigma Aldrich, USA) and RO
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20-1724 (17.5 M,  Roche) for 24 h to tighten junctions and elevate
resistance [37,39].
At a TEER value of 427.8 ± 62.9  cm2 (day 4 of co-culture), the
permeability assay for indolinone was  performed. Before the exper-
iment, working solutions consisting of indolinone (5 M)  and Na-F
(10 g/ml) for layer integrity control were prepared in pre-warmed
(37 ◦C) RHB. To protect cell layer integrity, RHB contained 0.1% BSA.
Tissue culture inserts with RBECs and pericytes were transferred
into a new 24-well plate containing 700 l of RHB for apical to
basolateral (A to B) permeability measurements or 700 l working
solution for basolateral to apical (B to A) transport assays. Medium
in inserts (apical compartment) was subsequently replaced with
300 l working solution for A to B or 300 l RHB for B to A trans-
port tests. The 24-well plate was  incubated at 37 ◦C on a horizontal
shaker (100 rpm, Biosan, Latvia) for 1 h. Aliquots of 250 l and
650 l were collected from the apical and basolateral compart-
ments and stored below −65 ◦C until analysis. Concentration of
Na-F was  measured by a Fluostar Optima ﬂuorescent multiplate
reader (BMG Labtechnologies, Germany).
2.4.3. BBB permeability calculation
The apparent permeability coefﬁcient (Papp) for indolinone and
Na-F was calculated in centimeters per second (cm/s) according to
the equation [40]:
Papp (cm/s) = VR
ACD0
×
(
CR
t
)
where VR is the volume in the receiver compartment, A is the surface
area of the ﬁlter membrane (0.336 cm2 for 24-well inserts, 4.7 cm2
for six-well inserts), CD0 is the initial concentration in the donor
compartment, and CR/t is the change of concentration over time
in the receiver compartment.
Recovery  for indolinone and Na-F was  calculated according to
the equation:
Recovery (%) = CDf VD + CRf VR
CD0VD
× 100
where CDf and CRf are the ﬁnal concentrations of the compound
in the donor and receiver compartments, respectively, CD0 is the
initial concentration in the donor compartment, and VD and VR are
the volumes in the donor and receiver compartments, respectively.
All results are expressed as means ± S.E.M.
Low  permeability and high efﬂux can be limiting factors for BBB
penetration. A common way  of quantifying P-gp interaction in vitro
is by calculating the efﬂux ratio (ER) across P-gp expressing cell
monolayers, which is deﬁned as [41–45]:
ER = Papp B→A
Papp A→B
Compounds showing an ER > 2.0 usually indicate P-gp efﬂux.
To conﬁrm that indolinone and Na-F did not attach to the plastic
material and that the diffusion barrier was  only provided by the cell
monolayer, control experiments were performed using collagen-
coated inserts without cells.
2.5. Transporter studies
2.5.1. Calcein-AM uptake in porcine brain capillary endothelial
cells  (PBCECs)
The  calcein-AM uptake assay was  performed in primary porcine
brain capillary endothelial cells (PBCECs) seeded in 96-well plates
(Corning Costar) at a density of 2.5 × 105 cells/cm2. Culture medium
was Earl’s Medium 199 (Biochrom, Berlin, Germany) supplemented
with l-glutamine, penicillin, streptomycin, gentamycin, and FBS.
After achieving conﬂuence, the cells were used for the calcein assay
as previously described [46]. Brieﬂy, cells were washed twice with
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re-warmed Krebs–Ringer Buffer (KRB) and then incubated for
5 min  with 100 l of 2 M calcein-AM in KRB at 37 ◦C. After this
re-incubation time, 100 l of indolinone at increasing concentra-
ions in KRB was added to each well to achieve a ﬁnal concentration
f 5, 50, and 500 M indolinone. Stock solution of indolinone was
repared in DMSO. Dilutions were then made with KRB. The ﬁnal
oncentration of DMSO on the cells did not exceed 1%. At this con-
entration, DMSO did not affect the assay [46]. After an incubation
ime of 30 min  at 37 ◦C, the cells were washed twice with cold
5 ◦C) KRB and subsequently incubated with 200 l 1% Triton-X
n KRB for 20 min. Fluorescence was measured in a plate reader
Tecan, Inﬁnite F200 Pro) with an excitation/emission wavelength
f 485/520 nm.  Intracellular ﬂuorescence was obtained by subtrac-
ing background ﬂuorescence of control wells. Calcein uptake was
xpressed as % of control (KRB).
.5.2. Cellular uptake assay
The cell uptake assay was also performed with PBCECs. The
ells were treated as described above and also seeded in a 96-well
late [47]. Conﬂuent cells were washed twice with KRB, then pre-
ncubated for 15 min  at 37 ◦C with 200 l KRB. After removal of KRB,
he cells were incubated with 200 l indolinone in KRB (100 and
000 M)  at 37 ◦C for 30 min. The cells were again washed twice
ith KRB, followed by incubation with 200 l 1% Triton-X in KRB for
0 min  at 37 ◦C. Indolinone content was determined by LC–MS/MS
s described in Section 2.2. The area of each well was 0.32 cm2.
ased on the presumption that the cell monolayer had a height of
 m,  the total volume of the cells in one well was 0.096 l. This vol-
me was taken into consideration when the content of indolinone
in 200 l KRB) was calculated.
. Results and discussion
.1. Chromatographic performance and method validation
.1.1. Chromatographic performance
Based on the slow inter-conversion at RT [9,28] of (E,Z)-3-(4-
ydroxy-3,5-dimethoxybenzylidene)indolin-2-one (indolinone)
Fig. 1A), both E and Z isomers peak areas were integrated and
uantiﬁed in RHB (Fig. 1). Since isotope-labeled indolinone was
ot available, the structurally related (E,Z)-3-(benzylidenyl)-
ndolin-2-one was selected as I.S. (Fig. 1B) [22]. For quantiﬁcation
f analyte and I.S., an identical peak integration of both E and Z
somers was performed (Fig. 2). The calibration curve ranging from
0.0 to 3000 ng/ml was ﬁtted by least-square quadratic regression,
nd a weighting factor of 1/X2 was applied. The mean coefﬁcient
f determination (R2) was  0.9919 (Supplementary Table 1), and
cceptance criteria were fulﬁlled [2,3] (Supplementary Table 1).
Supplementary table related to this article can be found, in the
nline version, at http://dx.doi.org/10.1016/j.jpba.2014.05.026.
.1.2. Assessment of carry-over
The  mean carry-over was 0.00% (acceptance criteria: below 20%)
or indolinone (Fig. 2A) and 0.0839% (below 5%) for I.S. (Fig. 2B).
ence, the carry-over did not impact precision and accuracy of the
ethod (Supplementary Table 2).
Supplementary table related to this article can be found, in the
nline version, at http://dx.doi.org/10.1016/j.jpba.2014.05.026.
.1.3. Selectivity for indolinone
Selectivity  imprecision (CV%) for the six samples at the LLOQduplicates, three different RHB batches) was 8.34% (below 20%)
nd inaccuracy (RE%) was −12.3% (within ±20%), indicating that
he quantiﬁcation method was selective for indolinone (Supple-
entary Table 3).
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Supplementary table related to this article can be found, in the
online version, at http://dx.doi.org/10.1016/j.jpba.2014.05.026.
3.1.4. Speciﬁcity for indolinone
The peak areas measured in the blank RHB sample were 0.00%
(below 20%), demonstrating that the method was speciﬁc for
indolinone (data not shown).
3.1.5. Intra-run and inter-run repeatability for indolinone
Intra-run imprecision (CV%) was 6.29% (below 20%) for the LLOQ,
and 1.88–5.62% (below 15%) of the nominal value for all the other
QCs (Supplementary Table 4). The inaccuracy (RE%) was 6.57%
(within ±20%) for the LLOQ and −10.1% to 2.33% (within ±15%)
of the nominal values for the other QC levels (Supplementary Table
4). Inter-run imprecision (CV%) ranged from 1.49% to 5.87% (below
20% for LLOQ, and below 15% for all other QC levels), and the inac-
curacy (RE%) was  between −9.50% and −0.0589% (below 20% for
LLOQ, and below 15% for all other QC levels) (Supplementary Table
4). According to international guidelines [2,3], the method was thus
precise and accurate.
Supplementary table related to this article can be found, in the
online version, at http://dx.doi.org/10.1016/j.jpba.2014.05.026.
3.1.6. Extraction yield
The  absolute recovery of indolinone was 81.5% for QCL
(90.0 ng/ml), 91.3% for QCM (1500 ng/ml), and 91.8% for QCH
(2400 ng/ml) (Supplementary Table 5). For the I.S., an absolute
recovery of 83.6% was determined (Supplementary Table 5). Conse-
quently, the extraction yield was  proven to be consistent, precise,
and reproducible according to FDA guidance [2].
Supplementary table related to this article can be found, in the
online version, at http://dx.doi.org/10.1016/j.jpba.2014.05.026.
3.1.7. Dilution test
For  both QC series, imprecision (CV%) was  below 15% (6.36% for
dilution factor 100 and 4.48% for dilution factor 10), and inaccuracy
(RE%) was within ±15% of the nominal values (−8.62% and 7.27%,
respectively) (Supplementary Table 6). Hence, precision and accu-
racy of the method was  not affected by dilution of samples up to
100-fold.
Supplementary table related to this article can be found, in the
online version, at http://dx.doi.org/10.1016/j.jpba.2014.05.026.
3.1.8. Processed sample stability at autosampler conditions
At  both concentration levels (90.0 ng/ml and 2400 ng/ml),
imprecision (CV%) was below 15% (5.13% and 3.14%, respectively,
data not shown), and inaccuracy (RE%) was  within ±15% of the
nominal values (−0.191% and −11.5%, respectively) (Supplemen-
tary Table 7). Thus, processed samples of indolinone proved to be
stable for at least 28 h at autosampler conditions (10 ◦C, protected
from light).
Supplementary table related to this article can be found, in the
online version, at http://dx.doi.org/10.1016/j.jpba.2014.05.026.
3.1.9. Freeze and thaw cycle stability
Imprecision (CV%) for the six replicates at the QCL (90.0 ng/ml)
and the QCH (2400 ng/ml) was  below 15% (4.69% and 3.52%, respec-
tively, data not shown), and inaccuracy (RE%) was  within ±15%
(12.6% and 0.564%, respectively) (Supplementary Table 7), demon-
strating that indolinone stored below −65 ◦C in RHB was stable for
at least three freeze and thaw cycles.3.1.10. Biological samples stability on benchtop at RT
Imprecision (CV%) for the six replicates of QCL (90.0 ng/ml) and
QCH (2400 ng/ml) exceeded 15%, and inaccuracy was not within
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C), and 1000 ng/ml of I.S. (D), of RHB spiked at 3000 ng/ml (ULOQ) of indolinone (E
15% of the nominal values, indicating that indolinone was not sta-
le when stored for 4 h at RT (data not shown). For this reason, the
enchtop stability test was reduced to 3 h. Under these new condi-
ions, imprecision (CV%) for the six replicates at low concentration
90.0 ng/ml) was 3.13%, and for the six replicates at high concentra-
ion (2400 ng/ml) it was  2.43% (data not shown). Inaccuracy (RE%)
as 5.38% and −4.40%, respectively (Supplementary Table 7). Con-
equently, samples were shown to be stable for 3 h under benchtop
onditions (RT) (Supplementary Table 7)..1.11. Biological samples long-term stability below −65 ◦C
As  the slope of the calculated linear regression was 0.900 (accep-
ance criteria: 1 ± 0.15), the stability of the samples stored below
65 ◦C for 16 days could be conﬁrmed (Fig. 3).
146 for indolinone (A) and for I.S. (B), of RHB spiked at 30.0 ng/ml (LLOQ) of indolinone
1000 ng/ml of I.S. (F).
3.1.12. Stock solutions stability test
Our previous study demonstrated that stock solutions of
indolinone and I.S. stored below −65 ◦C for 190 days and kept for
ca. 6 h at RT were stable, since the degradation expressed by the
difference percentage (−1.11% and −1.46% for indolinone and I.S.,
respectively) was below 5% [22].
3.2. In silico prediction of blood–brain barrier permeability
In silico methods are nowadays routinely used for a rapid
assessment of physico-chemical properties of compounds. Descrip-
tor values averaged over the 18 low energy conformers of
(E,Z)-indolinone show no violation of Lipinski’s rule of ﬁve [21]
(MW  < 500, cLogP < 5, donorHB < 5, acceptHB < 10; Table 1) along
242 E.A. Jähne et al. / Journal of Pharmaceutical and Biomedical Analysis 98 (2014) 235–246
Table 1
Mean  values of the most relevant in silico pharmacokinetic descriptors for (E,Z)-indolinone.
QikProp descriptors (3D) Chemaxon Marvin (2D)
Compound MW donorHB acceptHB cLogPo/w cLogBB Human oral absorption (%) PSA (Å2) cLogPo/w PSA (Å2)
(E,Z)-indolin-2-one 297.30 2.00 4.75 2.44 −0.78 93.2 77.8 2.65 67.8
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iig. 3. Long-term stability (LTS) of indolinone in RHB for 16 days below −65 ◦C.
ith a high predicted human oral absorption (93.2%). The values of
oth 2D- and 3D-based PSA descriptor were not only well below the
aximum acceptable threshold of 140 A˚2 for good oral absorption,
ut also meet the criteria for a passive permeation through the BBB
PSA < 90 A˚2) [48]. Similarly, both predicted cLogPo/w values were
ithin the range that is favorable for blood–brain transport. On the
ther hand, the specialized QikProp model for brain/blood parti-
ioning predicted a cLogBB of −0.78 (usual range from −3.0 to 1.2)
ndicating a slight preference for the blood environment [49].
.3. Blood–brain barrier screening
.3.1. Human in vitro BBB model
In the in vitro BBB model with immortalized human brain
apillary endothelial cells (hBMEC cell line) [25], the Papp of
ndolinone for apical to basolateral transport (Papp A→B) was
9.2 ± 0.485 × 10−6 cm/s (Table 2). Compared to the Papp A→B of the
egative control Na-F (3.20 ± 0.0295 × 10−6 cm/s), this value was
onsiderably higher and suggested that indolinone may  cross the
BB. The Papp value for basolateral to apical transport (Papp B→A)
as 21.7 ± 0.326 × 10−6 cm/s (Table 3). The efﬂux ratio of 1.13 indi-
ated no active efﬂux mediated transport for indolinone (ER < 2.0)
41–45].
The  recovery of indolinone was ≥88.9% in all experiments,
uggesting that the obtained Papp values were reliable. A recov-
ry above 80% is needed for an acceptable approximation of the
app value [50]. After each permeability experiment, TEER values
ere determined, and they were found to be in the same range
43.1 ± 0.431  cm2, Fig. 4) as before the assay. This indicated that
arrier integrity of the cell monolayers was maintained through-
ut the experiments, and that indolinone did not affect cell layer
ntegrity.
.3.2. Animal in vitro BBB models
.3.2.1. Primary co-culture rat/bovine in vitro BBB model. The Papp
f Na-F in the presence of indolinone (2.28 ± 0.168 × 10−6 cm/s)
Table 4) was in the same range as that of Na-F alone
data not shown). This result attested the integrity of the
ell monolayer during the transport experiment. The Papp A→B
27.1 ± 1.67 × 10−6 cm/s) was more than 10-fold higher than that of
a-F and hence, suggested high BBB permeability. Given that Papp
→B of indolinone across membranes with cells and control mem-
ranes (i.e. without cells) were very close, that data suggested that
ndolinone is freely diffusing across BBECs.
147Fig. 4. Mean TEER values () and CCl values () recorded real-time by the CellZscope
system of hBMEC cells grown on 24-well tissue culture inserts. (*) Insert transfer to
24-well plate for indolinone permeability assay. (**) Insert transfer to CellZscope
(37 ◦C) for barrier integrity control.
3.3.2.2. Primary triple co-culture rat in vitro BBB model. The in vitro
BBB model composed of primary RBECs, rat pericytes, and rat glial
cells formed a tight barrier with a TEER value of 427.8 ± 62.9  cm2,
and a Papp A→B 0.884 ± 0.186 × 10−6 cm/s for Na-F (Table 5). The
Papp A→B of indolinone was 56.2 ± 3.63 × 10−6 cm/s (Table 5). Com-
pared to the Papp A→B of the paracellular permeability marker Na-F
this value was 60 times higher (Table 5) and hence, suggested
that indolinone crossed the BBB very effectively. The Papp value of
indolinone from basolateral to apical was 34.6 ± 1.41 × 10−6 cm/s
(Table 6). The efﬂux ratio was  below 1 and indicated no active
mediated efﬂux mechanism for indolinone (ER < 2.0) in the triple
co-culture model. TEER values recorded after the experiments
(189.1 ± 8.52  cm2) were lower than prior to the assay. This could
be explained by cell disturbance due to a switch from cell culture
medium to buffer, and to the lack of barrier stabilizing factors from
glial cells and culture medium. However, the resistance remained
well above the threshold indicative of barrier tightness [39,51]. The
Na-F permeability coefﬁcients also indicated a preserved barrier
function, and no harmful effect of indolinone on RBECs.
3.4. Transporter studies
3.4.1. Calcein-AM uptake in porcine brain capillary endothelial
cells  (PBCEC)
In  PBCEC, the calcein assay is speciﬁc for assessing P-gp trans-
port activity, and the known P-gp inhibitor verapamil (positive
control) increased cellular calcein ﬂuorescence by 500% compared
to the control (KRB) (Fig. 5). Treatment with indolinone at 5, 50,
and 500 M led to no calcein accumulation, indicating that the
compound was neither a P-gp substrate nor a P-gp inhibitor (Fig. 5).
3.4.2. Cellular uptake assay
The validated LC–MS/MS method for quantiﬁcation ofindolinone in RHB was  used to quantify the content of indolinone
in the lysing medium (mixture of KRB and 1% Triton). No analytical
interferences were found showing that the RHB quantitative
method can be applied to such an assay (data not shown).
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Table 2
Screening of indolinone regarding its ability to cross the in vitro human BBB model using immortalized human brain capillary endothelial cells (hBMEC cell line) from the apical (A) to the basolateral (B) compartment (n = 2–3).
In vitro human BBB model
(hBMEC  cell line)
Transport
direction
Samples Time of withdrawal
(min)
Mean  concentration
(ng/ml)
Mean  amount (ng) Papp of analyte ± S.E.M.
(×10−6 cm/s)
Papp of Na-F ± S.E.M.
(×10−6 cm/s)
Recovery of
analyte  (%)
Control inserts
(without cells) A to B
Donor  compartment (300 l) 60  1272 381 – – –
Receiver compartment (1200 l) 60  118 142 71.2 74.0 106a
Inserts with
cells
A  to B
Donor  compartment (300 l) 60  1337 401 – – –
Receiver compartment (1200 l) 60 31.9 38.3 19.2 ± 0.485 3.20 ± 0.0295 88.9a
a The recovery was  assessed with the experimental concentration of the WS (1647 ng/ml).
Table 3
Screening of indolinone regarding its ability to cross the in vitro human BBB model using immortalized human brain capillary endothelial cells (hBMEC cell line) from the basolateral (B) to the apical (A) compartment (n = 2–3).
In vitro human BBB model
(hBMEC)
Transport
direction
Samples  Time of withdrawal
(min)
Mean concentration
(ng/ml)
Mean  amount
(ng)
Papp of analyte ± S.E.M.
(×10−6 cm/s)
Papp of Na-F ± S.E.M.
(×10−6 cm/s)
Recovery of
analyte  (%)
Control inserts
(without cells) B to A
Donor  compartment (1200 l) 60  1647 1976 – – –
Receiver compartment (300 l) 60 328 98.5 49.4 50.2 105a
Inserts with
cells
B  to A
Donor  compartment (1200 l) 60 1448 1738 – – –
Receiver compartment (300 l) 60 144 43.3 21.7 ± 0.326 3.10 ± 0.0231 90.1a
a The recovery was  assessed with the experimental concentration of the WS  (1647 ng/ml).
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Table 4
Screening of indolinone regarding its ability to cross the in vitro animal BBB model using primary bovine capillary endothelial cells and primary rat brain glial cells from the apical (A) to the basolateral (B) compartment (n = 3).
In vitro primary triple
co-culture  BBB rat model
Transport
direction
Samples  Time of withdrawal
(min)
Mean concentration
(ng/ml)
Mean amount
(ng)
Papp of analyte ± S.E.M.
(×10−6 cm/s)
Papp of Na-F ± S.E.M.
(×10−6 cm/s)
Recovery of
analyte  (%)
Control inserts
(without cells)
A
to
B
Donor compartment (2500 l) 60 1230 1844 – – –
Receiver  compartment
(2500  l)
60 302 755 27.9 ± 1.19 24.2  ± 1.24 105a
Inserts with
cells
A  to B
Donor compartment (300 l) 60 937 1406 – – –
Receiver  compartment (700 l) 60 303 757 27.1 ± 1.67 2.28  ± 0.168 87.3a
a The recovery was  assessed with the experimental concentration of the WS (1669 ng/mL).
Table 5
Screening of indolinone regarding its ability to cross the in vitro animal BBB model using primary rat brain endothelial cells, pericytes and astrocytes from the apical (A) to the basolateral (B) compartment (n = 3 for control inserts,
n  = 4 for inserts with cells seeded).
In vitro primary triple
co-culture  BBB rat model
Transport
direction
Samples Time of withdrawal
(min)
Mean concentration
(ng/ml)
Mean amount
(ng)
Papp of analyte ± S.E.M.
(×10−6 cm/s)
Papp of Na-F ± S.E.M.
(×10−6 cm/s)
Recovery of
analyte  (%)
Control inserts
(without cells) A  to B
Donor compartment (300 l) 60 862 259 – – –
Receiver compartment (700 l) 60 188 132 71.6 ± 0.813 124 ± 2.63 85.4a
Inserts with
cells
A to B
Donor compartment (300 l) 60 775 232 – – –
Receiver compartment (700 l) 60 148 104 56.2 ± 3.63 0.884 ± 0.186 73.6a
a The recovery was  assessed with the experimental concentration of the WS  (1523 ng/ml).
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Fig. 5. Calcein-AM uptake assay in primary porcine brain capillary endothelial cells
150(PBCECs). Indolinone was tested at 5, 50, and 500 M in KRB. Pure KRB was used as
control. Verapamil (50 M,  P-gp inhibitor) was  used as positive control.
At 100 M of indolinone, all measured concentrations were
below the LLOQ of the method (30.0 ng/ml), whereas at 1000 M of
indolinone, the concentration inside the cells was 433.3 M after
30 min, demonstrating that indolinone can easily penetrate PBCEC
layers.
4. Conclusions
We developed a LC–MS/MS method for (E,Z)-3-(4-hydroxy-
3,5-dimethoxybenzylidene)indolin-2-one (indolinone) in RHB and
validated the assay according to EMA  and FDA guidelines [2,3].
(E,Z)-3-(Benzylidenyl)-indolin-2-one, a closely related synthetic
compound, was used as I.S. [22]. The standard calibration curve of
indolinone in RHB in the range of 30.0–3000 ng/ml was quadratic
and a weighting factor of 1/X2 was applied. The LLOQ was
30.0 ng/ml. Dilution of samples up to 100-fold did not affect pre-
cision and accuracy. The carry-over was within the acceptance
criteria. Indolinone was stable for 3 h at RT, and for three succes-
sive freeze and thaw cycles. The processed samples could be stored
in the autosampler at 10 ◦C for at least 28 h. Moreover, indolinone
was stable for at least 16 days in RHB when stored below −65 ◦C.
These data demonstrated that the method was selective, speciﬁc,
precise, accurate, and capable of producing reliable results. A com-
parison of two in vitro primary animal BBB models (co-culture
bovine/rat BBB model, and triple co-culture rat brain endothelial
cells/pericytes/astrocytes BBB model) and an immortalized mono-
culture human model (hBMEC cell line) as a possible surrogate BBB
model were used for screening indolinone regarding its ability to
cross the BBB. The data obtained with the two  well-established ani-
mal  in vitro BBB models showed good correlation with our human
in vitro mono-culture model and were indicative of a high BBB
permeation potential of indolinone. These ﬁndings were corrobo-
rated by in silico prediction of BBB penetration. Finally, calcein-AM
and uptake assays showed that indolinone accumulated in PBCECs
and was neither a P-gp inhibitor nor a P-gp substrate. This was
conﬁrmed by calculation of the efﬂux ratio which was  found to
be lower than 2. The validated LC–MS/MS assays will be used for
further bioavailability studies addressing oral bioavailability and
pharmacokinetic properties.
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ELECTRONIC SUPPLEMENTARY MATERIAL  
 
Supplementary Table 1: Calibrators and calibration curve parameters. Response: A × Conc.
2
 + B × Conc. + C, 
Quadratic regression, 1/X
2
 weighting, Origin: excluded 
Run 
ID 
Concentration (ng/ml) Regression parameters 
30.0 100 250 500 1000 2000 3000 A B C 
r-
squared 
1 30.3 *82.8 *167 462 940 1993 2971 
0.0000000183 
0.000189 0.00134 0.9958 
 30.2 92.2 274 *597 1105 2018 3000    
2 29.8 87.8 223 489 975 1852 2699 
0.0000000173 
0.000186 0.00177 0.9896 
 31.3 101 252 574 1107 2088 3258    
3 26.0 *74.5 *204 *391 857 1813 2680 
0.0000000196 
0.000266 0.000830 0.9858 
 34.0 98.4 262 506 1066 2270 3295    
4 29.1 85.4 227 507 971 1889 2758 
0.0000000112 
0.000235 0.000108 0.9913 
 32.4 97.9 252 565 1106 2163 3094    
5 29.8 96.0 235 528 1027 1936 3008 
0.0000000126 
0.000232 0.00360 0.9973 
 30.8 98.9 237 552 PC 1957 3029    
Mean 30.4 94.7 245 523 1017 1998 2979 0.0000000158 0.000221 0.00153 0.9919 
S.D. 2.11 5.69 17.8 39.0 87.7 142 214 0.00000000368 0.0000339 - - 
CV% 6.94 6.01 7.25 7.47 8.63 7.12 7.17     
RE% 1.19 -5.27 -1.97 4.55 1.73 -0.111 -0.692     
* >15.0% outside acceptance criteria, not used for calculations; PC: poor chromatography 
 
Supplementary Table 2: Carry-over assessment for indolinone as analyte, and for (E,Z)-3-(benzylidenyl)-
indolinone as I.S. 
Run ID Replicate Peak response (counts) Carry-over (%) Mean Carry-over (%) 
Blank sample LLOQ 
Analyte IS Analyte IS Analyte IS Analyte IS 
1 1 0.00 105 714 101049 0.00 
0.00 
0.104 
0.0912 
0.00 0.0975 
 2 0.00 109 844 119573 
2 1 0.00 113 877 119688 0.00 0.0943 0.00 0.0927 
 2 0.00 107 888 116847 0.00 0.0912 
3 1 0.00 112 1185 163695 0.00 0.0684 0.00 0.0860 
 2 0.00 162 1244 156293 0.00 0.104 
4 1 0.00 128 1395 176048 0.00 0.0726 0.00 0.0792 
 2 0.00 145 1471 169168 0.00 0.0858 
5 1 0.00 103 1776 169019 0.00 0.0607 0.00 0.0639 
 2 0.00 105 1688 156900 0.00 0.0670 
     Mean 0.00 0.0839   
 
 
Supplementary Table 3: Selectivity test at the LLOQ for indolinone, based on 3 different RHB batches. 
Nominal level (ng/ml) 30.0 
Mean 26.3 
S.D. 2.19 
CV% 8.34 
RE% -12.3 
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Supplementary Table 4: Intra-run and inter-run imprecision (expressed as CV%) and inaccuracy (expressed as 
RE%) of QC samples, based on 3 series of 6 replicates for each level. 
Nominal level 
(ng/ml) 
30.0 90.0 1500 2400 3000 
Intra-run Mean 32.0 92.1 1529 2362 2696 
Intra-run S.D. 2.01 5.18 83.4 44.3 60.8 
Intra-run CV% 6.29 5.62 5.45 1.88 2.26 
Intra-run RE% 6.57 2.33 1.92 -1.60 -10.1 
Inter-run Mean 28.8 89.9 1456 2301 2715 
Inter-run S.D. 1.69 3.58 42.2 70.3 40.4 
Inter-run CV% 5.87 3.98 2.90 3.05 1.49 
Inter-run RE% -3.94 -0.0589 -2.93 -4.12 -9.50 
 
 
Supplementary Table 5: Absolute extraction yield of indolinone and I.S. (E,Z)-3-(benzylidenyl)-indolin-2-one 
(n = 6). 
QC nominal level (ng/ml) 90.0 1500 2400 
Absolute recovery (%) 81.5 91.3 91.8 
CV% 6.59 4.53 10.6 
SD 5.37 4.14 9.71 
 
I.S. level (ng/mL) 433 
Absolute recovery (%) 83.6 
CV% 4.00 
SD 3.34 
 
 
Supplementary Table 6: Dilution test. 
Nominal level (ng/ml) 15000 
Dilution factor 10X 100X 
Mean 16091 13707 
S.D. 721 872 
CV% 4.48 6.36 
RE% 7.27 -8.62 
 
 
Supplementary Table 7: Short-term and long-term stabilities in RHB during storage in various conditions 
(expressed as RE%) (n = 6). 
Nominal level (ng/ml) 90.0 2400 
Three successive freeze/thaw 
cycles below -65°C 
12.6 0.564 
Stored RHB at RT for 3 h 5.38 -4.40 
Processed RHB at 10°C for 28 h -0.191 -11.5 
Stored RHB below -65°C for 16 
days 
-8.91 
 
4.27 
 
 
 
 
 
 
 
 
  
153
  
 
 
154
  
 
 
 
 
4 Conclusions and outlook 
 
  
155
Drug candidates targeting the CNS need to enter the brain by crossing the BBB in order to reach their 
sites of action. However, only a small percentage (2%) of small drug molecules has been estimated to 
successfully overcome the BBB [1]. Therefore, lead compounds targeting the brain should be screened 
for their ability to permeate this cellular hurdle already at an early stage of the drug development 
process, in order to reduce their failure rate later on at a clinical stage. 
Despite considerable efforts in the past years, there is still an urgent need for more reliably predictive 
in vitro BBB models, especially human ones. While primary human cells are difficult to obtain on 
ethical grounds, suffer from batch-to-batch variation, and are suitable only for low throughput 
screenings, immortalized human brain capillary endothelial cell lines generally show deficiencies such 
as relatively low barrier tightness and high paracellular permeation of negative control compounds. 
Due to their human origin, however, the risk of obtaining permeability data confounded by species 
differences is reduced. Moreover, the ease of culture of immortalized cell lines allows for moderate to 
high throughput screening. The aim of this thesis was thus to establish and validate an in vitro human 
BBB model based on an immortalized human brain microvascular endothelial cell line, and to apply it 
to drug permeability studies of natural product derived lead candidates. 
To establish an improved in vitro human BBB model, we compared in a first step four currently 
available human brain microvascular endothelial cell lines (hCMEC/D3, hBMEC, TY10, and BB19) 
regarding their ability to form endothelial cell monolayers with sufficient barrier tightness in a 24-well 
Transwell model. TEER values were recorded in real-time every hour using an automated CellZscope 
system [2] in order to obtain highly standardized data. The 24-well format was selected due to its 
better suitability for higher throughput screening compared to the 12-well and 6-well format. Under 
the conditions examined in our experiments, mono-cultures of hBMEC cell line exhibited highest 
TEER values (around 40 Ωcm2) and lowest leakage of the fluorescent barrier integrity markers Na-F 
and LY (Papp values in the range of 3–5 x 10
-6
 cm/s). Immortalized human astrocytes (SVG-A) and 
pericytes (HBPCT) in co-culture with endothelial cells did not have an impact on barrier tightness of 
the endothelial monolayers, suggesting that none of the investigated endothelial cell lines was able to 
positively respond to stimuli from astrocytic or pericytic cells. hBMEC cells were shown to express 
the tight junction proteins ZO-1 and claudin-5, and the endothelial marker protein VE-cadherin, 
confirming their endothelial lineage. Our studies clearly showed that the optimization of culture 
conditions such as growth medium composition, coating material and procedure, cell seeding density, 
and the selection of appropriate tissue culture inserts are critical when establishing a BBB model with 
the cell lines used in this study. In conclusion, hBMEC cell line was considered as the most suitable 
cell line in terms of barrier tightness, and was thus selected for the establishment of an immortalized 
human in vitro BBB model [3]. To our knowledge, this cell line has not been widely used for drug 
permeability studies, and no validation of a hBMEC cell line-based Transwell assay has been reported.  
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Besides the endothelial cell lines used in this comparative study, further immortalized brain capillary 
endothelial cell lines from human origin have been generated in the past two decades (Table 2, 
Chapter 2.3.3). However, at the time we started the project, only four endothelial cell lines were 
accessible (i.e. hCMEC/D3, hBMEC, TY10, and BB19). Given the urgent need for human in vitro 
BBB models, the generation and characterization of new immortalized cell lines derived from human 
brain endothelial cells would thus be of great value to the scientific community.  
The hBMEC cell line-based in vitro BBB model was validated in a next step with a representative 
series of structurally diverse compounds known to cross the BBB to a varying extent. Antipyrine, 
caffeine, diazepam, and propranolol were selected as positive controls. Atenolol, cimetidine, 
quinidine, and vinblastine served as negative controls. For each substance, an individual quantitative 
UHPLC-MS/MS assay in RHB was developed and validated in terms of selectivity, precision, and 
reliability according to FDA and EMA bioanalytical guidelines for industry [4,5]. During method 
validation, numerous biological and analytical challenges were encountered, such as short-term and 
long-term instabilities of analytes in RHB, non-specific adsorption of the compounds to various 
surfaces, erroneous results due to the selection of unsuitable I.S., and interferences of co-eluting 
compounds during UHPLC-MS/MS analysis. This demonstrated that careful method development is 
of high importance, and that major precautions for sample analysis need to be taken prior to 
quantification of the compounds in RHB. 
The immortalized in vitro human BBB model correctly predicted the BBB permeability of the selected 
control compounds, with the exception of one negative control (quinidine). This compound showed an 
unexpectedly high BBB permeation. Since quinidine is an inhibitor and substrate of P-gp [6], the high 
permeability might be due to a low expression of P-gp by hBMEC cells and/or saturation of P-gp, 
enabling the small basic lipophilic compound to easily permeate the endothelial cell monolayer. 
According to in silico calculated descriptor values, quinidine should be able to permeate the BBB. 
However, a detailed study on expression and functional activity of P-gp by hBMEC cell line would be 
necessary to clarify this apparently contradictory experimental finding. In the course of such a study, a 
comprehensive characterization of the cell line also in terms of uptake proteins, as was carried out for 
the hCMEC/D3 cell line [7,8], would be highly desirable.  
According to Gumbleton and Audus, a cell-based in vitro BBB model should display the following 
features: 1) a restrictive paracellular barrier; 2) a physiologically realistic cell architecture; 3) 
functional expression of key transporter mechanisms; 4) and allow ease of culture to facilitate high 
throughput screening [9]. By using an immortalized cell line of human brain microvascular endothelial 
origin, criteria two (physiologically realistic cell architecture) and four (ease of culture) are fulfilled. 
Regarding the first criterion (restrictive paracellular barrier), hBMEC cells were shown to produce 
endothelial monolayers with TEER values in the range of 20–40 Ωcm2. Compared to primary animal 
models, where TEER values in the range of 400–1500 Ωcm2 can be reached [10–13], this is 
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considerably lower. It is also lower than the threshold of 150–200 Ωcm2, above which reasonable drug 
permeability results are expected [9,14–16]. However, permeability coefficients for Na-F and LY in 
our model (Papp 3–5 x 10
-6
 cm/s) were in a similar range than those obtained in other primary and 
immortalized in vitro BBB models (in the range of 0.5–6 x 10-6 cm/s) [10,11], indicating a reasonably 
tight barrier formed by hBMEC cells. Moreover, permeability data for the natural alkaloid tryptanthrin 
and for several phenolic compounds (that were screened in the course of two other projects before 
validation of the model) were in agreement with permeability data from two well-established primary 
animal in vitro BBB models (unpublished data), further corroborating the validity of our immortalized 
in vitro human BBB model. Criterion three (functional expression of key transporters) might possibly 
not be fulfilled by our model, as quinidine (negative control, P-gp inhibitor and substrate) erroneously 
showed a high permeability across hBMEC monolayers. Despite this constraint (lack of discrimination 
between passive diffusion and active efflux of compounds), we conclude that our model represents a 
promising tool for early BBB permeability assessment of lead candidates in drug discovery, as it is of 
human origin (thus reducing the risk for data confounded by species differences), easy and fast to set 
up, and thus amenable to moderate to higher throughput screening. Hence, it might be easily 
implemented in the pharmaceutical industry as an alternative to the commonly used PAMPA-BBB and 
Caco-2 models that both suffer from severe limitations (PAMPA-BBB is not cell-based, and Caco-2 
models are not reliably predictive of in vivo BBB permeability) (see Chapter 2.3.3). Nevertheless, 
results obtained by the hBMEC cell line-based model need to be evaluated critically, and should 
ideally be complemented by in silico BBB permeability predictions and/or in vitro data from efflux 
pump interaction assays (e.g. MDR1-MDCK Transwell assay). 
After validation, we evaluated the alkaloid piperine from Piper nigrum L. (Piperaceae) and five 
selected piperine analogs with positive allosteric GABAA receptor modulatory activity for their ability 
to permeate the BBB in the immortalized human in vitro BBB model. Since GABAA receptors are 
expressed in the CNS, lead candidates modulating this target need to enter the brain by crossing the 
BBB. For comparative purposes, the compounds were screened in parallel in a recently developed 
human stem cell in vitro BBB model [17], and in a primary animal co-culture (bovine endothelial/rat 
astrocytes) in vitro BBB model [18]. Additionally, in silico data for BBB permeability were 
calculated. For each compound, a quantitative UHPLC-MS/MS assay in the corresponding matrix was 
developed, and permeability coefficients for each model were determined.  
In vitro prediction data obtained in the two human models were in good agreement, while permeability 
data from the animal model differed to some extent. In all three BBB models, piperine and the 
semisynthetic derivative SCT-64 displayed the highest BBB permeability potential. This was 
corroborated by in silico prediction data. For the other analogs (SCT-66, SCT-29, LAU397, and 
LAU399), permeability was low to moderate in the two human BBB models, and moderate to high in 
the animal BBB model. Efflux ratios (ER) calculated from bidirectional permeability experiments 
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indicated that the compounds were not substrates of active efflux. We conclude that further in vivo 
experiments are necessary to evaluate the extent of brain penetration of the compounds. Moreover, 
pharmacokinetic properties and drug metabolism of the compounds should be evaluated. Several 
studies are currently in progress in our laboratory, and will serve to select the most promising 
candidate molecule for further development or for the next cycle of medicinal chemistry optimization. 
Generally, data discrepancies from model to model, or from one laboratory to the next, may be due to 
species differences in endothelial cells, and/or differences  in experimental protocols and data analysis 
(e.g. material of filter insert, transport medium composition, screening concentration, quantification 
method, determination of permeability coefficients etc.). To date, no general guidelines for the 
performance of in vitro BBB permeability assays exist. Recommendations for the standardization of 
drug permeability studies, elaborated by BBB experts in a collaborative effort, would thus be of great 
value to the scientific community [19]. 
Beyond GABAA receptor modulating compounds, the indolinone derivative (E,Z)-3-(4-hydroxy-3,5-
dimethoxybenzylidene)indolin-2-one (indolinone) from Isatis tinctoria L. (Brassicaceae) was screened 
in our immortalized in vitro human BBB model [20]. The compound had previously been shown to 
possess potent anti-allergic and anti-inflammatory properties, and thus represents a promising lead 
candidate for the development of new anti-allergic drugs [21]. In the human in vitro BBB model, 
indolinone showed a high BBB permeation potential. This finding was corroborated by in vitro 
permeability data from two well-established primary animal in vitro BBB models (co-culture 
bovine/rat model [13] and triple co-culture rat model [10]), and by in silico prediction data. Moreover, 
two specific efflux pump interaction assays suggested that no active mediated transport mechanism 
was involved for the compound. To minimize CNS-related adverse effects, low permeability of 
indolinone across the BBB would be of advantage. Results obtained in this study suggested the 
opposite (i.e. high BBB permeation). To confirm these findings, more detailed studies to assess CNS 
exposure in vivo would be desirable. If the compound indeed penetrates the brain, it remains to be 
evaluated if the possible unwanted side effects may present a safety issue, and/or if inflammation 
within the CNS might possibly be a new therapeutic area for the compound. 
For correct data interpretation, it is important to be aware that in vitro Transwell assays primarily 
provide information on BBB permeability, i.e. on the rate of brain penetration (see Chapter 2.3 for 
detailed discussion). For drugs targeting the CNS, however, a high extent of brain penetration is 
likewise favorable. Even more importantly, the free drug concentration at the target site should be at a 
pharmacologically relevant level. However, techniques to evaluate these aspects of brain penetration 
(e.g. brain microdialysis) are more sophisticated, expensive, and time-consuming than simple in vitro 
methods. Therefore, they are usually employed only at a later stage of the drug development process 
for selected compounds. At an early stage, in vitro models (such as the established BBB model in this 
project) are ideal to obtain first insights into brain exposure of new lead candidates, and for the 
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ranking of a series of promising compounds regarding their BBB permeability to facilitate the 
selection for further development. 
In future studies, the established immortalized in vitro human BBB model may be applied to drug 
permeability studies of further bioactive natural products or natural product derived lead compounds. 
In addition to piperine, numerous promising GABAA receptor modulators from plants have been 
identified and isolated in our research group. Among these are sandaracopimaric acid from Biota 
orientalis [22], β-asarone from Acorus calamus [23], and dehydroabietic acid from Boswellia thurifera 
[24], to name only a few. As mentioned above, BBB permeability assessment of these compounds 
may facilitate the selection of the most promising lead candidates for further development and/or for 
optimization by medicinal chemistry to improve brain penetration characteristics. Another project in 
our research group focuses on the identification of bioactive compounds from plants that modulate 
myotonic dystrophy type 1. Lead candidates targeting this disease should ideally not penetrate the 
brain in order to have a reduced CNS side effect profile. BBB permeability assessment of these natural 
products may thus provide valuable information if unwanted side effects have to be anticipated, and 
may support the selection of ideal lead candidates for further in vivo testing. Lastly, efforts have been 
made in collaboration with the Swiss Tropical and Public Health Institute (STPH) in Basel to identify 
bioactive compounds from plants with promising activity against trypanosoma. These protozoa are the 
causative agent of human African trypanosomiasis, also called sleeping sickness, for which no 
generally satisfying treatment is available to date. At stage two of the disease, the parasites infiltrate 
the CNS [25]. Therefore, drug candidates with antitrypanosomal activity should be able to permeate 
the BBB. The immortalized hBMEC cell line-based BBB model may thus be utilized to bring forward 
lead compounds of natural origin with promising activity against these parasites. 
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